WO2021159035A1 - Oncolytic virus compositions and methods for the treatment of cancer - Google Patents
Oncolytic virus compositions and methods for the treatment of cancer Download PDFInfo
- Publication number
- WO2021159035A1 WO2021159035A1 PCT/US2021/016973 US2021016973W WO2021159035A1 WO 2021159035 A1 WO2021159035 A1 WO 2021159035A1 US 2021016973 W US2021016973 W US 2021016973W WO 2021159035 A1 WO2021159035 A1 WO 2021159035A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acd47
- cells
- cancer
- antibody
- oncolytic virus
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 202
- 238000000034 method Methods 0.000 title claims abstract description 136
- 244000309459 oncolytic virus Species 0.000 title claims abstract description 126
- 201000011510 cancer Diseases 0.000 title claims abstract description 97
- 238000011282 treatment Methods 0.000 title abstract description 51
- 239000000203 mixture Substances 0.000 title abstract description 28
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims abstract description 78
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims abstract description 67
- 208000015181 infectious disease Diseases 0.000 claims abstract description 55
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 363
- 208000005017 glioblastoma Diseases 0.000 claims description 150
- 150000007523 nucleic acids Chemical class 0.000 claims description 103
- 210000000822 natural killer cell Anatomy 0.000 claims description 86
- 102000039446 nucleic acids Human genes 0.000 claims description 68
- 108020004707 nucleic acids Proteins 0.000 claims description 68
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 60
- 241000700584 Simplexvirus Species 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 57
- 230000000174 oncolytic effect Effects 0.000 claims description 53
- 206010033128 Ovarian cancer Diseases 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 208000023275 Autoimmune disease Diseases 0.000 claims description 41
- 230000003612 virological effect Effects 0.000 claims description 40
- 239000002246 antineoplastic agent Substances 0.000 claims description 34
- 230000004913 activation Effects 0.000 claims description 32
- 208000032839 leukemia Diseases 0.000 claims description 31
- 230000003013 cytotoxicity Effects 0.000 claims description 29
- 231100000135 cytotoxicity Toxicity 0.000 claims description 29
- 230000001965 increasing effect Effects 0.000 claims description 29
- 210000004881 tumor cell Anatomy 0.000 claims description 29
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 23
- 239000003937 drug carrier Substances 0.000 claims description 22
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 19
- 230000009885 systemic effect Effects 0.000 claims description 18
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 17
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 17
- 230000002601 intratumoral effect Effects 0.000 claims description 17
- 208000006673 asthma Diseases 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 14
- 101150096316 5 gene Proteins 0.000 claims description 13
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 229960000572 olaparib Drugs 0.000 claims description 12
- 239000012661 PARP inhibitor Substances 0.000 claims description 11
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 11
- 238000009169 immunotherapy Methods 0.000 claims description 11
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 230000008102 immune modulation Effects 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 238000002626 targeted therapy Methods 0.000 claims description 7
- 238000002659 cell therapy Methods 0.000 claims description 6
- 230000008105 immune reaction Effects 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims description 5
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims description 5
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims description 5
- 208000026872 Addison Disease Diseases 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 208000009137 Behcet syndrome Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 5
- 206010034277 Pemphigoid Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 206010047642 Vitiligo Diseases 0.000 claims description 5
- 201000009961 allergic asthma Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 5
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims description 5
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 206010021198 ichthyosis Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 5
- 230000002147 killing effect Effects 0.000 claims description 5
- HAVFFEMDLROBGI-UHFFFAOYSA-N m8926c7ilx Chemical compound C1CC(O)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 HAVFFEMDLROBGI-UHFFFAOYSA-N 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 5
- 229950011068 niraparib Drugs 0.000 claims description 5
- 229950007072 pamiparib Drugs 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229950004707 rucaparib Drugs 0.000 claims description 5
- 201000000306 sarcoidosis Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 229950004550 talazoparib Drugs 0.000 claims description 5
- 208000025721 COVID-19 Diseases 0.000 claims description 4
- 206010035148 Plague Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 4
- 206010057293 West Nile viral infection Diseases 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 4
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 208000006379 syphilis Diseases 0.000 claims description 4
- 229950011257 veliparib Drugs 0.000 claims description 4
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 206010018612 Gonorrhoea Diseases 0.000 claims description 3
- 208000001786 gonorrhea Diseases 0.000 claims description 3
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 23
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 110
- 241000699670 Mus sp. Species 0.000 description 89
- 210000002540 macrophage Anatomy 0.000 description 86
- 230000000694 effects Effects 0.000 description 85
- 206010057249 Phagocytosis Diseases 0.000 description 66
- 230000008782 phagocytosis Effects 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 57
- 241000700605 Viruses Species 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 51
- 241000699666 Mus <mouse, genus> Species 0.000 description 48
- 238000013456 study Methods 0.000 description 44
- -1 PD035901 Chemical compound 0.000 description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 34
- 239000006228 supernatant Substances 0.000 description 34
- 239000011780 sodium chloride Substances 0.000 description 32
- 238000002347 injection Methods 0.000 description 31
- 239000007924 injection Substances 0.000 description 31
- 230000004083 survival effect Effects 0.000 description 31
- 238000001994 activation Methods 0.000 description 29
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 29
- 238000003556 assay Methods 0.000 description 28
- 238000009739 binding Methods 0.000 description 28
- 238000001727 in vivo Methods 0.000 description 28
- 239000003981 vehicle Substances 0.000 description 28
- 230000027455 binding Effects 0.000 description 27
- 230000006870 function Effects 0.000 description 27
- 238000007912 intraperitoneal administration Methods 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 25
- 238000000684 flow cytometry Methods 0.000 description 24
- 238000012384 transportation and delivery Methods 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 23
- 239000012636 effector Substances 0.000 description 23
- 210000000987 immune system Anatomy 0.000 description 23
- 230000000903 blocking effect Effects 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 20
- 210000002865 immune cell Anatomy 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 19
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 19
- 238000002513 implantation Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 238000013518 transcription Methods 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 17
- 230000000259 anti-tumor effect Effects 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 230000003993 interaction Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 16
- 108090000765 processed proteins & peptides Chemical group 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 102000044459 human CD47 Human genes 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 14
- 230000002441 reversible effect Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108010087819 Fc receptors Proteins 0.000 description 13
- 102000009109 Fc receptors Human genes 0.000 description 13
- 208000009889 Herpes Simplex Diseases 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 238000011319 anticancer therapy Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 230000006051 NK cell activation Effects 0.000 description 9
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 9
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 241001529453 unidentified herpesvirus Species 0.000 description 9
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 8
- 230000003622 anti-hsv Effects 0.000 description 8
- 238000011717 athymic nude mouse Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000005746 immune checkpoint blockade Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108020004463 18S ribosomal RNA Proteins 0.000 description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010061309 Neoplasm progression Diseases 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 238000003306 harvesting Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 102220333682 rs886041346 Human genes 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000007910 systemic administration Methods 0.000 description 7
- 230000005751 tumor progression Effects 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 102000026633 IL6 Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 210000003501 vero cell Anatomy 0.000 description 6
- UQNRTPFLTRZEIM-MRWUDIQNSA-N (2s)-2-amino-3-hydroxy-n-[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;hydrochloride Chemical compound Cl.C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 UQNRTPFLTRZEIM-MRWUDIQNSA-N 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 229920001184 polypeptide Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000005748 tumor development Effects 0.000 description 5
- 241000711404 Avian avulavirus 1 Species 0.000 description 4
- 108010006654 Bleomycin Proteins 0.000 description 4
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 4
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 description 4
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000009175 antibody therapy Methods 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000012379 oncolytic virotherapy Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 description 3
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000700586 Herpesviridae Species 0.000 description 3
- 101100059527 Homo sapiens CD47 gene Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 3
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 101150100944 Nos2 gene Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 241000702263 Reovirus sp. Species 0.000 description 3
- 241000837158 Senecavirus A Species 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229960001220 amsacrine Drugs 0.000 description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 3
- 230000003095 anti-phagocytic effect Effects 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- KLEPCGBEXOCIGS-XUZZJYLKSA-N ethyl N-[4-[[(2S,4S)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@H]1O[C@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-XUZZJYLKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 229960000752 etoposide phosphate Drugs 0.000 description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 230000006867 granzyme B production Effects 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 238000002625 monoclonal antibody therapy Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229950003600 ombrabulin Drugs 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 3
- 229960003440 semustine Drugs 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 108010047846 soblidotin Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229950006050 spiromustine Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108010029464 tasidotin Proteins 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- 229960004355 vindesine Drugs 0.000 description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 2
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 2
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- RTHKPHCVZVYDFN-UHFFFAOYSA-N 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol Chemical compound NC1=NC=CC(C=2C3=C(O)C=CN=C3N3C(N)=NC=CC3=2)=N1 RTHKPHCVZVYDFN-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- LDZJNMJIPNOYGA-UHFFFAOYSA-N C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O Chemical compound C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O LDZJNMJIPNOYGA-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
- 241000712045 Morbillivirus Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 101100323865 Xenopus laevis arg1 gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229950004955 adozelesin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 229950006844 bizelesin Drugs 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229950009494 bropirimine Drugs 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- 229950007509 carzelesin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NQGMIPUYCWIEAW-OVCLIPMQSA-N chembl1834105 Chemical compound O/N=C/C1=C(SC)C(OC)=CC(C=2N=CC=CC=2)=N1 NQGMIPUYCWIEAW-OVCLIPMQSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 108010083340 cryptophycin 52 Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 108010045524 dolastatin 10 Proteins 0.000 description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
- 229950004203 droloxifene Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 229950001426 erbulozole Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical class ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 etanidazole Drugs 0.000 description 2
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- 229950005096 fazarabine Drugs 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 102000055062 human IL12A Human genes 0.000 description 2
- 102000055222 human IL1B Human genes 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 229960003951 masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- 229950002676 menogaril Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 238000011201 multiple comparisons test Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229950008017 ormaplatin Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- 229950009351 perfosfamide Drugs 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 208000031223 plasma cell leukemia Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229960004293 porfimer sodium Drugs 0.000 description 2
- 229950004406 porfiromycin Drugs 0.000 description 2
- 238000012910 preclinical development Methods 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 rogletimide Drugs 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N rohitukine Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- CGFVUVWMYIHGHS-UHFFFAOYSA-N saintopin Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 2
- HAOCRCFHEPRQOY-JKTUOYIXSA-N spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229950002376 tirapazamine Drugs 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- TVPNFKRGOFJQOO-UHFFFAOYSA-N topsentin b1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 108700029852 vapreotide Proteins 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 2
- 229950003017 zeniplatin Drugs 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- OTWVIYXCRFLDJW-QMVMUTFZSA-N (1-hydroxy-1-phosphonooxyethyl) dihydrogen phosphate;rhenium-186 Chemical compound [186Re].OP(=O)(O)OC(O)(C)OP(O)(O)=O OTWVIYXCRFLDJW-QMVMUTFZSA-N 0.000 description 1
- FNEOHTTZLPHOSX-KZNAEPCWSA-N (1r)-1-[(2r,5r)-5-(hydroxymethyl)oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H](CO)O1 FNEOHTTZLPHOSX-KZNAEPCWSA-N 0.000 description 1
- XJYQGNNBDGDYCE-DXBBTUNJSA-N (1r)-1-[(2r,5r)-5-[(1s)-1-hydroxypent-4-enyl]oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H]([C@@H](O)CCC=C)O1 XJYQGNNBDGDYCE-DXBBTUNJSA-N 0.000 description 1
- MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
- MXABZXILAJGOTL-AUYMZICSSA-N (2S)-N-[(2S)-1-[(2S)-1-[(2S,3S)-1-[(2S)-1-[2-[(2S)-1,3-dihydroxy-1-[(E)-1-hydroxy-1-[(2S,3S)-1-hydroxy-3-methyl-1-[[(2Z,6S,9S,12R)-5,8,11-trihydroxy-9-(2-methylpropyl)-6-propan-2-yl-1-thia-4,7,10-triazacyclotrideca-2,4,7,10-tetraen-12-yl]imino]pentan-2-yl]iminobut-2-en-2-yl]iminopropan-2-yl]imino-2-hydroxyethyl]imino-1,5-dihydroxy-5-iminopentan-2-yl]imino-1-hydroxy-3-methylpentan-2-yl]imino-1-hydroxy-3-methylbutan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[[(2S)-1-[(Z)-2-[[(2S)-2-(dimethylamino)-1-hydroxypropylidene]amino]but-2-enoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1-hydroxypropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1-hydroxypropylidene]amino]pentanediimidic acid Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@@H](\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)[C@H](C)\N=C(/O)[C@@H](\N=C(/O)\C(=C\C)\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)\C(=C\C)\N=C(/O)[C@H](C)\N=C(/O)[C@@H]1CCCN1C(=O)\C(=C\C)\N=C(/O)[C@H](C)N(C)C)C(C)C)C(C)C)C(\O)=N\[C@@H](CCC(O)=N)C(\O)=N\C\C(O)=N\[C@@H](CO)C(\O)=N\C(=C\C)\C(\O)=N\[C@@H]([C@@H](C)CC)C(\O)=N\[C@H]1CS\C=C/N=C(O)\[C@@H](\N=C(O)/[C@H](CC(C)C)\N=C1\O)C(C)C MXABZXILAJGOTL-AUYMZICSSA-N 0.000 description 1
- MRJQTLJSMQOFTP-JGTKTWDESA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 MRJQTLJSMQOFTP-JGTKTWDESA-N 0.000 description 1
- KJTPWUVVLPCPJD-VGOFMYFVSA-N (2e)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C/C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-VGOFMYFVSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2e,4e,6e)-7-[(1r,5r,6s)-3-[[(2e,4e)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2s)-2-[(3s,6s)-6-[2-[(1r,2r,4as,8as)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2s)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- RDIMTXDFGHNINN-UHFFFAOYSA-N (3R,9R,10R)-1-heptadecen-4,6-diyne-3,9,10-triol Natural products CCCCCCCC(O)C(O)CC#CC#CC(O)C=C RDIMTXDFGHNINN-UHFFFAOYSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3s,10r,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 description 1
- FRCJDPPXHQGEKS-BCHFMIIMSA-N (4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-2-(2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carboxamide Chemical compound C[C@H]1OC(=N[C@@H]1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-BCHFMIIMSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4as,12br)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- VTTMWBPZTZHGLU-IVSQCGTASA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-16-[(e)-1-[2-(hydroxymethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-5,5,7,9,13-pentamethyl-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(CO)=N1 VTTMWBPZTZHGLU-IVSQCGTASA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'r)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8r,9s,10r,13s,14s,16r)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- CNTMOLDWXSVYKD-PSRNMDMQSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound OC(=O)C(/C)=C/[C@H](C(C)C)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC)C(C)(C)C1=CC=CC=C1 CNTMOLDWXSVYKD-PSRNMDMQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- NUXKIZBEPYVRKP-RWBWKAGLSA-N 1xa5 Chemical compound O([C@]12[C@@H]3N(C)C4=C([C@]53CCN3CC=C[C@@]([C@@H]53)(CC)C2)C=C(C(=C4)OC)[C@]2(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C2)C[C@@](C3)(O)CC)C(=O)N(CCCl)C1=O NUXKIZBEPYVRKP-RWBWKAGLSA-N 0.000 description 1
- LNELBQZKXVASLW-AWEZNQCLSA-N 2,2,2-trifluoro-n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(=O)C(F)(F)F)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC LNELBQZKXVASLW-AWEZNQCLSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(e)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-n-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2h-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- JARCFMKMOFFIGZ-UHFFFAOYSA-N 4,6-dioxo-n-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide Chemical compound O=C1NC(=S)NC(=O)C1C(=O)NC1=CC=CC=C1 JARCFMKMOFFIGZ-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CTSNHMQGVWXIEG-UHFFFAOYSA-N 4-amino-n-(5-chloroquinoxalin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C(Cl)=CC=C2)C2=N1 CTSNHMQGVWXIEG-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N 4-hydroxyphenyl retinamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(e)-5-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VGULLEUAAMBZTQ-UHFFFAOYSA-N 5-desacetylaltohyrtin A Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C VGULLEUAAMBZTQ-UHFFFAOYSA-N 0.000 description 1
- DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- YHSMSRREJYOGQJ-UHFFFAOYSA-N 5-nonyloxytryptamine Chemical compound CCCCCCCCCOC1=CC=C2NC=C(CCN)C2=C1 YHSMSRREJYOGQJ-UHFFFAOYSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78nz2pmp25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N 8,10-dihydroimidazo[4,5-a]acridin-9-one Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- ZUZXYJOSNSTJMU-UHFFFAOYSA-N 9-cyclohexyl-2-n,6-n-bis[(4-methoxyphenyl)methyl]purine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C3CCCCC3)C2=N1 ZUZXYJOSNSTJMU-UHFFFAOYSA-N 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000035805 Aleukaemic leukaemia Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- NQGMIPUYCWIEAW-UHFFFAOYSA-N Antibiotic SF 2738 Natural products COc1cc(nc(C=NO)c1SC)-c1ccccn1 NQGMIPUYCWIEAW-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N Arg-Lys-Glu-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N Azatyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 101150084532 CD47 gene Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- DFDTZECTHJFPHE-UHFFFAOYSA-N Crambescidin 816 Natural products C1CC=CC(CC)OC11NC(N23)=NC4(OC(C)CCC4)C(C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)CC(O)CCN)C3(O)CCC2C1 DFDTZECTHJFPHE-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-UHFFFAOYSA-N Curacin A Natural products C=CCC(OC)CCC(C)=CC=CCCC=CC1CSC(C2C(C2)C)=N1 LUEYTMPPCOCKBX-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N Curacin A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- PQNNIEWMPIULRS-UHFFFAOYSA-N Cytostatin Natural products CC=CC=CC=CC(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- OALVLUFFPXEHFO-UHFFFAOYSA-N Diazonamide A Natural products O1C=2C34C(O)OC5=C3C=CC=C5C(C3=5)=CC=CC=5NC(Cl)=C3C(=C(N=3)Cl)OC=3C=2N=C1C(C(C)C)NC(=O)C(NC(=O)C(N)C(C)C)CC1=CC=C(O)C4=C1 OALVLUFFPXEHFO-UHFFFAOYSA-N 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- VQNATVDKACXKTF-UHFFFAOYSA-N Duocarmycin SA Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C(C64CC6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 241000725630 Ectromelia virus Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001197893 Glyptemys herpesvirus Species 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 241000557766 Guthriea Species 0.000 description 1
- 108010072471 HTI-286 Proteins 0.000 description 1
- ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 101150076998 ICP34.5 gene Proteins 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 108700022013 Insecta cecropin B Proteins 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- ZHTRILQJTPJGNK-FYBAATNNSA-N Leinamycin Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
- ZHTRILQJTPJGNK-UHFFFAOYSA-N Leinamycin Natural products C1CC(C)=CC(O)C(=O)C=CC=CC(N=2)=CSC=2C(C)NC(=O)CC21S(=O)SC(=O)C2(C)O ZHTRILQJTPJGNK-UHFFFAOYSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- LMVRPBWWHMVLPC-KBPJCXPTSA-N Leptolstatin Natural products CC(CC=CC(=CC(C)C(=O)C(C)C(O)C(C)CC(=CCO)C)C)C=C(C)/C=C/C1CC=CC(=O)O1 LMVRPBWWHMVLPC-KBPJCXPTSA-N 0.000 description 1
- 206010053180 Leukaemia cutis Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- BLOFGONIVNXZME-UHFFFAOYSA-N Mannostatin A Natural products CSC1C(N)C(O)C(O)C1O BLOFGONIVNXZME-UHFFFAOYSA-N 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108700021154 Metallothionein 3 Proteins 0.000 description 1
- 102100028708 Metallothionein-3 Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100533558 Mus musculus Sipa1 gene Proteins 0.000 description 1
- HFPXYDFQVINJBV-UHFFFAOYSA-N Mycaperoxide B Natural products O1OC(C(C)C(O)=O)CCC1(C)CCC1(O)C2(C)CCCC(C)(C)C2CCC1C HFPXYDFQVINJBV-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 1
- GTEXXGIEZVKSLH-UHFFFAOYSA-N Naphterpin Natural products O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1C1C=C(C)CCC1C(C)(C)O2 GTEXXGIEZVKSLH-UHFFFAOYSA-N 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- BUSGWUFLNHIBPT-UHFFFAOYSA-N Nisamycin Natural products O=C1C2OC2C(C=CC=CC=CC(=O)O)(O)C=C1NC(=O)C=CC=CC1CCCCC1 BUSGWUFLNHIBPT-UHFFFAOYSA-N 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- WQLDJUQUFZDTSD-XXODBJNXSA-N O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 WQLDJUQUFZDTSD-XXODBJNXSA-N 0.000 description 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- VTAZRSXSBIHBMH-UHFFFAOYSA-N Ophiocordin Natural products OC1=CC(C(=O)O)=CC(O)=C1C(=O)C1=C(O)C=CC=C1C(=O)NC1C(OC(=O)C=2C=CC(O)=CC=2)CCCNC1 VTAZRSXSBIHBMH-UHFFFAOYSA-N 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- LKBBOPGQDRPCDS-UHFFFAOYSA-N Oxaunomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(O)C(CC)(O)CC1OC1CC(N)C(O)C(C)O1 LKBBOPGQDRPCDS-UHFFFAOYSA-N 0.000 description 1
- VYOQBYCIIJYKJA-UHFFFAOYSA-N Palauamine Natural products C1N2C(=O)C3=CC=CN3C3N=C(N)NC32C2C1C(CN)C(Cl)C12NC(N)=NC1O VYOQBYCIIJYKJA-UHFFFAOYSA-N 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- FRCJDPPXHQGEKS-UHFFFAOYSA-N Parabactin Natural products CC1OC(=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-UHFFFAOYSA-N 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- APNRZHLOPQFNMR-UHFFFAOYSA-N Phenazinomycin Natural products C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1CC=C(C)CCC1C(=C)CCCC1(C)C APNRZHLOPQFNMR-UHFFFAOYSA-N 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- PICZCWCKOLHDOJ-UHFFFAOYSA-N Pseudoaxinellin Natural products N1C(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C1CC1=CC=CC=C1 PICZCWCKOLHDOJ-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 101150027249 RL1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N Sarcophytol A Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- 241001632234 Senecavirus Species 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- GCEUCUGYUPYUEC-UHFFFAOYSA-N Spongistatin 3 Natural products COC1CC2CC(=O)C(C)C(OC(=O)C)C(C)C(=C)CC3CC(C)(O)CC4(CCCC(CC(=O)OC5C(C)C(OC(CC(=C)CC(O)C=CC(=C)Cl)C5O)C(O)C6(O)CC(O)C(C)C(CCCC=C/C7CC(O)CC(C1)(O2)O7)O6)O4)O3 GCEUCUGYUPYUEC-UHFFFAOYSA-N 0.000 description 1
- JOEPUFOWFXWEDN-UHFFFAOYSA-N Spongistatin 5 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 JOEPUFOWFXWEDN-UHFFFAOYSA-N 0.000 description 1
- BTCJGYMVVGSTDN-UHFFFAOYSA-N Spongistatin 7 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 BTCJGYMVVGSTDN-UHFFFAOYSA-N 0.000 description 1
- GLMCWICCTJHQKE-UHFFFAOYSA-N Spongistatin 9 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 GLMCWICCTJHQKE-UHFFFAOYSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- PTTJLTMUKRRHAT-VJAKQJMOSA-N Taccalonolide A Chemical compound C([C@@H]1C(=O)[C@@H]2O)[C@@H]3O[C@@H]3[C@H](OC(C)=O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2[C@@H](OC(C)=O)[C@H]3[C@@]4(C)[C@](C)(O)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]2(C)[C@@H](OC(C)=O)[C@H]1OC(C)=O PTTJLTMUKRRHAT-VJAKQJMOSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- WXZSUBHBYQYTNM-UHFFFAOYSA-N Tetrazomine Natural products C1=CC=2CC(N34)C(N5C)C(CO)CC5C4OCC3C=2C(OC)=C1NC(=O)C1NCCCC1O WXZSUBHBYQYTNM-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 1
- IBEDDHUHZBDXGB-UHFFFAOYSA-N Tubulysin A Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC(O)=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C IBEDDHUHZBDXGB-UHFFFAOYSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 101710183617 Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-VRSYWUPDSA-N [(1s,2e,7s,10e,12r,13r,15s)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-VRSYWUPDSA-N 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- VQSGYKUTGGRSPK-SIOACEIBSA-N [(3s,4s,7s)-2-[3-[(2s,5s,8s,11s,14r,17r,20s,23r,26r)-11,14-bis(2-amino-2-oxoethyl)-5,20-bis[(1r)-1-hydroxyethyl]-8-methyl-17,23-bis(2-methylpropyl)-26-octyl-3,6,9,12,15,18,21,24,27-nonaoxo-1,4,7,10,13,16,19,22,25-nonazacycloheptacos-2-yl]propyl]-5-chloro- Chemical compound N1C(=O)[C@@H](CCCCCCCC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1[C@@]2(OCCC2)[C@@H](O)C2=C(Cl)C(=O)[C@@](C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-SIOACEIBSA-N 0.000 description 1
- IVCRCPJOLWECJU-XQVQQVTHSA-N [(7r,8r,9s,10r,13s,14s,17s)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 IVCRCPJOLWECJU-XQVQQVTHSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8e,10e,12e)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950000616 acronine Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- HLAKJNQXUARACO-UHFFFAOYSA-N acylfulvene Natural products CC1(O)C(=O)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- WJSAFKJWCOMTLH-UHFFFAOYSA-N adecypenol Natural products OC1C(O)C(CO)=CC1N1C(NC=NCC2O)=C2N=C1 WJSAFKJWCOMTLH-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229950010949 ambamustine Drugs 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010055530 arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide Proteins 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 229950006933 atrimustine Drugs 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- UZCPCRPHNVHKKP-UHFFFAOYSA-N axinastatin 2 Natural products CC(C)CC1NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC(=O)C(NC1=O)C(C)C)C(C)C UZCPCRPHNVHKKP-UHFFFAOYSA-N 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- RTGMQVUKARGBNM-UHFFFAOYSA-N axinastatin 3 Natural products CCC(C)C1NC(=O)C(CC(C)C)NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC1=O)C(C)C RTGMQVUKARGBNM-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 150000004200 baccatin III derivatives Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229950002370 bisnafide Drugs 0.000 description 1
- NPSOIFAWYAHWOH-UHFFFAOYSA-N bistratene A Natural products O1C(CC(=O)C=CC)CCC(O2)(O)CC(C)C2CCCNC(=O)C(C)C2OC(CCC(C)C=C(C)C(C)O)CCCCC(C)C1CC(=O)NC2 NPSOIFAWYAHWOH-UHFFFAOYSA-N 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229950002361 budotitane Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- WIUSFZNUZWLLDZ-UHFFFAOYSA-N caribaeolin Natural products C1=CC(OC)(C(=CC2C(C(C=CC2C(C)C)(C)O)C2)COC(C)=O)OC1(C)C2OC(=O)C=CC1=CN(C)C=N1 WIUSFZNUZWLLDZ-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-UHFFFAOYSA-N caribaeoside Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(C=CC1C(C)C)(C)O)C1C=C2COC1OCC(O)C(O)C1OC(C)=O KGOMYXIKIJGWKS-UHFFFAOYSA-N 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- BZXULYMZYPRZOG-UHFFFAOYSA-N centaureidin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 BZXULYMZYPRZOG-UHFFFAOYSA-N 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N chembl118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-DKNGGRFKSA-N chembl1916173 Chemical compound C(/[C@H]1[C@H]([C@](C=C[C@@H]1C(C)C)(C)O)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O KGOMYXIKIJGWKS-DKNGGRFKSA-N 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- DCKFXSZUWVWFEU-JECTWPLRSA-N chembl499423 Chemical compound O1[C@@H](CC)CCCC[C@]11NC(N23)=N[C@]4(O[C@H](C)CCC4)[C@@H](C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)C[C@@H](O)CCN)[C@@]3(O)CC[C@H]2C1 DCKFXSZUWVWFEU-JECTWPLRSA-N 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 108010076060 chlorofusin Proteins 0.000 description 1
- VQSGYKUTGGRSPK-UHFFFAOYSA-N chlorofusin Natural products N1C(=O)C(CCCCCCCC)NC(=O)C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C1CCCN1C2(OCCC2)C(O)C2=C(Cl)C(=O)C(C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- 229950000634 cicaprost Drugs 0.000 description 1
- 229950011359 cirolemycin Drugs 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229950007258 crisnatol Drugs 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- YFGZFQNBPSCWPN-UHFFFAOYSA-N cryptophycin 52 Natural products C1=CC(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 YFGZFQNBPSCWPN-UHFFFAOYSA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- PESYEWKSBIWTAK-UHFFFAOYSA-N cyclopenta-1,3-diene;titanium(2+) Chemical compound [Ti+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 PESYEWKSBIWTAK-UHFFFAOYSA-N 0.000 description 1
- YXQWGVLNDXNSJJ-UHFFFAOYSA-N cyclopenta-1,3-diene;vanadium(2+) Chemical compound [V+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YXQWGVLNDXNSJJ-UHFFFAOYSA-N 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N cytarabine ocfosfate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- YCWXIQRLONXJLF-PFFGJIDWSA-N d06307 Chemical compound OS(O)(=O)=O.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC YCWXIQRLONXJLF-PFFGJIDWSA-N 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- WRPLJTYNAMMOEE-TXILBGFKSA-N desmethyleleutherobin Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(CO[C@H]2[C@H]([C@H](O)[C@H](O)CO2)OC(C)=O)/[C@]2(O)O[C@@]1(C)C=C2)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 WRPLJTYNAMMOEE-TXILBGFKSA-N 0.000 description 1
- WRPLJTYNAMMOEE-UHFFFAOYSA-N desmethyleleutherobin Natural products C1=CC2(C)OC1(O)C(COC1C(C(O)C(O)CO1)OC(C)=O)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 WRPLJTYNAMMOEE-UHFFFAOYSA-N 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 229950005878 dexverapamil Drugs 0.000 description 1
- 229950010621 dezaguanine Drugs 0.000 description 1
- YKBUODYYSZSEIY-PLSHLZFXSA-N diazonamide a Chemical compound N([C@H]([C@]12C=3O4)O5)C6=C2C=CC=C6C(C2=6)=CC=CC=6NC(Cl)=C2C(=C(N=2)Cl)OC=2C=3N=C4[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CC2=CC=C5C1=C2 YKBUODYYSZSEIY-PLSHLZFXSA-N 0.000 description 1
- KYHUYMLIVQFXRI-UHFFFAOYSA-N didemnin B Natural products CC1OC(=O)C(CC=2C=CC(OC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C(C)C(=O)C(C(C)C)OC(=O)CC(O)C(C(C)CC)NC(=O)C1NC(=O)C(CC(C)C)N(C)C(=O)C1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-UHFFFAOYSA-N 0.000 description 1
- 108010061297 didemnins Proteins 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- CZLKTMHQYXYHOO-QTNFYWBSSA-L disodium;(2s)-2-[(2-phosphonatoacetyl)amino]butanedioic acid Chemical compound [Na+].[Na+].OC(=O)C[C@@H](C(O)=O)NC(=O)CP([O-])([O-])=O CZLKTMHQYXYHOO-QTNFYWBSSA-L 0.000 description 1
- SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005510 duocarmycin SA Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229950005678 ecomustine Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229950011461 edelfosine Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- HYSIJEPDMLSIQJ-UHFFFAOYSA-N ethanolate;1-phenylbutane-1,3-dione;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)[CH-]C(=O)C1=CC=CC=C1.CC(=O)[CH-]C(=O)C1=CC=CC=C1 HYSIJEPDMLSIQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl n-[4-[[(2r,4r)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229950006000 flezelastine Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950004217 forfenimex Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 229950010404 fostriecin Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229950009926 idramantone Drugs 0.000 description 1
- 229950006905 ilmofosine Drugs 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 229940091204 imlygic Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229960003795 iobenguane (123i) Drugs 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- 229950000855 iroplact Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229950010984 irsogladine Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 229950007654 itasetron Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- RBBBWKUBQVARPL-UHFFFAOYSA-N lissoclinamide 7 Natural products N1C(=O)C(N=2)CSC=2C(CC=2C=CC=CC=2)NC(=O)C(N=2)CSC=2C(C(C)C)NC(=O)C(C(O2)C)N=C2C2CCCN2C(=O)C1CC1=CC=CC=C1 RBBBWKUBQVARPL-UHFFFAOYSA-N 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 108091005452 macrophage Fc receptors Proteins 0.000 description 1
- 229950001474 maitansine Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N mannostatin A Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108700025096 meterelin Proteins 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- BDXPYXUQAYIUFG-UHFFFAOYSA-N methyl 3,5-diiodo-4-(4-methoxyphenoxy)benzoate Chemical compound IC1=CC(C(=O)OC)=CC(I)=C1OC1=CC=C(OC)C=C1 BDXPYXUQAYIUFG-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N metoprine, methodichlorophen Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950008541 mirimostim Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 mitindomide Drugs 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 229950008012 mofarotene Drugs 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- JNGQUJZDVFZPEN-UHFFFAOYSA-N n-[[4-(5-bromopyrimidin-2-yl)oxy-3-methylphenyl]carbamoyl]-2-(dimethylamino)benzamide Chemical compound CN(C)C1=CC=CC=C1C(=O)NC(=O)NC(C=C1C)=CC=C1OC1=NC=C(Br)C=N1 JNGQUJZDVFZPEN-UHFFFAOYSA-N 0.000 description 1
- UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 229950010676 nartograstim Drugs 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229940125745 nitric oxide modulator Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 osaterone Drugs 0.000 description 1
- ODHHTIYRUDURPW-UHFFFAOYSA-N ottelione A Natural products C1=C(O)C(OC)=CC=C1CC1C(C(=O)C=CC2=C)C2C(C=C)C1 ODHHTIYRUDURPW-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- ZCKMUKZQXWHXOF-UHFFFAOYSA-N panaxytriol Natural products CCC(C)C(C)C(C)C(C)C(C)C(O)C(O)CC#CC#CC(O)C=C ZCKMUKZQXWHXOF-UHFFFAOYSA-N 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229950003440 panomifene Drugs 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005547 pelareorep Drugs 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950000039 peldesine Drugs 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- LCADVYTXPLBAGB-GNCBHIOISA-N phenalamide A1 Natural products CC(CO)NC(=O)C(=CC=CC=C/C=C/C(=C/C(C)C(O)C(=CC(C)CCc1ccccc1)C)/C)C LCADVYTXPLBAGB-GNCBHIOISA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 108700033545 romurtide Proteins 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 1
- YADVRLOQIWILGX-UHFFFAOYSA-N sarcophytol N Natural products CC(C)C1=CC=C(C)CCC=C(C)CCC=C(C)CC1O YADVRLOQIWILGX-UHFFFAOYSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229950004296 soblidotin Drugs 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229950004225 sonermin Drugs 0.000 description 1
- 229950004796 sparfosic acid Drugs 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- YBZRLMLGUBIIDN-NZSGCTDASA-N spicamycin Chemical compound O1[C@@H](C(O)CO)[C@H](NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1N=CN2 YBZRLMLGUBIIDN-NZSGCTDASA-N 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N spicamycin Natural products O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- DTFYGLNONOLGOT-UHFFFAOYSA-N spongistatin 2 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC=C)OC1C2C DTFYGLNONOLGOT-UHFFFAOYSA-N 0.000 description 1
- VGULLEUAAMBZTQ-YGHPZBLNSA-N spongistatin 3 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](OC(C)=O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C VGULLEUAAMBZTQ-YGHPZBLNSA-N 0.000 description 1
- KRUKGDRIKMPUNX-JWFNSJLHSA-N spongistatin 4 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C KRUKGDRIKMPUNX-JWFNSJLHSA-N 0.000 description 1
- KRUKGDRIKMPUNX-UHFFFAOYSA-N spongistatin 4 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C KRUKGDRIKMPUNX-UHFFFAOYSA-N 0.000 description 1
- GQOOASKKXHUNEJ-PYATXCCJSA-N spongistatin 6 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C=C)OC1[C@@H]2C GQOOASKKXHUNEJ-PYATXCCJSA-N 0.000 description 1
- WYJXOZQMHBISBD-UHFFFAOYSA-N spongistatin 8 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 WYJXOZQMHBISBD-UHFFFAOYSA-N 0.000 description 1
- RSHMLTSGIURLKH-SJMMKZBFSA-N spongistatin-2 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C=C)O[C@@H]2[C@@H]1C RSHMLTSGIURLKH-SJMMKZBFSA-N 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 201000010033 subleukemic leukemia Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- PTTJLTMUKRRHAT-KYDPQNDISA-N taccalonolide A Natural products O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H]2[C@]3(C)[C@H](OC(=O)C)[C@H]4O[C@H]4C[C@@H]3C(=O)[C@H](O)[C@H]2[C@@H]2[C@@H](OC(=O)C)[C@H]3[C@@]4(C)[C@@](O)(C)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]12C)C PTTJLTMUKRRHAT-KYDPQNDISA-N 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 229950005667 tallimustine Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229950010168 tauromustine Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 229950003046 tesevatinib Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-UHFFFAOYSA-N thaliblastine Natural products CN1CCC2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC2=C(CC3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-UHFFFAOYSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- UPGGKUQISSWRJJ-UHFFFAOYSA-N thiocoraline Natural products CN1C(=O)CNC(=O)C(NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)CSC(=O)C(CSC)N(C)C(=O)C(N(C(=O)CNC2=O)C)CSSCC1C(=O)N(C)C(CSC)C(=O)SCC2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-UHFFFAOYSA-N 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 108010013515 thymopoietin receptor Proteins 0.000 description 1
- 229950010183 thymotrinan Drugs 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- ONYVJPZNVCOAFF-UHFFFAOYSA-N topsentin Natural products Oc1ccc2cc([nH]c2c1)C(=O)c3ncc([nH]3)c4c[nH]c5ccccc45 ONYVJPZNVCOAFF-UHFFFAOYSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 238000011247 total mesorectal excision Methods 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 108010061145 tubulysin A Proteins 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 turosteride Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229950008261 velaresol Drugs 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- XLQGICHHYYWYIU-UHFFFAOYSA-N veramine Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CC=C3C2(C)C(C)C21CCC(C)CN2 XLQGICHHYYWYIU-UHFFFAOYSA-N 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000000316 virotherapy Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 108010079700 vitilevuamide Proteins 0.000 description 1
- UFOVYHGILLJGLP-UHFFFAOYSA-N vitilevuamide Chemical compound N1C(=O)C(NC(=O)CCC(O)=O)CSCC(C(NC(C(=O)NC(=C)C(=O)NC(CC(C)CC)C(=O)NC(C(=O)N(C)C(C(O)COC)C(=O)NC(CO)C(=O)OC2C)C(C)C)C(C)CC)=O)NC(=O)C3CCCN3C(=O)C(CC=3C=CC=CC=3)NC(=O)C2NC(=O)C(CC(C)CC)NC(=O)C(C)NC(=O)C1CC1=CC=CC=C1 UFOVYHGILLJGLP-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- DVPVGSLIUJPOCJ-XXRQFBABSA-N x1j761618a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVPVGSLIUJPOCJ-XXRQFBABSA-N 0.000 description 1
- 229950005561 zanoterone Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- SEQUENCE_LISTING_ST25.TXT created on February 5, 2021, 11,491 bytes, machine format IBM-PC, MS Windows operating system, is hereby incorporated by reference.
- Oncolytic viral (OV) therapy has been recognized as a promising approach for cancer treatment. It differs from traditional gene therapy where a viral vector serves for delivery of a specific gene. OV therapy utilizes the virus itself as an immune stimulatory agent that can also selectively replicate in tumor cells resulting in their lysis without harming normal tissues.
- the concept of OV therapy has existed for decades. OV therapy is effective at treating preclinical models of brain tumors with a genetically engineered herpes simplex virus type I (HSV-1) containing a mutation in the thymidine kinase ( ⁇ K) gene. This encouraged researchers to further modify the viral genome to design an oncolytic HSV-1 (oHSV). Over the past two decades, it has been established that oHSV can boost systemic immunity and therefore the anti-tumor immune response.
- HSV-1 herpes simplex virus type I
- GBM Glioblastoma
- chemo- and radiotherapy are the most common and aggressive primary malignant brain tumor.
- GBM patients who undergo the standard of care, including surgical resection, chemotherapy and radiotherapy have a median survival of only approximately 15 months. Due to the early infiltrative nature of the disease, a complete surgical resection of GBM is largely unachievable.
- the intrinsic resistance of GBM to the chemo- and radiotherapy also contributes to the poor clinical outcomes. Given these attributes, new therapeutic agents are urgently needed for to improve the median survival. (See, for example, Ref. 1). Provided herein are solutions to these and other problems in the art.
- Ovarian cancer is the most lethal gynecological malignancies (see, for example, Refs. 44-47). Although a lot of efforts have been made for improving the treatment of ovarian cancer by more aggressive surgical approaches and the introduction of more effective chemotherapy, the 5-year overall survival for the advanced ovarian cancer is approximately 30%. Increasing evidence, from preclinical and clinical data, indicates that immunotherapy approaches that harness and enhance antitumor effector cells, such as immune checkpoint blockade therapy and tumor specific monoclonal antibody therapy, have led to clinical benefits for ovarian cancer (see, for example, Ref. 48).
- CD47 was first identified as a tumor antigen on human ovarian cancer in the 1980s (see, for example, Refs. 49-50). CD47 overexpression is found to be associated with poor prognosis in ovarian cancer (see, for example, Refs. 51-52). CD47 provides a “do not eat” signal by binding to its receptor, signal regulatory protein alpha (SIRPa) on macrophages and suppresses the phagocytosis (see, for example, Refs. 53-54). Targeting CD47 therapy has been proven as an effective treatment for ovarian cancer, with several clinical trials (see, for example, Refs. 51, 55, 56).
- SIRPa signal regulatory protein alpha
- antibody drugs such as intravenous (i.v.), subcutaneous (s.c.), or intramuscular (i.m.) administration result in limited tumor tissue distribution of the antibodies, but leave most of the administrated antibodies remaining in the peripheral circulatory system that leads to side effects (see, for example, Refs. 57-58).
- a recombinant oncolytic virus including an expression cassette encoding an anti-CD47 antibody.
- a recombinant oncolytic virus including a nucleic acid encoding an anti-CD47 antibody.
- a pharmaceutical composition including a recombinant oncolytic virus as described herein, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition further includes an anti-cancer agent.
- a combination therapy including a pharmaceutical composition that includes a recombinant oncolytic herpes simplex virus as described herein and an anticancer agent.
- the anti-cancer agent is a checkpoint inhibitor.
- a method for killing tumor cells in a subject including administering to a subject an effective amount of the recombinant oncolytic virus according to any embodiment as described herein. In an aspect, the method further includes administering to a subject an anti-cancer agent.
- a method of treating cancer to a subject in need including administering to the subject an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- the method further includes administering to a subject an anti cancer agent.
- FIGS. 1A-1E depict construction and characterization of OV-Q1, OV-Hu5F9-Gl and OV-Hu5F9-G4 (Hu5F9 also known as aCD47 (alpha-CD47) throughout this specification).
- FIG. 1A shows a schematic map of oncolytic viruses used in this study. Top: genetic map of wild type HSV-1. Second: genetic map of control oHSV, OV-Q1, with deletion of two copies of g34.5, dysfunction of ICP6, and insertion of the GFP gene. Third: genetic map of OV-Hu5F9-Gl showing the inserted coding gene of IgGl version of anti-CD47 (aCD47-Gl) that is constructed on human IgGl scaffold.
- the light chain and heavy chain coding genes of aCD47-Gl are linked by a T2A sequences and are driven by the viral pIE4/5 promoter.
- FIG. IB shows immunoblotting performed with concentrated supernatants of engineered CHO cells and oHSV-infected U251T2 cells. Lentiviral-infected CHO cells (CHO-aCD47-Gl and CHO-aCD47-G4) were used to produce pure aCD47-Gl and aCD47-G4.
- FIG. 1C shows that human CD47 binding affinity of aCD47-Gl and aCD47-G4 were tested by flow cytometry assay. Stained cells were tested on flow cytometry, aCD47-Gl and aCD47-G4 both showed dose-dependent increase on APC signal.
- FIG. IE shows that aCD47-Gl and aCD47-G4 yields of OV-aCD47-Gl- and OV- aCD47-G4-infected GBM cells were tested by ELISA assay.
- FIGS. 2A-2D demonstrate viral production and infectivity of OV-aCD47-Gl and OV- aCD47-G4.
- FIG. 2A shows that U251T2 and Gli36AEGFR cells were infected with OV-Q1, OV- aCD47-Gl or OV-aCD47-G4 at the indicated MOIs. Cell survival was analyzed at 5 days after infection by CCK8 assay. The dose response curves were established for each virus to calculate the viral Lethal Dose 50 (LD50, pfu/mL).
- FIG. 2B shows that U251T2 and Gli36AEGFR cells were infected with OV-Q1, OV-aCD47-Gl or OV-aCD47-G4 at a MOI of 3. The supernatants were harvested at indicated time points and checked for viral reproduction using a plaque assay in Vero cells.
- FIG. 2C shows that OV-aCD47-Gl and OV-aCD47-G4-infected U251T2 GBM cells (Fig. 2C) produce similar amounts of oHSV when compared to the same GBM cells infected with the parental oHSV OV-Q1.
- FIG. 2D shows that OV-aCD47-Gl and OV-aCD47-G4-infected Gli36 GBM cells (FIG. 2D) produce similar amounts of oHSV when compared to the same GBM cells infected with the parental oHSV OV-Q1. Therefore, engineering oHSV to infect GBM with Hu5F9-Gl or Hu5F9-G4 did not affect their oncolysis or viral production.
- FIGS. 3A-3H demonstrate aCD47-Gl and aCD47-G4 induce phagocytosis of GMB cells by macrophages.
- FIGS. 3A-3D show examination of the effect of aCD47-Gl and aCD47- G4 purified from CHO cells on phagocytosis of GBM cells by bone-marrow-derived-macrophages (BMDM).
- BMDM bone-marrow-derived-macrophages
- 3D cells were labeled with CFSE and co-cultured with BMDM at the ratio of 1:2 in the presence of control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml.
- Percentage of BMDM uptake of labeled tumor cells (CD1 lb+ and CFSE+) were measured by flow cytometry assay to evaluate the phagocytosis rates.
- FIGS. 3E-3F show conditional media of OV-aCD47-Gl- and OV- OV-aCD47-G4-infected GBM cells induce phagocytosis of GBM cells by BMDM.
- GBM43 and BT422 cells were labeled with CFSE and co-cultured with BMDM at the ratio of 1:2 in the presence of supernatants from OV-Q1, OV- aCD47-Gl- or OV-aCD47-G4 infected U251T2 cells that were collected at 24 hours after infection.
- Percentage of BMDM uptake of labeled tumor cells (CDllb+ and CFSE+) were measured by flow cytometry assay to evaluate the phagocytosis rates.
- FIG. 3G shows results from phagocytosis assay performed with Fc receptor blocking.
- FIG. 3H shows cytokine gene transcription assay results.
- FIGS. 4A-4E demonstrate aCD47-Gl but not aCD47-G4 induces cytotoxicity of human NK cells against GBM cells.
- FIGS. 4A-4B show cytotoxicity of human primary NK cells against aCD47-Gl- and aCD47-G4-treated GBM43 (FIG. 4A) and BT422 (FIG. 4B) cells at the effectortarget ratios of 40:1, 20:1 and 10:1.
- FIG. 4C shows cytotoxicity of human primary NK cells against GBM43 cells that were treated with conditional medium from OV-Q1-, OV-aCD47- Gl- or OV-aCD47-G4-infected U251T2 cells.
- FIG. 4D shows that aCD47-Gl but not aCD47-G4 induces expression of the NK cell activation marker CD69 when co-cultured with GBM43 cells that were pretreated with aCD47-Gl or aCD47-G4.
- FIG. 4E is a graphical representation of the data in Fig. 4D.
- FIGS. 5A-5E shows a comparison of the effectiveness of OV-aCD47-Gl versus OV- aCD47-G4 to improve in vivo oncolytic virotherapy of GBM in an orthotopic model of human GBM.
- FIG. 5A shows experimental timeline for in vivo studies.
- An orthotopic model of human GBM was established by i.c. injection of 1 x 10 5 GBM43-FFL human GBM cells into athymic nude mice. Seven days later, mice were intratumorally injected with a vehicle control or 2 c 10 5 PFU of OV-Q1, OV-aCD47-Gl, or OV-aCD47-G4.
- FIG. 5B shows time-lapse luciferase imaging of GBM43-FLL GMB mice with indicated treatments.
- FIG. 5C shows survival of GBM43 tumor-bearing mice treated with OV-Q1, OV- aCD47-Gl, OV-aCD47-G4 or vehicle control.
- FIG. 5D shows individual body weights recorded in mice treated on the experimental study.
- FIGS. 6A-6D demonstrate OV-aCD47-Gl is safer and more effective than the combination of OV-Q1 and i.p. administrated aCD47-Gl.
- FIG. 6A shows experimental timeline for in vivo studies. Xenograft GBM mouse models were established by intracranially injecting 1 c 10 5 GBM43-FLL cells to athymic nude mice. Fourteen days later, mice were intratumorally injected with 2 c 10 5 PFU of OV-Q1, OV-aCD47-Gl or vehicle. The group of OV-Ql-plus- Hu5F9-Gl received i.p.
- FIG. 6B shows survival of GBM43 tumor-bearing mice treated with OV-Q1, OV-Q1 plus aCD47-Gl, OV-aCD47-Gl, or vehicle control as indicated in FIG. 6A.
- FIG. 6C shows experimental timeline for in vivo studies. Xenograft GBM mouse models were established by intracranially injecting 1 c 10 5 GBM43 cells to athymic nude mice. Twenty-one days later, mice were intratumorally injected with 2 c 10 5 PFU of OV-Q1, OV-aCD47-Gl or vehicle.
- FIG. 6D shows that the plasma concentration of aCD47-Gl in different groups were measured by ELISA assay.
- FIGS. 7A-7B are graphs showing dose-dependent binding.
- FIG. 7A show IgGl and IgG4 versions of anti-CD47 (aCD47) both exhibit dose-dependent binding affinity to CD47 positive cells.
- FIG. 7B shows that IgGl and IgG4 versions of anti-CD47 (aCD47) both block the binding sites of CD47 in a dose-dependent manner.
- FIGS. 8A-8D show that aCD47-Gl but not aCD47-G4 induces cytotoxicity of human NK cells against GBM cells.
- FIG. 8A shows cytotoxicity of human primary NK cells against Gli36AEGFR human GBM cells pretreated with different doses of aCD47-Gl or aCD47-G4 for 20 min. The NK cells were added to the pre-treated GBM cells without washing at the effectortarget ratios of 40: 1, 20: 1 and 10:1 in a 51 Cr release assay.
- FIG. 8A shows cytotoxicity of human primary NK cells against Gli36AEGFR human GBM cells pretreated with different doses of aCD47-Gl or aCD47-G4 for 20 min. The NK cells were added to the pre-treated GBM cells without washing at the effectortarget ratios of 40: 1, 20: 1 and 10:1 in a 51 Cr release assay.
- FIG. 8B shows cytotoxicity of primary human NK cells against aCD47-Gl- and aCD47-G4-pretreated three human GBM lines: GBM30, U251T2 and LN229.
- FIG. 8C shows aCD47-Gl but not aCD47-G4 induced the expression of the NK cell activation marker CD69.
- GBM30 or U251T2 human GBM cells that were pretreated with aCD47-Gl or aCD47-G4 at the concentration of 1 pg/ml and then co-cultured with primary human NK cells at a ratio of 1 : 1 for 4 hours.
- FIG. 8D shows a statistic summary of the data provided in FIG. 8C.
- the bars left to right in top panel are NK + GBM30, NK + GBM30 + aCD47-Gl, NK+ GBM30 + aCD47-G4.
- the bars left to right in bottom panel areNK + U251T2, NK + U251T2 + oCD47-Gl, NK + U251T2 + aCD47-G4.
- Experiments in FIG. 8C and FIG. 8D were repeated with primary NK cells isolated from 4 different donors with similar results. All experiments were performed with four donors in triplicate. Error bars represent standard deviations of means of four donors.
- FIG. 9 shows percentage of BMDM phagocytosis of GBM43 cells (CDllb+CFSE+) assayed by flow cytometry.
- BMDM were incubated with vehicle control or human IgGl at the dose of 10 pg/ml for 30 min prior to co-culture with GBM43 cells in the presence of increasing aCD47-Gl for 2 hours.
- FIG. 10 shows expression levels of Argl, Ccl2, Illb, 116, 1110, 1112b, and Nos2 where BMDM were cocultured with GBM43 cells at a ratio of 1 : 1 with or without aCD47-Gl or aCD47-G4 for 6 hours.
- FIG. 11 shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of GBM43 cells by primary human macrophages.
- FIG. 12 shows shows the effect of conditioned media from OV-aCD47-Gl- and OV- aCD47-G4-infected U251T2 human GBM cells on phagocytosis of GBM43 cells by primary human macrophages.
- FIGS. 13A-13B show the effect of coculturing primary human macrophages with GBM43 cells at a ratio of 1 : 1 with or without aCD47-Gl or aCD47-G4 (bars left to right for each indicated transcript is without antibody, with aCD47-Gl, or with aCD47-G4, correspondingly) for 6 hours on transcription of IL1B, IL6, IL10, NOS2 (FIG. 13A) and IL12A (FIG. 13B).
- FIG. 14 shows an experimental timeline for in vivo studies using an orthotopic model of human GBM.
- Groups 2, 3 and 4 received intracranial injection of oHSV (OV-Q1 or OV-aCD47-Gl) at a dose of 2 c 10 5 PFU per mouse on day 21.
- Group 1 received saline as control.
- Group 3 received i.p. injection of purified aCD47-Gl at the dose of 150 pg per mouse.
- Groups 1, 2, and 4 received i.p. injection of saline as control. All mice were euthanized on day 23 for blood and brain harvesting.
- FIGS. 15A-15C shows OV-aCD47-Gl is effective for locoregional delivery of the anti-CD47 antibody, while systemic administration of aCD47-Gl is not effective.
- FIG. 15A shows the concentration of aCD47-Gl in plasma was measured by ELISA in mice from different treatments. The columns left to right are saline, OV-Q1, OV-Q1 plus aCD47-Gl, and OV- aCD47-Gl.
- FIG. 15C shows slides from the brain tissues isolated from experimental mice were subjected to H&E and immunohistochemical staining, the latter with anti-HSV, anti-human Fc, which identifies IgG, anti-CDllb or anti-NKp46 antibodies. Images with high and low magnifications are shown in FIG. 15B and FIG. 15C, respectively. The boxed images in FIG. 15B are shown in higher power in FIG. 15C. Data presented are represented of one (FIG. 15B and FIG. 15C) or three (FIG. 15A) mice of at least three mice in total with similar data. Error bars (FIG. 15A) represent standard deviations of means of three mice.
- FIG. 16 shows an experimental timeline for in vivo studies using an orthotopic model of human GBM.
- mice were implanted with 1 c 10 5 GBM43 cells i.c..
- Groups 2, 3 and 4 received intratumoral injection of oHSV (OV-Q1 or OV-aCD47-Gl) at a dose of 2 x 10 5 PFU per mouse on day 21.
- Group 1 received saline as control.
- Group 3 received i.p. injection of purified aCD47-Gl at the dose of 150 pg per mouse per day.
- Groups 1, 2, and 4 received i.p. injections of saline as control. All mice were euthanized on day 25 for blood and brain harvesting.
- FIGS. 17A-17C shows that OV-aCD47-Gl infection continuously delivers anti-CD47 antibody to the tumor microenvironment, while systemic infusion of aCD47-Gl does not.
- concentration of aCD47-Gl in plasma was measured by ELISA in mice from different treatments (FIG. 17A).
- the columns left to right are saline, OV-Q1, OV-Q1 plus aCD47-Gl, and OV-aCD47-Gl.
- One-way ANOVA with P values corrected for multiple comparisons by Bonferroni method multiple comparisons test (n 3 mice).
- FIG. 17B and 17C Slides from the brains isolated from experimental mice were subjected to H&E staining and immunohistochemical staining, the latter with anti-HSV, anti -human Fc, which identifies IgG, anti-CDllb or anti-NKp46 antibodies.
- H&E staining and immunohistochemical staining the latter with anti-HSV, anti -human Fc, which identifies IgG, anti-CDllb or anti-NKp46 antibodies.
- High and low magnifications of brain H&E and IHC with anti-HSV, anti-human Fc, anti-CDl lb and anti-Nkp46 staining at the tumor implantation site are shown in C and D, respectively.
- the images in FIG. 17B are exactly represent high magnification of the boxed area in FIG. 17C.
- Data presented are represented of one (FIGS. 17B and 17C) or three (B) mice of at least three mice in total with similar data. Error bars (
- FIGS. 18A-18E show a comparison of the effectiveness of OV-aCD47-Gl versus OV- aCD47-G4 as well as combined locoregional deliveries of OV-Q1 and aCD47-Gl in an immunocompetent mouse GBM model.
- FIG. 18A shows an experimental timeline for in vivo studies. An immunocompetent mouse GBM model was established by i.c. injection of 1 x 10 5
- CT2A-hCD47 mouse GBM cells (expressing human CD47) into C57BL/6 mice. Three days later, mice were intratumorally injected with a vehicle control or 2 c 10 5 PFU of OV-Q1, OV- aCD47-Gl or OV-aCD47-G4. Mice were weighed every other day, and luciferase-based images were taken from 11 days post tumor implantation to evaluate tumor progression.
- FIG. 18C shows individual body weights recorded in mice treated on the experimental study.
- FIG. 18D shows an experimental timeline for the survival study.
- An immunocompetent mouse GBM model was established by i.c. injection of 1 x 10 5 CT2A-hCD47 mouse GBM cells (expressing human CD47) into C57BL/6 mice. Three days later, mice were intratumorally injected with vehicle control or 2 c 10 5 PFU of OV-Q1, or OV-aCD47-Gl. Osmotic pumps were implanted on day 4 to the mice for continuous administration of aCD47- G1 until day 7. Mice were monitored twice a day to evaluate for tumor development.
- FIG. 19 shows characterization of OV-Q1, OV-aCD47-Gl and OV-aCD47-G4.
- A2780 cells were incubated with different concentrations of unlabeled aCD47-Gl or aCD47-G4 mAh followed by incubation with a conjugated anti-human CD47 and assessed by flow cytometry.
- FIG. 20 shows aCD47-Gl and aCD47-G4 yields from supernatants of OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells as determined by ELISA assay.
- FIGS. 21A-21D shows aCD47-Gl and aCD47-G4 induce phagocytosis of A2780 ovarian cells.
- FIG. 21A shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of A2780 cells by primary human macrophages.
- FIG. 21B shows conditional media from OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells induce phagocytosis against A2780 cells by primary human macrophages. Phagocytosis was assayed by flow cytometry.
- FIG. 21A shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of A2780 cells by primary human macrophages.
- FIG. 21B shows conditional media from OV-aCD47-Gl-
- FIG. 21C shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of A2780 cells by BMDMs. Percentage of BMDM phagocytosis of A2780 cells (CDllb+CFSE+) was assayed by flow cytometry.
- FIG. 21D shows conditional media from OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells induce phagocytosis against A2780 cells by BMDMs. Phagocytosis was assayed by flow cytometry.
- FIGS. 22A-22B show transcription assays. Primary human macrophages were cocultured with A2780 cells at a ratio of 1 : 1 with or without aCD47-Gl or aCD47-G4 for 6 hours after which gene transcripts were quantified.
- FIG. 22A shows expression levels of ILlb, IL6, IL10, and INOS.
- FIG. 22B shows expression levels of IL12. All experiments were performed at least with three human donors or mice. Error bars represent standard deviations of triplicates.
- FIGS. 23A-23E show that aCD47-Gl but not aCD47-G4 induces cytotoxicity of human NK cells against ovarian cells.
- FIG. 23 A shows cytotoxicity of human primary NK cells against aCD47-Gl- and aCD47-G4-treated A2780 human ovarian cells.
- FIG. 23B shows cytotoxicity of human primary NK cells against A2780 cells that were treated with conditional media from OV-Q1-, OV-aCD47-Gl- or OV-aCD47-G4-infected A2780 cells.
- FIG. 23 A shows cytotoxicity of human primary NK cells against aCD47-Gl- and aCD47-G4-treated A2780 human ovarian cells.
- FIG. 23B shows cytotoxicity of human primary NK cells against A2780 cells that were treated with conditional media from OV-Q1-, OV-aCD47-Gl- or OV-aCD47-G4-inf
- FIG. 23 C shows CD69 expression of NK cells when co-cultured with A2780 cells that were pretreated with aCD47-Gl or aCD47-G4 detected by flow cytometry (columns left to right are control, aCD47- Gl, and aCD47-G4).
- FIG. 23 D shows CD69 expression of NK cells when co-cultured with A2780 cells with conditional media from uninfected, OV-Q1-, OV-aCD47-Gl- or OV-aCD47- G4-infected A2780 cells detected by flow cytometry (columns left to right are uninfected, OV- Q1 -infected, OV-aCD47-Gl -infected, and OV-aCD47-G4-infected).
- FIG. 23E shows Granzyme b production by NK cells when co-cultured with A2780 cells that were pretreated with aCD47-Gl or aCD47-G4 detected by flow cytometry. All experiments were performed with three donors in triplicate. Error bars represent standard deviations of means of three donors.
- FIG. 24 shows OV-aCD47-Gl improves the therapeutic efficacy against ovarian tumor.
- An orthotopic model of human ovarian tumor was established by s.c. injection of 5 c 10 6 A2780 cells. One day later, mice were intratumorally injected with a vehicle control or 1 c 10 5 PFU of OV-Q1, OV-aCD47-Gl, or OV-aCD47-G4.
- FIG. 24 shows tumor volume of ovarian tumor growth in mice with indicated treatments.
- X-axis shows days post-implantation.
- FIG. 25 shows OV-aCD47-Gl enhances the therapeutic efficacy (percent survival) in an immunocompetent ovarian cancer mouse model.
- X-axis shows days post tumor implantation.
- FIG. 26 shows an enhanced effect in vitro and in vivo for the combination of OV- aCD47-Gl with olaparib.
- recombinant oncolytic viruses expressing an anti-CD47 antibody are, inter alia, recombinant oncolytic viruses expressing an anti-CD47 antibody and methods for the treatment of cancer, immune disorders, and infectious disease.
- the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/- 10% of the specified value. In embodiments, about means the specified value.
- virus or “virus particle” are used according to its plain ordinary meaning within virology and refers to a virion including the viral genome (e.g. DNA, RNA, single strand, double strand), viral capsid and associated proteins, and in the case of enveloped viruses (e.g. herpesvirus), an envelope including lipids and optionally components of host cell membranes, and/or viral proteins.
- viral genome e.g. DNA, RNA, single strand, double strand
- enveloped viruses e.g. herpesvirus
- an envelope including lipids and optionally components of host cell membranes, and/or viral proteins e.g. DNA, RNA, single strand, double strand
- enveloped viruses e.g. herpesvirus
- replica is used in accordance with its plain ordinary meaning and refers to the ability of a cell or virus to produce progeny.
- replicate refers to the biological process of producing two identical replicas of DNA from one original DNA molecule.
- replica includes the ability of a virus to replicate (duplicate the viral genome and packaging said genome into viral particles) in a host cell and subsequently release progeny viruses from the host cell, which results in the lysis of the host cell.
- a “replication-competent” virus as provided herein refers to a virus (herpes virus) that is capable of replicating in a cell (e.g., a cancer cell).
- oncolytic virus is used in accordance with its plain ordinary meaning and refers to a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis (directly lysing cells), they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic viruses are thought not only to cause direct destruction of the tumor cells, but also to stimulate host anti-tumor immune system responses. Oncolytic viruses include adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, vaccinia, and the senecavirus.
- recombinant virus is a virus produced by recombining pieces of nucleic acid (e.g. DNA) using recombinant nucleic acid technology.
- a “recombinant oncolytic virus” is an concolytic virus produced by recombining pieces of nucleic acid (e.g. DNA) using recombinant nucleic acid technology.
- herpes simplex virus refers to members of the Herpesviridae family.
- Herpes simplex virus 1 and 2 also known by their taxonomical names Human alphaherpesvirus 1 and Human alphaherpesvirus 2
- HSV-1 and HSV-2 also known by their taxonomical names Human alphaherpesvirus 1 and Human alphaherpesvirus 2
- Human alphaherpesvirus 1 and Human alphaherpesvirus 2 are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans.
- g34.5 gene or “gamma-34.5 gene” is used in accordance with its plain ordinary meaning and refers to a herpes simplex virus neurovirulence gene.
- ICP6 or “ICP6 gene” is used in accordance with its plain ordinary meaning and refers to a gene that encodes a viral ribonucleotide reductase (vRR).
- vRR viral ribonucleotide reductase
- cancer is used in accordance with its plain ordinary meaning and refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemias, lymphomas, carcinomas and sarcomas.
- Examples of cancers that may be treated with a compound, composition, or method provided herein include brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, Medulloblastoma, melanoma, cervical cancer, gastric cancer, ovarian cancer, lung cancer, cancer of the head, Hodgkin's Disease, and Non-Hodgkin's Lymphomas.
- Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung carcinoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract
- leukemia is used in accordance with its plain ordinary meaning and refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
- leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymph
- chronic inflammatory cancer is used in accordance with its plain ordinary meaning and refers broadly to as used herein, relates to its usual an customary meaning of a cancer related to a chronic inflammatory condition.
- Chronic inflammatory conditions related to cancers include, but are not limited to, those provided in the table below.
- an “overactive immune system” is used in accordance with its plain ordinary meaning and refers to an immune system that reacts to allergen in the environment that are normally harmless. Conditions related to an overactive immune system include asthma, eczema, and allergic rhinitis.
- an "autoimmune disease” as used herein refers to a disease or disorder that arises from altered immune reactions by the immune system of a subject, e.g., against substances tissues and/or cells normally present in the body of the subject.
- Autoimmune diseases include, but are not limited to, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemph
- infectious disease is used in accordance with its plain ordinary meaning and refers to a disease or condition that can be caused by organisms such as a bacterium, virus, fungi or any other pathogenic microbial agents.
- infectious disease is caused by a pathogenic bacteria.
- Pathogenic bacteria are bacteria which cause diseases (e.g., in humans).
- infectious disease is a bacteria associated disease (e.g., tuberculosis, which is caused by Mycobacterium tuberculosis).
- Non-limiting bacteria associated diseases include pneumonia, which may be caused by bacteria such as Streptococcus and Pseudomonas; or foodbome illnesses, which can be caused by bacteria such as Shigella, Campylobacter, and Salmonella.
- Bacteria associated diseases also includes tetanus, typhoid fever, diphtheria, syphilis, and leprosy.
- the disease is Bacterial vaginosis (i.e.
- bacteria that change the vaginal microbiota caused by an overgrowth of bacteria that crowd out the Lactobacilli species that maintain healthy vaginal microbial populations e.g., yeast infection, or Trichomonas vaginalis
- Bacterial meningitis i.e. a bacterial inflammation of the meninges
- Bacterial pneumonia i.e. a bacterial infection of the lungs
- Urinary tract infection e.erial gastroenteritis
- Bacterial skin infections e.g. impetigo, or cellulitis.
- the infectious disease is human immunodeficiency virus (HIV), COVID-19, West Nile fever, Zika, malaria, Japanese encephalitis, tularemia, Chagas, sandfly fever, plague, rickettsiosis, influenza, cervicovaginal infections, and decubitus ulcers.
- HIV human immunodeficiency virus
- COVID-19 West Nile fever
- Zika Zika
- malaria Japanese encephalitis
- tularemia Chagas
- sandfly fever plague
- rickettsiosis influenza
- cervicovaginal infections and decubitus ulcers.
- patient or “subject in need thereof’ is used in accordance with its plain ordinary meaning and refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a composition, compound, or method as provided herein.
- Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.
- a patient is human.
- the subject has, had, or is suspected of having cancer.
- control or “control experiment” are used in accordance with its plain ordinary meaning and refer to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).
- treating or “treatment” are used in accordance with its plain ordinary meaning and refer to to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being.
- the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
- the term "treating" and conjugations thereof, may include prevention of an injury, pathology, condition, or disease.
- treating includes preventing.
- treating does not include preventing.
- the term “prevent” is used in accordance with its plain ordinary meaning and refers to a decrease in the occurrence of disease symptoms in a patient.
- the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.
- terapéuticaally effective dose or amount an amount of cells, agents, or compounds described herein that brings about a positive therapeutic response in a subject in need of, such as an amount that restores function and/or results in the elimination and/or reduction of tumor and/or cancer cells.
- the exact amount (of cells or agents) required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, mode of administration, and the like.
- An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.
- a “combined therapeutically effective dose or amount dose” refers a combination of therapies that together brings about a positive therapeutic response in a subject in need of, such as an amount that restores function and/or results in the elimination and/or reduction of tumor and/or cancer cells.
- the term “immune response” is used in accordance with its plain ordinary meaning and refers to a response by an organism that protects against disease. The response can be mounted by the innate immune system or by the adaptive immune system, as well known in the art.
- cytotoxicity is used in accordance with its plain ordinary meaning and refers to quality of being toxic to cells.
- antibody-dependent cellular cytotoxicity As used herein, the terms “antibody-dependent cellular cytotoxicity”, “ADCC”, and “antibody-dependent cell-mediated cytotoxicity” are used in accordance with their plain ordinary meanings and refer to an immune mechanism through which Fc receptor-bearing effector cells can recognize and kill antibody-coated target cells expressing tumor- or pathogen-derived antigens on their surface.
- the terms “antibody-dependent cellular phagocytosis” and “ADCP” are used in accordance with their plain ordinary meanings and refer to the mechanism by which antibody-opsonized target cells activate the Fc receptors on the surface of macrophages to induce phagocytosis, resulting the ingestion and degradation of the target cell.
- the macrophage Fc receptors refer to all classes of Fey receptors.
- the terms “adaptive immune response”, “acquired immune system”, and “specific immune system” are used in accordance with their plain ordinary meanings and refer to a subsystem of the overall immune system that is composed of specialized, systemic cells and processes that eliminate designated targets.
- the targets are designated by identification via immunological memory. Immunological memory is created when the immune system had previously encountered the immune assault, and retained a record of it.
- NK cells are used in accordance with their plain ordinary meaning and refer to a type of cytotoxic lymphocyte involved in the innate immune system.
- the role NK cells play is typically analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells may provide rapid responses to virus- infected cells, acting at around 3 days after infection, and respond to tumor formation.
- immune cells detect major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis.
- MHC major histocompatibility complex
- NK cells typically have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction.
- T cells are used in accordance with their plain ordinary meaning and refer to a type of lymphocyte (a subtype of white blood cell) inolved in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells, by the presence of a T-cell receptor on the cell surface. T cells include, for example, natural killer T (NKT) cells, cytotoxic T lymphocytes (CTLs), regulatory T (Treg) cells, and T helper cells. Different types of T cells can be distinguished by use of T cell detection agents.
- NKT natural killer T
- CTLs cytotoxic T lymphocytes
- Treg regulatory T
- T helper cells Different types of T cells can be distinguished by use of T cell detection agents.
- tumor microenvironment As used herein, the terms “tumor microenvironment”, “TME”, and “cancer microenvironment” are used in accordance with its plain ordinary meaning and refer to the non neoplastic cellular environment of a tumor, including blood vessels, immune cells, fibroblasts, cytokines, chemokines, non-cancerous cells present in the tumor, and proteins produced.
- activation means positively affecting (e.g. increasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the activator.
- activation may reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.
- activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein associated with a disease (e.g., a protein that is decreased in a disease relative to a non-diseased control).
- Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein
- agonist As used herein, the terms “agonist,” “activator,” “upregulator,” etc. are used in accordance with its plain ordinary meaning and refer to a substance capable of detectably increasing the expression or activity of a given gene or protein.
- the agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
- inhibition As used herein, the terms “inhibition”, “inhibit”, “inhibiting” and the like are used in accordance with its plain ordinary meaning and refer to an interaction that negatively affecting (e.g. decreasing) the activity or function of the protein or cell relative to the activity or function of the protein or cell in the absence of the inhibitor. In embodiments, inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments, inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target.
- inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.
- inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein).
- inhibition refers to a reduction of activity of a target protein or cell from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation or cell activations).
- the terms “inhibitor,” “repressor” or “antagonist” or “downregulator” are used in accordance with its plain ordinary meaning and refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein.
- the antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
- nucleic acid As may be used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid oligomer,” “oligonucleotide,” “nucleic acid sequence,” “nucleic acid fragment” and
- polynucleotide are used interchangeably and are intended to include, but are not limited to, a polymeric form of nucleotides covalently linked together that may have various lengths, either deoxyribonucleotides or ribonucleotides, or analogs, derivatives or modifications thereof. Different polynucleotides may have different three-dimensional structures, and may perform various functions, known or unknown.
- Non-limiting examples of polynucleotides include a gene, a gene fragment, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, a ribozyme, cDNA, a recombinant polynucleotide, a branched polynucleotide, a plasmid, a vector, isolated DNA of a sequence, isolated RNA of a sequence, a nucleic acid probe, and a primer.
- Polynucleotides useful in the methods of the disclosure may comprise natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or a combination of such sequences.
- nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like).
- sequences are then said to be “substantially identical.”
- This definition also refers to, or may be applied to, the compliment of a test sequence.
- the definition also includes sequences that have deletions and/or additions, as well as those that have substitutions.
- the preferred algorithms can account for gaps and the like.
- identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.
- expression is used in accordance with its plain ordinary meaning and refers to any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
- the term “expression cassette” refers to a distinct component of vector DNA consisting of a gene and regulatory sequence to be expressed by a transfected cell. In each successful transformation, the expression cassette directs the cell's machinery to make RNA and protein(s). Some expression cassettes are designed for modular cloning of protein-encoding sequences so that the same cassette can easily be altered to make different proteins.
- An expression cassette is composed of one or more genes and the sequences controlling their expression.
- An expression cassette comprises three components: a promoter sequence, an open reading frame, and a 3' untranslated region that, in eukaryotes, usually contains a polyadenylation site. Different expression cassettes can be transfected into different organisms including bacteria, yeast, plants, and mammalian cells as long as the correct regulatory sequences are used.
- cytokine is used in accordance with its plain ordinary meaning and refers to a broad category of small proteins (-5-20 kDa) that are important in cell signaling. Cytokines are peptides, and cannot cross the lipid bilayer of cells to enter the cytoplasm. Cytokines are involved in autocrine signaling, paracrine signaling and endocrine signaling as immunomodulating agents. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.
- Cytokines are produced by a broad range of cells, including immune cells like macrophages, B lymphocytes, T lymphocytes and mast cells, as well as endothelial cells, fibroblasts, and various stromal cells; a given cytokine may be produced by more than one type of cell.
- antibody refers to a polypeptide encoded by an immunoglobulin gene or functional fragments thereof that specifically binds and recognizes an antigen.
- the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
- the specified antibodies bind to a particular protein at least two times the background and more typically more than 10 to 100 times background.
- Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein.
- polyclonal antibodies can be selected to obtain only a subset of antibodies that are specifically immunoreactive with the selected antigen and not with other proteins.
- This selection may be achieved by subtracting out antibodies that cross-react with other molecules.
- a variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein.
- solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
- immunoglobulin domain or “Ig-domain” are used in accordance with their plain and ordinary meanings and refer to any of the recombinant or naturally-occurring forms of the Ig-domain or variants or homologs thereof that maintain the Ig- domain fold or three-dimensional structure.
- the Ig-domain belongs to a family of protein folds that consist of a 2-layer sandwich of 7-9 antiparallel beta-strands arranged in two beta-sheets with a Greek-key topology.
- the folding pattern typically consists of (N-terminal beta-hairpin-in sheet l)-(beta-hari pin-in sheet 2)-(beta-strand in sheet l)-(C-terminal beta-hairpin in sheet 2) linkages.
- Immunoglobulin domains are the primary components of antibodies, and a large set of extracellular surface receptors, including receptor tyrosine kinases.
- An example of an immunoglobulin (antibody) structural unit comprises a tetramer.
- Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa).
- the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- variable heavy chain refers to the variable region of an immunoglobulin heavy chain, including an Fv, scFv, dsFv or Fab; while the terms “variable light chain,” “VL” or “VL” refer to the variable region of an immunoglobulin light chain, including of an Fv, scFv, dsFv or Fab.
- antibody functional fragments include, but are not limited to, complete antibody molecules, antibody fragments, such as Fv, single chain Fv (scFv), complementarity determining regions (CDRs), V L (light chain variable region), V H (heavy chain variable region), Fab, F(ab)2' and any combination of those or any other functional portion of an immunoglobulin peptide capable of binding to target antigen (see, e.g., FUNDAMENTAL IMMUNOLOGY (Paul ed., 4th ed. 2001).
- various antibody fragments can be obtained by a variety of methods, for example, digestion of an intact antibody with an enzyme, such as pepsin; or de novo synthesis.
- Antibody fragments are often synthesized de novo either chemically or by using recombinant DNA methodology.
- the term antibody includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries.
- chimeric antibody is used in accordance with its plain ordinary meaning and refers to an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.
- the preferred antibodies of, and for use according to the invention include humanized and/or chimeric monoclonal antibodies.
- IgG immunoglobulin G
- IgG immunoglobulin G
- the terms "Immunoglobulin G” or “IgG” are used in accordance with their plain and ordinary meanings and refer to any of the recombinant or naturally-occurring forms of the IgG antibody protein or variants or homologs thereof that maintain IgG activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to IgG).
- the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring IgG
- IgG antibodies are composed of four separate chains (two identical light chains and two identical heavy chains) that form a homodimer (via inter-heavy chain disulfide) of heterodimers (one light chain and one heavy chain interchain disulfide) in a canonical Y-shaped quaternary structure.
- the light chain includes a variable immunoglobulin domain (VL) and a constant immunoglobulin domain (CL).
- the heavy chain includes one variable immunoglobulin domain (VH) and three constant immunoglobulin domains (CHI, CH2, CH3).
- the variable domains form the antigen-recognition surface of an IgG antibody.
- CD47 and “Cluster of Differentiation 47” and integrin associated protein” or “IAP” refer to a transmembrane protein that in humans is encoded by the CD47 gene.
- CD47 belongs to the immunoglobulin superfamilyand partners with membrane integrins and also binds the ligands thrombospondin- 1 (TSP-1) and signal-regulatory protein alpha (SIRPa).
- TSP-1 thrombospondin- 1
- SIRPa signal-regulatory protein alpha
- CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is ubiquitously expressed in human cells and has been found to be overexpressed in many different tumor cells. Expression in equine cutaneous tumors has been reported as well.
- anti-CD47 antibody refers to a protein capable of binding CD47 protein.
- Examples includes Hu5F9 (also known as 5F9).
- An anti-CD47 monoclonal antibody with an IgGl isotype is referred to as aCD47-Gl (or Hu5F9-Gl or 5 F9- Gl).
- An anti-CD47 monoclonal antibody with an IgG4 isotype is referred to as aCD47-G4 (or Hu5F9-G4 or 5fp-G4).
- SIRPa signal regulatory protein a
- CD47 also called the "don't eat me” signal. This interaction negatively controls effector function of innate immune cells such as host cell phagocytosis.
- the named protein includes any of the protein’s naturally occurring forms, variants or homologs that maintain the protein transcription factor activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the native protein).
- variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring form.
- the protein is the protein as identified by its NCBI sequence reference. In other embodiments, the protein is the protein as identified by its NCBI sequence reference, homolog or functional fragment thereof.
- immunotherapy and “immunotherapeutic agent” are used in accordance with their plain ordinary meaning and refer to the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Such immunotherapeutic agents include antibodies and cell therapy.
- checkpoint inhibitor is used in accordance with its plain ordinary meaning and refers to a drug, often made of antibodies, that unleashes an immune system attack on cancer cells.
- An important part of the immune system is its ability to tell between normal cells in the body and those it sees as “foreign.” This lets the immune system attack the foreign cells while leaving the normal cells alone.
- checkpoints which are molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system. Drugs that target these checkpoints are known as checkpoint inhibitors.
- PD-1 is used in accordance with its plain ordinary meaning and refers to a checkpoint protein on immune cells called T cells. It acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body. It does this when it attaches to PD-L1, a protein on some normal (and cancer) cells. When PD-1 binds to PD-L1, the signal notifies the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps them evade immune attack.
- PD-L1 or “programmed death-ligand 1 (PD-L1)” refers to a 40kDa type 1 transmembrane protein that plays a role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states. It appears that upregulation of PD-L1 may allow cancers to evade the host immune system.
- CD 152 cluster of differentiation 152
- anticancer agent and “anticancer therapy” are used in accordance with their plain ordinary meaning and refer to a molecule or composition (e.g. compound, peptide, protein, nucleic acid, drug, antagonist, inhibitor, modulator) or regimen used to treat cancer through destruction or inhibition of cancer cells or tissues.
- Anticancer therapy includes chemotherapy, radiation therapy, surgery, targeted therapy, immunotherapy, and cell therapy.
- Anticancer agents and/or anticancer therapy may be selective for certain cancers or certain tissues.
- an anti-cancer therapy is an immunotherapy.
- anticancer agent or therapy may include a checkpoint inhibitor.
- the anti-cancer agent or therapy is a cell therapy.
- an anti-cancer agent is an agent identified herein having utility in methods of treating cancer.
- an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer.
- anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/ AZD6244,
- alkylating agents e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusit
- platinum-based compounds e.g. cisplatin, oxaloplatin, carboplatin
- anthracenedione e.g., mitoxantrone
- substituted urea e.g., hydroxyurea
- methyl hydrazine derivative e.g., procarbazine
- adrenocortical suppressant e.g., mitotane, aminoglutethimide
- epipodophyllotoxins e.g., etoposide
- antibiotics e.g., daunorubicin, doxorubicin, bleomycin
- enzymes e.g., L-asparaginase
- inhibitors of mitogen-activated protein kinase signaling e.g.
- Taxol.TM i.e. paclitaxel
- Taxotere.TM compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS- 10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g.
- Epothilone E Epothilone F
- Epothilone B N-oxide Epothilone AN-oxide
- 16-aza-epothilone B 21-aminoepothilone B (i.e. BMS-310705)
- 21- hydroxy epothilone D i.e. Desoxyepothilone F and dEpoF
- 26-fluoroepothilone i.e. NSC-654663
- Soblidotin i.e. TZT-1027
- LS-4559-P Pulacia, i.e.
- LS-4577 LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS- 164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e.
- ILX-651 and LU-223651 SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, i.e.
- T-900607 RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asia Medica), D-68144 (Asia Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (i.e.
- NSCL-96F03-7 D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e.
- SPA- 110 trifluoroacetate salt
- D-82317 Zentaris
- D-82318 Zentaris
- SC-12983 NCI
- steroids e.g., dexamethasone
- finasteride aromatase inhibitors
- gonadotropin-releasing hormone agonists GnRH
- goserelin or leuprolide adrenocorticosteroids
- progestins e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate
- estrogens e.g., diethlystilbestrol, ethinyl estradiol
- antiestrogen e.g., tamoxifen
- androgens e.g.
- gefitinib Iressa TM
- erlotinib Tarceva TM
- cetuximab ErbituxTM
- lapatinib TykerbTM
- panitumumab VectibixTM
- vandetanib CaprelsaTM
- afatinib/BIBW2992 CI-1033/canertinib, neratinib/HKI-272, CP- 724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), PARP inhibitors (olaparib, rucaparib, nirapa
- administering means oral administration, administration as a suppository, topical contact, intravenous, systemic, intracavitary, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
- Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
- Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
- the administering does not include administration of any active agent other than the recited active agent.
- systemic administration refers to a route of administration into the circulatory system so that the entire body of a subject is affected. Systemic administration incldes enteral and parenteral administrion.
- the term “intracavitary administration” refers to a route of administration within any natural, non-pathologic cavity.
- “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient.
- Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethy cellulose, polyvinyl pyrrolidine, and colors, and the like.
- Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
- auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
- auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure.
- the term "co-administer” refers to a composition described herein that is administered at the same time, just prior to, or just after the administration of one or more additional therapies.
- the compounds provided herein can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound).
- the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
- the term "about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/- 10% of the specified value. In embodiments, about includes the specified value.
- a “synergistic amount” as used herein refers to the sum of a first amount (e.g., an amount of a compound provided herein) and a second amount (e.g., a therapeutic agent) that results in a synergistic effect (i.e. an effect greater than an additive effect). Therefore, the terms “synergy”, “synergism”, “synergistic”, “combined synergistic amount”, and “synergistic therapeutic effect” which are used herein interchangeably, refer to a measured effect of the compound administered in combination where the measured effect is greater than the sum of the individual effects of each of the compounds provided herein administered alone as a single agent.
- a recombinant oncolytic virus including an expression cassette encoding an anti-CD47 antibody.
- a recombinant oncolytic virus including a nucleic acid encoding an anti-CD47 antibody.
- An oncolytic virus is defined by its ability to selectivity replicate and kill dividing cells as compared to non-dividing cells. It may be a native virus that is naturally oncolytic or may be engineered by modifying one or more viral genes so as to increase tumor selectivity and/or preferential replication in dividing cells, such as those involved in DNA replication, nucleic acid metabolism, host tropism, surface atachment, virulence, lysis and spread (see for example Kim et al., 2001, Nat. Med. 7: 781; Wong et al., 2010, Viruses 2: 78-106). One may also envisage placing one or more viral gene(s) under the control of event or tissue-specific regulatory elements (e.g. promoter).
- event or tissue-specific regulatory elements e.g. promoter
- Exemplary oncolytic viruses include without limitation reovirus, Seneca Valley virus (SVV), vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), herpes simplex virus (HSV), morbillivirus virus, retrovirus, influenza virus, Sin bis virus, poxvirus, adenovirus, or the like.
- SVV Seneca Valley virus
- VSV vesicular stomatitis virus
- NDV Newcastle disease virus
- HSV herpes simplex virus
- morbillivirus virus retrovirus
- influenza virus Sin bis virus
- poxvirus poxvirus
- adenovirus or the like.
- the oncolytic virus is a herpes virus.
- the Herpesviridae are a large family of DNA viruses that all share a common structure and are composed of relatively large double- stranded, linear DNA genomes encoding 100-200 genes encapsided within an icosahedral capsid which is enveloped in a lipid bilayer membrane.
- the oncolytic herpes virus can be derived from different types of HSV.
- the oncolytic herpes virus is HSV1.
- the oncolytic herpes virus is HSV2.
- the herpes virus may be genetically modified so as to restrict viral replication in tumors or reduce its cytotoxicity in non-dividing cells.
- any viral gene involved in nucleic acid metabolism may be inactivated, such as thymidine kinase (Martuza et al., 1991, Science 252: 854-6), ribonucleotide reductase (RR) (Boviatsis et al., Gene Ther. 1: 323-31; Mineta et al., 1994, Cancer Res. 54: 3363-66), or uracil-N-glycosylase (Pyles et al.,
- Another aspect involves viral mutants with defects in the function of genes encoding virulence factors such as the ICP34.5 gene (Chambers et al., 1995, Proc. Natl. Acad. Sci. USA 92: 1411-5).
- Representative examples of oncolytic herpes virus include NV1020 (e.g. Geevarghese et al., 2010, Hum. Gene Ther. 21(9): 1119-28) and T-VEC (Andtbacka et al., 2013, J. Clin. Oncol. 31, abstract number LBA9008).
- the oncolytic virus is a reovirus.
- a representative example includes Reolysin (under development by Oncolytics Biotech; NCT01166542).
- the oncolytic virus is a Seneca Valley virus.
- a representative example includes NTX-010 (Rudin et al., 2011, Clin. Cancer. Res. 17(4): 888-95).
- the oncolytic virus is a vesicular stomatitis virus (VSV).
- VSV vesicular stomatitis virus
- the oncolytic virus is a Newcastle disease virus.
- Representative examples include without limitation the 73-T PV701 and HDV-HUJ strains as well as those described (e.g. Phuangsab et al., 2001, Cancer Lett. 172(1): 27-36; Lorence et al., 2007, Curr. Cancer Drug Targets 7(2): 157-67; Freeman et al., 2006, Mol. Ther. 13(1): 221-8).
- the oncolytic virus is a morbillivirus which can be obtained from the paramyxoviridae family.
- the oncolytic virus is a measles virus.
- Representative examples of oncolytic measles viruses include without limitation MV-Edm (McDonald et al., 2006; Breast Cancer Treat. 99(2): 177-84) and HMWMAA (Kaufmann et al., 2013, J. Invest. Dermatol. 133(4): 1034-42)
- the oncolytic virus is an adenovirus.
- Methods are available in the art to engineer oncolytic adenoviruses.
- Various aspects include the replacement of viral promoters with tumor-selective promoters or modifications of the El adenoviral gene product(s) to inactivate its/their binding function with p53 or retinoblastoma (Rb) protein that are altered in tumor cells.
- the adenovirus E1B55 kDa gene cooperates with another adenoviral product to inactivate p53 (p53 is frequently dysregulated in cancer cells), thus preventing apoptosis.
- Representative examples of oncolytic adenovirus include ONYX-015 (e.g. Khuri et al., 2000, Nat. Med 6(8): 879-85) and H101 also named Oncorine (Xia et al., 2004, Ai Zheng 23(12): 1666-70).
- the oncolytic virus is a poxvirus.
- poxvirus refers to a virus belonging to the Poxviridae family.
- the poxvirus can be of the Chordopoxviridae subfamily and can be of the Orthopoxvirus genus. Sequences of the genome of various poxviruses, for example, the vaccinia virus, cowpox virus, Canarypox virus, Ectromelia virus, Myxoma virus genomes are available in the art and specialized databases such as Genbank (accession number NC_006998, NC_003663, NC_005309, NC_004105,
- the oncolytic poxvirus can be an oncolytic vaccinia virus.
- Vaccinia viruses are members of the poxvirus family characterized by a 200 kb double-stranded DNA genome that encodes numerous viral enzymes and factors that enable the virus to replicate independently from the host cell machinery.
- the majority of vaccinia virus particles is intracellular (IMV for intracellular mature virion) with a single lipid envelop and remains in the cytosol of infected cells until lysis.
- the other infectious form is a double enveloped particle (EEV for extracellular enveloped virion) that buds out from the infected cell without lysing it.
- the anti-CD47 antibody can be a humanized antibody.
- humanized antibodies refers to monoclonal antibodies and antigen binding fragments thereof, including the nucleic acids encoding an antibody disclosed herein, that have binding and functional properties according to the disclosure similar to those disclosed herein, and that have framework and constant regions that are substantially human or fully human surrounding CDRs derived from a non-human antibody.
- Framework region or “framework sequence” refers to any one of framework regions 1 to 4.
- Humanized antibodies and antigen binding fragments encompassed by the present disclosure include molecules wherein any one or more of framework regions 1 to 4 is substantially or fully human, i.e., wherein any of the possible combinations of individual substantially or fully human framework regions 1 to 4, is present.
- this includes molecules in which framework region 1 and framework region 2, framework region 1 and framework region 3, framework region 1, 2, and 3, etc., are substantially or fully human
- Substantially human frameworks are those that have at least 80% sequence identity to a known human germline framework sequence.
- the substantially human frameworks have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, to a framework sequence disclosed herein, or to a known human germline framework sequence.
- CDRs encompassed by the present disclosure include not only those specifically disclosed herein, but also CDR sequences having sequence identities of at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to a CDR sequence disclosed herein.
- CDRs encompassed by the present disclosure include not only those specifically disclosed herein, but also CDR sequences having 1, 2, 3, 4, 5, or 6 amino acid changes at corresponding positions compared to CDR sequences disclosed herein. Such sequence identical, or amino acid modified, CDRs preferably bind to the antigen recognized by the intact antibody.
- sequence identity means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Identity can be readily calculated by known methods, including but not limited to those described in: Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H.
- Optimal alignment of sequences for comparison can be conducted, for example, by the local homology algorithm of Smith & Waterman, by the homology alignment algorithms, by the search for similarity method or, by computerized implementations of these algorithms (GAP, BESTFIT, PASTA, and TFASTA in the GCG Wisconsin Package, available from Accelrys, Inc., San Diego, Calif., United States of America), or by visual inspection. See generally, (Altschul, S. F. et al., J. Mol. Biol. 215: 403-410 (1990) and Altschul et al. Nucl. Acids Res. 25: 3389-3402 (1997)).
- BLAST algorithm One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in (Altschul, S., et al., NCBI NLMNIH Bethesda, Md. 20894; & Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990).
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
- This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold.
- HSPs high scoring sequence pairs
- These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them.
- the word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always; 0) and N (penalty score for mismatching residues; always; 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached.
- the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
- the BLASTP program uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix.
- the BLAST algorithm In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences.
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- P (N) the smallest sum probability
- a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is in one embodiment less than about 0.1, in another embodiment less than about 0.01, and in still another embodiment less than about 0.001.
- Fully human frameworks are those that are identical to a known human germline framework sequence.
- Human framework germline sequences can be obtained from ImMunoGeneTics (IMGT) via their website or from The Immunoglobulin FactsBook by Marie- Paule Lefranc and Gerard Lefranc, Academic Press, 2001, ISBN 012441351.
- germline light chain frameworks can be selected from the group consisting of: A11, A17, A18, A19, A20, A27, A30, LI, L1I, L12, L2, L5, L15, L6, L8, 012, 02, and 08
- germline heavy chain framework regions can be selected from the group consisting of: VH2-5, VH2-26, VH2- 70, VH3-20, VH3-72, VHI-46, VH3-9, VH3-66, VH3-74, VH4-31, VHI-18, VHI-69, VI-13-7, VH3-11, VH3-15, VH3-21, VH3-23, VH3-30, VH3-48, VH4-39, VH4-59, and VH5-5I.
- Humanized antibodies in addition to those disclosed herein exhibiting similar functional properties according to the present disclosure can be generated using several different methods.
- the parent antibody compound CDRs are grafted into a human framework that has a high sequence identity with the parent antibody compound framework.
- the sequence identity of the new framework will generally be at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identical to the sequence of the corresponding framework in the parent antibody compound.
- frameworks having fewer than 100 amino acid residues In the case of frameworks having fewer than 100 amino acid residues, one, two, three, four, five, six, seven, eight, nine, or ten amino acid residues can be changed. This grafting may result in a reduction in binding affinity compared to that of the parent antibody. If this is the case, the framework can be back-mutated to the parent framework at certain positions based on specific criteria disclosed by Queen et al. (1991) Proc. Natl. Acad. Sci. USA 88:2869. Additional references describing methods useful in humanizing mouse antibodies include U.S. Pat. Nos. 4,816,397; 5,225,539; and 5,693,761; computer programs ABMOD and ENCAD as described in Levitt (1983) J. Mol. Biol.
- the identification of residues to consider for back-mutation can be carried out as follows:
- the framework amino acid of the human germ-line sequence that is being used (the “acceptor framework”) is replaced by a framework amino acid from a framework of the parent antibody compound (the “donor framework”):
- the amino acid in the human framework region of the acceptor framework is unusual for human frameworks at that position, whereas the corresponding amino acid in the donor immunoglobulin is typical for human frameworks at that position;
- the position of the amino acid is immediately adjacent to one of the CDRs; or
- any side chain atom of a framework amino acid is within about 5-6 angstroms (center-to-center) of any atom of a CDR amino acid in a three dimensional immunoglobulin model.
- Another approach to generating human engineered antibodies exhibiting similar functional properties to the antibody compounds disclosed herein involves randomly mutating amino acids within the grafted CDRs without changing the framework, and screening the resultant molecules for binding affinity and other functional properties that are as good as or better than those of the parent antibody compounds.
- Single mutations can also be introduced at each amino acid position within each CDR, followed by assessing the effects of such mutations on binding affinity and other functional properties. Single mutations producing improved properties can be combined to assess their effects in combination with one another.
- a person skilled in the art can use common techniques, e.g., site-directed mutagenesis, to substitute amino acids within the presently disclosed CDR and framework sequences and thereby generate further variable region amino acid sequences derived from the present sequences. Up to all naturally occurring amino acids can be introduced at a specific substitution site, including conservative amino acid substitutions as are well known to those of ordinary skill in the art. The methods disclosed herein can then be used to screen these additional variable region amino acid sequences to identify sequences having the indicated in vitro and/or in vivo functions. In this way, further sequences suitable for preparing human engineered antibodies and antigen-binding portions thereof in accordance with the present disclosure can be identified.
- amino acid substitution within the frameworks can include one, two, three, four, five, six, seven, eight, nine, or ten positions within any one or more of the 4 light chain and/or heavy chain framework regions disclosed herein.
- amino acid substitution within the CDRs is restricted to one, two, three, four, or five positions within any one or more of the 3 light chain and/or heavy chain CDRs. Combinations of the various changes within these framework regions and CDRs described above are also possible.
- the recombinant oncolytic virus includes a nucleic acid sequence encoding an anti-CD47 antibody.
- the antibody encoded by the oncolytic virus of the invention can be of any origin, e.g. human, humanized, animal (e.g. rodent or camelid antibody) or chimeric. It may be of any isotype (e.g. IgGl, IgG2, IgG3, IgG4). In addition, it may be glycosylated, partially glycosylated or non-glycosylated (e.g. by mutating one or more residue(s) within the site(s) of glycosylation).
- the term antibody also includes bispecific or multispecific antibodies so long as they exhibit the binding specificity described herein.
- the nucleic acid sequence encoding an anti-CD47 antibody can include a nucleic acid encoding a light chain signal peptide.
- the nucleic acid sequence encoding a light chain signal peptide is SEQ ID NO. :2.
- the nucleic acid sequence encoding an anti-CD47 antibody can include a nucleic acid encoding a light chain variable region.
- the nucleic acid sequence encoding a light chain variable region is SEQ ID NO.: 3.
- the nucleic acid sequence encoding an anti-CD47 antibody can include a nucleic acid encoding a light chain constant region.
- the nucleic acid sequence encoding a light chain constant region is SEQ ID NO.:4.
- the nucleic acid sequence encoding an anti-CD47 antibody can encode an anti-CD47 (aCD47) IgG antibody utilizing the techniques of CDR grafting described above to provide a scaffold of an IgG (an antibody that incorporates portions of heavy chains of an IgG).
- the IgG is selected from IgGl, IgG2, IgG3, and IgG4.
- the nucleic acid sequence encoding an anti-CD47 IgG antibody e.g. IgGl or IgG4
- the nucleic acid sequence encoding a heavy chain signal peptide is SEQ ID NO.:5.
- the nucleic acid sequence encoding an anti-CD47 IgG antibody can include a nucleic acid encoding a heavy chain variable region. In aspects, the nucleic acid sequence encoding a heavy chain variable region is SEQ ID NO.: 6. [0133] The nucleic acid sequence encoding an anti-CD47 antibody can encode an anti-CD47 (aCD47) IgGl antibody. The nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain constant region CHi. In aspects, the nucleic acid sequence encoding a IgGl heavy chain constant region CHi is SEQ ID NO.: 7.
- the nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain hinge.
- the nucleic acid sequence encoding a IgGl heavy chain hinge is SEQ ID NO.: 8.
- the nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain constant region CEE.
- the nucleic acid sequence encoding a IgGl heavy chain constant region CEE is SEQ ID NO.: 9.
- the nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain constant region CEE.
- the nucleic acid sequence encoding a IgGl heavy chain constant region CEE is SEQ ID NO.: 10.
- the recombinant oncolytic virus includes a nucleic acid sequence encoding an aCD47 IgG2 antibody. In embodiments, the recombinant oncolytic virus includes a nucleic acid sequence encoding an aCD47 IgG3 antibody.
- the recombinant oncolytic virus includes a nucleic acid sequence encoding an aCD47 IgG4 antibody.
- the nucleic acid sequence encoding an anti-CD47 IgG4 antibody can include a nucleic acid encoding IgG4 heavy chain constant region CEE.
- the nucleic acid sequence encoding an IgG4 heavy chain constant region CEE is SEQ ID NO. : 11.
- the nucleic acid sequence encoding an anti-CD47 IgG4 antibody can include a nucleic acid encoding IgG4 heavy chain constant region CEE.
- the nucleic acid sequence encoding a IgGl heavy chain constant region CEE is SEQ ID NO.: 12.
- the oncolytic virus includes a nucleic acid sequence encoding an aCD47 ScFv.
- the terminal 1 kb of the long repeat region (RL) of the HSV-1 and HSV-2 genomes contain a gene (11-13), that confers neuro virulence. Deletion or mutation of this gene results in variants that grow as well as wild type virus on dividing cells of many established cell lines, but show impaired replication on non-dividing cells.
- the oncolytic virus provided herein can lack a functional g34.5 gene.
- the recombinant oncolytic virus does not include nucleic acid encoding a g34.5 gene.
- the oncolytic herpes simplex virus does not include nucleic acid encoding ay34.5 gene.
- the oncolytic herpes simplex 1 virus does not include nucleic acid encoding a g34.5 gene. In embodiments, the oncolytic herpes simplex 2 virus does not include nucleic acid encoding a g34.5 gene. In embodiments, the oncolytic herpes simplex virus does not include nucleic acid encoding a functional g34.5 gene. In embodiments, the oncolytic herpes simplex 1 virus does not include nucleic acid encoding a functional g34.5 gene. In embodiments, the oncolytic herpes simplex 2 virus does not include nucleic acid encoding a functional g34.5 gene.
- the ICP6 gene is a gene encoding the large subunit of ribonucleotide reductase (RR).
- RR is an enzyme necessary for virus DNA synthesis. Inactivation of this gene prevents virus replication in non-dividing cells. Only in cells which divide actively and have increased RR activity, the deficiency of the RR activity due to deletion of the ICP6 gene is compensated, enabling virus replication.
- the oncolytic virus provided herein can lack a functional IP6 gene.
- the recombinant oncolytic virus does not include nucleic acid encoding a functional ICP6 gene.
- the oncolytic herpes simplex virus does not include nucleic acid encoding a functional ICP6 gene.
- the oncolytic herpes simplex 1 virus does not include nucleic acid encoding a functional ICP6 gene.
- the oncolytic herpes simplex 2 virus does not include nucleic acid encoding a functional ICP6 gene.
- the nucleic acid encoding an anti-CD47 antibody operably linked to elements for transcription and translation operably linked to elements for transcription and translation.
- operably linked means that the nucleotide sequence of interest is linked to regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence.
- the regulatory sequence may include, for example, promoters, enhancers and other expression control elements (e.g., polyadenylation signals).
- promoters e.g., promoters, enhancers and other expression control elements (e.g., polyadenylation signals).
- Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells, and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the target cell, the level of expression desired, and the like.
- a vector has one or more transcription and/or translation control elements.
- Non-limiting examples of suitable eukaryotic promoters include those from cytomegalovirus (CMV) immediate early, HI, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retrovirus, human elongation factor- 1 promoter (EF1), a hybrid construct having the cytomegalovirus (CMV) enhancer fused to the chicken beta-actin promoter (CAG), murine stem cell virus promoter (MSCV), phosphogly cerate kinase- 1 locus promoter (PGK), and mouse metallothionein-I.
- CMV cytomegalovirus
- HSV herpes simplex virus
- LTRs long terminal repeats
- EF1 human elongation factor- 1 promoter
- CAG chicken beta-actin promoter
- MSCV murine stem cell virus promoter
- PGK phosphogly cerate kinase- 1 locus promoter
- the promoter can be a constitutive promoter (e.g., CMV promoter, UBC promoter). In some cases, the promoter can be a spatially restricted and/or temporally restricted promoter (e.g., a tissue specific promoter, a cell type specific promoter, etc.).
- the recombinant oncolytic virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter.
- the oncolytic herpes simplex virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter.
- the oncolytic herpes simplex 1 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter.
- the oncolytic herpes simplex 2 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter.
- the recombinant oncolytic virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter.
- the oncolytic herpes simplex virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter.
- the oncolytic herpes simplex 1 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter.
- the oncolytic herpes simplex 2 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter.
- HSV herpes simplex virus
- the HSV promoter is an immediate early (IE) promoter.
- the HSV IE promoter is an IE 4/5 promoter.
- the recombinant oncolytic virus can include a nucleic acid encoding a marker that can be used to determine whether the virus is present in the cell.
- the marker can be a selectable marker.
- a selectable marker is a gene introduced into a cell that confers a trait suitable for artificial selection.
- the recombinant oncolytic virus includes a nucleic acid encoding a marker within an ICP6 gene.
- the oncolytic herpes simplex virus includes a nucleic acid encoding a marker within an ICP6 gene.
- the oncolytic herpes simplex 1 virus includes a nucleic acid encoding a marker within an ICP6 gene.
- the oncolytic herpes simplex 2 virus includes a nucleic acid encoding a marker within an ICP6 gene.
- the marker is a selectable marker.
- the pharmaceutical composition has one or more compounds of the present disclosure and one or more pharmaceutically acceptable excipients.
- the pharmaceutical compositions, the compound, or pharmaceutically acceptable salt thereof is included in a therapeutically effective amount.
- a pharmaceutical composition including a recombinant oncolytic virus as described herein, and a pharmaceutically acceptable carrier.
- compositions of the present disclosure can be prepared and administered in a wide variety of dosage formulations.
- Compounds described can be administered orally, rectally, or by injection (e.g. intratumorally, intracavitary, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally).
- the compositions disclosed herein can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
- Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
- the compositions of the present disclosure can additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates.
- compositions disclosed herein can also be delivered as microspheres for slow release in the body.
- microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res.
- the formulations of the compositions of the present disclosure can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i. e.. by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
- liposomes particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present disclosure into the target cells in vivo.
- the compositions can also be delivered as nanoparticles.
- a pharmaceutical composition including a recombinant oncolytic virus encoding an anti-CD47 antibody, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) immediate early (IE) promoter, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition including a oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) immediate an IE 4/5 promoter promoter, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition further includes an anti-cancer agent.
- compositions provided herein are oncolytic viruses that express an anti-CD47 antibody. While not wishing to be held to theory, the oncolytic virus replicates preferentially in the tumor cell and and the anti-CD47 antibody binds to the CD47 receptor that helps the tumor evade the host immune system.
- the composition is administered directly to the tumor location. Methods for tumor location and access are known in the art. Compositions can be administered to a subject in need by any of the methods further described below. Progress in tumor killing can be monitored by any of the methods of imaging tumors or measuring tumor markers known in the art.
- a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- the pharmaceutical composition is co-admininstered with an anti-cancer therapy.
- the anti-cancer therapy can include, but is not limited to, chemotherapy (anti-cancer agents), radiation therapy, surgery, targeted therapy, immunotherapy, or cell therapy.
- Anticancer agents can include, but are not limited to, checkpoint inhibitors and PARP inhibitors (see “anticancer agents” in Definitions).
- the pharmaceutical composition and anti cancer agent can be in separate dosage formats.
- the pharmaceutical composition and anti-cancer agent can be in different types of dosage formats.
- the pharmaceutical composition and anti cancer agent can be administered by different routes of administration.
- the cancer is a chronic cancer.
- Chronic cancer is cancer that cannot be cured but that ongoing treatment, also called extended treatment, can control for months or years.
- extended treatment can control for months or years.
- the goal of extended treatment for cancer is to help patients live as well as possible for as long as possible. Cancer progression can be monitored by methods known in the art.
- the cancer is a solid tumor. Solid tumors include, but are not limited to, histiocytic lymphoma, cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.
- the cancer an inflammatory chronic cancer. Markers of inflammation, such at cytokine expression, can be monitored.
- the cancer is a CD47 expressing cancer. Because the recombinant oncolytic viruses disclosed herein express an anti-CD47 antibody, it would be expected that the compositions would be particularly effective in such cancers. A tumor type can be tested for the expression of CD47 by methods known in the art, such as by ELISA or FACS detection using an anti-CD47 antibody. Gliablastomas and ovarian cancers are demonstrated herein to express CD47.
- the cancer is glioblastoma, ovarian cancer, pancreatic cancer, leukemia, myeloma, or lymphoma.
- cancer is glioblastoma.
- cancer is ovarian cancer.
- cancer is pancreatic cancer.
- cancer is leukemia.
- cancer is myeloma.
- cancer is lymphoma.
- a method of treating a subject with an overactive immune system including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- the subject has asthma or eczema. In embodiments, the subject has asthma. In embodiments, the subject has eczema. In embodiments of methods of treating a subject with an overactive immune system, the subject has allergic rhinitis.
- a method of treating a subject with an autoimmune disease including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- the autoimmune disease is arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison’s disease, Vitiligo, asthma, and allergic asthma.
- SLE systemic l
- the autoimmune disease is arthritis. In embodiments, the autoimmune disease is rheumatoid arthritis. In embodiments, the autoimmune disease is psoriatic arthritis. In embodiments, the autoimmune disease is juvenile idiopathic arthritis. In embodiments, the autoimmune disease is scleroderma In embodiments, the autoimmune disease is systemic scleroderma. In embodiments, the autoimmune disease is multiple sclerosis. In embodiments, the autoimmune disease is systemic lupus erythematosus (SLE). In embodiments, the autoimmune disease is myasthenia gravis. In embodiments, the autoimmune disease is juvenile onset diabetes. In embodiments, the autoimmune disease is diabetes mellitus type 1.
- the autoimmune disease is Guillain-Barre syndrome. In embodiments, the autoimmune disease is Hashimoto’s encephalitis. In embodiments, the autoimmune disease is Hashimoto’s thyroiditis. In embodiments, the autoimmune disease is ankylosing spondylitis. In embodiments, the autoimmune disease is psoriasis. In embodiments, the autoimmune disease is Sjogren’s syndrome. In embodiments, the autoimmune disease is vasculitis. In embodiments, the autoimmune disease is glomerulonephritis. In embodiments, the autoimmune disease is auto-immune thyroiditis. In embodiments, the autoimmune disease is Behcet’s disease. In embodiments, the autoimmune disease is Crohn’s disease.
- the autoimmune disease is ulcerative colitis. In embodiments, the autoimmune disease is bullous pemphigoid. In embodiments, the autoimmune disease is sarcoidosis. In embodiments, the autoimmune disease is ichthyosis. In embodiments, the autoimmune disease is Graves ophthalmopathy. In embodiments, the autoimmune disease is inflammatory bowel disease. In embodiments, the autoimmune disease is Addison’s disease. In embodiments, the autoimmune disease is Vitiligo. In embodiments, the autoimmune disease is asthma. In embodiments, the autoimmune disease is allergic asthma.
- a method of treating a subject with an infectious disease including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- the recombinant oncolytic virus compositions disclosed herein can boost a subject’s immune system to fight off an infection.
- infectious disease is human immunodeficiency virus (HIV).
- infectious disease is COVID-19.
- infectious disease is influenza.
- infectious disease is pneumonia.
- infectious disease is syphilis. In embodiments infectious disease is anthrax. In embodiments infectious disease is gonorrhea. In embodiments infectious disease is HPV. In embodiments infectious disease is mononucleosis. In embodiments infectious disease is West Nile fever. In embodiments infectious disease is Zika. In embodiments infectious disease is malaria. In embodiments infectious disease is plague.
- immune modulation includes activating natural killer (NK) cells.
- NK cells can play a critical anti-tumor activity in cancers including GBM via natural cytotoxicity and ADCC, especially in combination with antibody therapy (see, for example, Ref. 31).
- Oncolytic virus compositions provided herein induce activation of NK cells.
- NK cell activation induction can be confirmed by cytotoxicity assays and by measuring the expression of the activation marker CD69 on NK cells, such as by flow cytometry (see Examples).
- activation of NK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity.
- activation of NK cells is measured as expression of CD69 on NK cells.
- activation of NK cells is measured as increased NK cell cytotoxicity.
- a method for increasing cytotoxicity of natural killer (NK) cells and/or CD8 T cells in a subject including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- a method for increasing survival and/or proliferation of immune cells in a subject including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
- the immune cell is a natural killer (NK) cell.
- the immune cell is a CD8 T-cell.
- compositions may be administered in a single dose (e.g. bolus injection) or multiple doses. If multiple administrations, they may be performed by the same or different routes and may take place at the same site or at alternative sites. It is also possible to proceed via sequential cycles of administrations that are repeated after a rest period. Intervals between each administration can be from several hours to one year (e.g. 24 h, 48 h, 72 h, weekly, every two weeks, monthly or yearly). Intervals can also be irregular (e.g. following tumor progression).
- the doses can vary for each administration within the range described above.
- Parenteral routes are intended for administration as an injection or infusion.
- Common parenteral injection types are intravenous (into a vein), intra-arterial (into an artery), intradermal (into the dermis), subcutaneous (under the skin), intramuscular (into muscle) and intratumoral (into tumor or at its close proximity).
- Infusions typically are given by intravenous route.
- Mucosal administrations include without limitation oral/alimentary, intranasal, intratracheal, intrapulmonary, intravaginal or intra-rectal route. Topical administration can also be performed using transdermal means (e.g. patch and the like).
- Administrations may use conventional syringes and needles (e.g. Quadrafuse injection needles) or any compound or device available in the art capable of facilitating or improving delivery of the active agent(s) in the subject.
- Routes of administration for the oncolytic virus include intravenous and intratumoral routes.
- administering includes intratumoral, systemic, or intracavitary administration. In embodiments, administering is intratumoral administration. In embodiments, administering is systemic administration. In embodiments, administering is intracavitary administration.
- compositions may be administered once or several time (e.g. 2, 3, 4, 5, 6, 7 or 8 times etc) at a dose within the range of from 10 7 to 5xl0 9 pfu.
- the time interval between each administration can vary from approximately 1 day to approximately 8 weeks, advantageously from approximately 2 days to approximately 6 weeks, preferably from approximately 3 days to approximately 4 weeks and even more preferably from approximately 1 week to approximately 3 weeks (e.g. every two weeks for example).
- the method of the invention provides a higher therapeutic efficacy than the one obtained in the same conditions with a similar oncolytic virus (without immune checkpoint modulator) or the immune checkpoint modulator either individually or even in co administration.
- the method of the invention provides at least 5%, at least 10%, at least 15%, at least 20%, or at least 25% more therapeutic efficacy than either the virus or the immune check point modulator alone or in co-administration.
- a higher therapeutic efficacy could be evidenced as described above in connection with the term “therapeutically effective amount” with a specific preference for a longer survival.
- kits including a different container (e.g., a sterile glass or plastic vial) for each virus dose to be administered.
- the kit can include a device for performing the administration of the active agents.
- the kit can also include a package insert including information concerning the compositions or individual component and dosage forms in the kit.
- Oncolytic virus provides a therapeutic approach for glioblastoma (GBM) as its mechanism of action is completely different from the standard approaches for the treatment of GBM.
- Oncolytic herpes simplex virus oHSV
- oHSV Oncolytic herpes simplex virus
- Talimogene laherparepvec the first FDA-approved oncolytic viral therapy, consists of an oHSV (see, for example, Ref. 2).
- oHSV has proven relatively safe and has shown some activity in treating GBM (see, for example, Ref. 3).
- data showed that oHSV treatment dramatically increased the intratumoral infiltration of immune cells (see, for example, Refs. 4-8)
- most tumor cells have evolved to engage the immune checkpoints and down-modulate the immune cells, thereby evading the anti-tumor immune response (see, for example, Refs. 9-10).
- engineering oHSV to express a transgene(s) that could enhance immune responses and/or block engagement of immune checkpoints could be an effective approach to improve the overall efficacy of oHSV against GBM.
- TAM Tumor-associated macrophages
- microglia are the major tumor-promoting immune cells in the GBM microenvironment (see, for example, Refs. 11-12)
- SIRP signal-regulatory proteina-CD47 pathway
- CD47-SIRPa myeloid checkpoint blockade has been shown to effectively enhance tumor phagocytosis and hence reduce tumor burden (see, for example, Refs. 16-18).
- a humanized anti- CD47 antibody which directly inhibits the CD47-SIRPa interaction, is currently in clinical trials showing strong activity against GBM (see, for example, Refs. 17, 19).
- this antibody was engineered on a human IgG4 scaffold to minimize Fc-dependent effector functions of innate immunity such as antibody-dependent cellular cytotoxicity (ADCC) and complement- dependent cytotoxicity (CDC) (see, for example, Ref. 20).
- ADCC antibody-dependent cellular cytotoxicity
- CDC complement- dependent cytotoxicity
- infusion toxicities and difficulty in passing through the blood brain barrier are challenges when the monoclonal antibody are administrated systemically to treat GBM.
- oHSV was engineered to express a full length, soluble anti-CD47 antibody with an IgGl scaffold (OV- H5F9-G1) and this was compared to another version that was engineered with an IgG4 scaffold (OV- H5F9-G4) in order to assess for locoregional treatment of glioblastoma (GBM), a devastating brain tumor without curative treatment options.
- IgGl scaffold OV- H5F9-G1
- IgG4 scaffold OV- H5F9-G4 scaffold
- the oHSV encodes a full-length anti-CD47 antibody that is secreted by the GBM and blocks the “don’t eat me” signal normally mediated by the interaction of the innate immune cell’s SIRP-a (a receptor) and its ligand, CD47, expressed by the tumor cell. Blocking this “don’t eat me” signal allows for cytotoxicity against the tumor cell by antibody-dependent cellular phagocytosis (ADCP).
- ADCP antibody-dependent cellular phagocytosis
- both versions of secreted antibodies blocked the CD47-SIRP-a axis, thereby enhancing phagocytosis of tumor cells by macrophages, with a stronger effect against GBM cells seen with the IgGl version due to: (1) an additional ADCP effect via binding with macrophage FcyRIIIA (CD 16) and (2) a strong antibody-dependent cellular cytotoxicity (ADCC) by CD16(+) natural killer (NK) cells.
- ADCC antibody-dependent cellular cytotoxicity
- OV-Hu5F9-Gl- or OV-Hu5F9-G4-infected GBM cells secrete a full-length anti-CD47 antibody.
- constructs of aCD47-Gl (IgGl version) and OV- aCD47-G4 (IgG4 version) were generated, that express an IgGl or IgG4 version of humanized anti -human CD47 antibody coding genes including a full-length of both heavy chain and light chain, driven by the promoter of the
- aCD47-G4 was re-constructed as previously reported (see, for example, Ref. 20).
- aCD47-Gl was constructed by replacing the human IgG4 constant region of aCD47-G4 with the human IgGl constant region.
- the light chain and heavy chains were linked with a T2A self-cleaving peptide as illustrated in Fig. 1 A.
- the top line of Fig. 1A is the genetic map of wild type HSV-1.
- the second line is a genetic map of control oHSV, OV-Q1, with deletion of two copies of g34.5, dysfunction of ICP6, and insertion of the GFP gene.
- the third line is a genetic map of OV- aCD47-Gl showing the inserted coding gene of IgGl version of anti-CD47 (Hu5F9-Gl) that is constructed on human IgGl scaffold.
- the light chain and heavy chain coding genes of Hu5F9-Gl are linked by a T2A sequences and are driven by the viral pIE4/5 promoter.
- the fourth line is the genetic map of OV-aCD47-G4 demonstrating the inserted coding gene of the IgG4 version of anti-CD47 (aCD47-G4) that is constructed on the scaffold of human IgG4 instead of IgGl.
- CD47 binding affinity and blocking activity of aCD47-Gl and aCD47-G4 were tested by a flow cytometric assay, using the antibodies purified from supernatants of cultured CHO cells lentivirally transduced with the corresponding coding vector.
- CD47(+) U251T2 cells were incubated with aCD47-Gl or aCD47-G4 at gradient concentrations. Results showed dose- dependent binding of aCD47-Gl and aCD47-G4 to CD47(+) U251T2 GBM cells, demonstrating that the two antibodies have almost equal binding affinity to the CD47(+) U251T2 cells (Fig. 7A).
- Fig. 1A The genetic maps of wild-type human HSV-1, OV-Q1, OV-aCD47-Gl and OV-aCD47-G4 are illustrated in Fig. 1A.
- Infection of GBM cells with OV-aCD47-Gl or OV-aCD47-G4 enabled the infected cells to secrete IgGl or IgG4 versions of anti-CD47, respectively.
- the yield of anti-CD47 from OV-aCD47-Gl- and OV-aCD47-G4- infected U251T2 GBM cells were quantified by flow cytometry assay, using corresponding antibodies purified from CHO cells with known concentrations as standards.
- the OV-5F9-G1- and OV-5F9-G4-infected U251T2 GBM cells released appreciable amount of anti-CD47 as early as 12 hours post infection, and the yields reached peak levels > 6 pg/ml in culture at 24 hours post infection (Fig. IE).
- OV-5F9-G1 and OV-5F9-G4 retain oncolytic potency and virus production.
- aCD47-Gl and aCD47-G4 were used as effector cells, as performed by many other groups 22 .
- Patient-derived GBM cells GBM43 and BT422 were used as target cells and were labeled with CFSE and pre-incubated with aCD47- G1 or aCD47-G4 purified from lentivirally infected CHO cells.
- Flow cytometry results showed that both aCD47-Gl and aCD47-G4 induced a significantly higher level of phagocytosis against GBM43 and BT422 cells compared to the corresponding OV-Q1 -infected GBM cells.
- the effect of aCD47-Gl on macrophage phagocytosis against GBM43 or BT422 cells was significantly higher than that observed for aCD47-G4 (Fig. 3A-D).
- IgG4-based antibodies have the effect of blocking CD47-SIRPa yet have a weak ADCP effect while IgGl-based antibodies block CD47-SIRPa and have a strong ADCP effect due to the difference between IgGl and IgG4 antibodies.
- aCD47-Gl was significantly higher than that of aCD47-G4.
- the effect of the purified aCD47-Gl had a dramatic increase while the effect of the purified aCD47-G4 had a moderate increase (Fig. 3A-D).
- Fig. 3A-D show that the phagocytosis increased by aCD47-Gl was mainly from ADCP and blocking CD47-SIRPa contributed substantially less.
- the phagocytosis assays were also repeated with the supernatants from OV-aCD47-Gl, OV-aCD47- G4 or OV-Q1 infected U251T2 GBM cells.
- FIG. 3G shows phagocytosis assay performed with Fc receptor blocking.
- BMDM cells were incubated with isotype human IgGl at the dose of 10 mg/ml for 30 min in advance.
- FIG. 3H shows cytokine gene transcription assay.
- BMDM were cocultured with GBM43 at the ratio of 1:1 with or without the presence of aCD47-Gl or aCD47-G4 for 6 hours. Then, total RNA was extracted and reverse-transcribed for detecting the transcription level of the indicated genes by real time PCR.
- aCD47-Gl induces potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against GBM
- NK cells play a critical anti-tumor activity in cancers including GBM via natural cytotoxicity and ADCC, especially in combination with antibody therapy (see, for example, Ref. 31).
- Hu5F9-Gl or Hu5F9-G4 affects NK cell anti-tumor activity
- freshly isolated human NK cells were used to measure the effect of the two antibodies on ADCC.
- Human GBM patients-derived tumor cells GBM43 and BT422 were used as target cells.
- the target cells were labeled with Chromium-51 ( 51 Cr) for 1 hour, and were then incubated with aCD47-Gl, aCD47-G4 purified from supernatants of lentivirus-infected CHO cells or vehicle for 30 min.
- the effector NK cells and the target cells were then co-cultured at the ratios of 40: 1, 20: 1 and 10: 1 for 4 hours. Released 51 Cr was measured for evaluating the levels of NK cell cytotoxicity.
- the results showed that when GBM43 and BT422 were used as target cells, aCD47-Gl but not aCD47-G4 induced strong NK cell cytotoxicity (Fig. 4A, 4B). This experiment was repeated with the supernatants from OV-aCD47-Gl- and OV-aCD47-G4-infected U251T2 GBM cells.
- the GBM43 cells incubated with the conditioned medium from OV-aCD47-Gl -infected U251T2 GBM cells underwent substantially more cytolysis than those incubated with the medium from OV-Q1- infected U251T2 cells.
- aCD47-Gl but not aCD47-G4 dramatically increased the surface expression of CD69 on NK cells
- Xenograft GBM mouse models were established by intracranially injecting 1 x 10 5 GBM43-FLL cells to athymic nude mice. Seven days later, mice were intratumorally injected with 2 c 10 5 PFU of OV-Q1, OV-aCD47-Gl, OV-aCD47-G4 or vehicle. Mice were weighed every day, and luciferase-based image were taken every 5 day from day 15 post tumor implantation to evaluate tumor progression.
- OV-aCD47-Gl was significantly more effective than OV-aCD47-G4 at inhibiting the progression of GBM tumors in vivo and both were superior to OV-Q1 (Fig. 5B-D).
- OV-Q1 slowed GBM progression moderately as compared to vehicle control and prolonged the median survival from 43 days to 51 days.
- OV-aCD47-G4 treatment prolonged median survival time of the GBM mice compared to both saline control and OV-Q1 treatment.
- Body weight recording of the experimental mice further indicated that the mice treated with OV-aCD47-Gl were healthier compared to mice in other groups at the late stage of the study with continuously increasing body weights (Fig. 5D)
- OV-aCD47-Gl is superior to OV-aCD47-G4 and to separate intracranial delivery of OV and systemic aCD47-Gl in improving outcome in an immunocompetent GBM model
- mice treated with OV-aCD47-Gl significantly prolonged their median survival when compared to those mice treated with OV-aCD47-G4, OV-Q1 or vehicle control (Fig. 18B).
- Fig. 18B we did not see a significant difference from the mice treated with OV-aCD47-G4 and either OV-Q1 or vehicle control (Fig. 18B).
- the human-CD47-mediated “don’t eat me” signal may not function well in the immunocompetent C57BL/6 mice; (2) the murine macrophages still receive the murine-CD47-mediated “don’t eat me” signal from the CT2A-hCD47 GBM that cannot be blocked by human aCD47-Gl or aCD47-G4; (3) human aCD47-Gl can still bind to a murine Fc receptor to induce ADCP or ADCC but aCD47-G4 cannot, as shown for other antibodies 33 .
- both OV-Q1 and aCD47-Gl delivery by the pump showed a modest but not statistically significant improvement in mouse survival (Fig. IE).
- OV-aCD47-Gl significantly prolonged the survival of the GBM mice when compared to OV-Q1 (Fig. 18E).
- OV-aCD47-Gl is the best among all the tested groups and in particular is statistically superior to the combination of i.c. OV-Q1 and aCD47-Gl delivery by the pump.
- the OV-aCD47-Gl therapeutic combines OV-Q1 and aCD47-Gl into a single agent, and the single agent shows therapeutic survival outcomes superior to aCD47-Gl alone, OV-Q1 alone, and their combination
- the two-in-one single agent i.e., an oncolytic virus expressing a full-length IgGl anti-CD47 antibody is an innovative, convenient, and effective approach for the treatment of experimental GBM.
- aCD47-Gl induces GBM phagocytosis via ADCP
- BMDM preincubating BMDM with high-dose (10 pg/ml) isotype human IgGl, which competes with aCD47-Gl to bind to Fc receptors, significantly inhibited aCD47-Gl -induced GBM phagocytosis by BMDM (Fig. 9).
- aCD47- G1 but not aCD47-G4 dramatically activated transcription of typical macrophage cytokine genes of mouse BMDM that have been reported to response to IgGl antibody (see, for example, Ref. 28), such as II lb, 116, 1110, III 2b and Nos2 (Fig. 10).
- aCD47-Gl and aCD47-G4 were also determined.
- primary human donor-derived macrophages were used as effector cells, as previously reported by other groups (see, for example, Ref. 29).
- Patient-derived GBM43 GBM cells labeled with CFSE were used as target cells.
- Target cells were cocultured with the human primary macrophages at a ratio of 2: 1 for 4 hours in the presence of aCD47-Gl or aCD47-G4 that purified from lentivirus-infected CHO cells.
- both aCD47-Gl and aCD47-G4 significantly enhanced the phagocytosis of GBM43 cells by human macrophages, although the effect of the former is more substantial than the latter due to having additional strong ADCP effect (Fig. 11). Similar results were found by using the unconcentrated supernatants from OV-aCD47-Gl-, OV-aCD47-G4- or OV-Q1 -infected U251T2 GBM cells.
- aCD47-Gl also activated the transcription of typical macrophage cytokine genes of human macrophages, such as IL1B, IL6, IL10, NOS2 (Fig. 13A) and IL12A (Fig. 13B).
- the increased phagocytosis effect of aCD47- G1 above vehicle control should be from both blockade of “don’t eat me” signaling and ADCP while the effect above aCD47-G4 should be from ADCP only, as IgGl rather than IgG4 antibodies can induce substantial ADCP via an Fc receptor-mediated effect, likely due to the distinct physical properties of IgGl and IgG4 antibodies (see, for example, Ref. 30).
- Group 1 saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus intraperitoneal (i.p.) delivery of aCD47-Gl; and Group 4, OV-aCD47-Gl.
- the viral dose for the two groups receiving an i.c. injection of OV-Q1 and the group receiving i.c. injection of OV-aCD47-Gl on day 21 was 2 c 10 5 plaque-forming unit (PFU) per mouse.
- Group 3 received i.p. aCD47-Gl at a dose of 150 pg per mouse on day 22.
- Mice in other groups received i.p. saline on day 22 as control. All mice were sacrificed on day 23 to determine the levels of the antibody in plasma by ELISA and in the central nervous system (CNS) by IHC (Fig. 14).
- mice with i.p. injection of aCD47-Gl had approximately 10 pg/ml of aCD47-Gl detected in the plasma, while Groups 1, 2 and 4 had no or little aCD47-Gl detected in the plasma (Fig. 15 A).
- Brains isolated from the experimental mice were used for histologic study. H&E staining was performed to distinguish GBM tissues from normal brain tissues (Figs. 15B and C).
- the immunohistochemical staining with an anti-HSV antibody, anti-human Fc antibody, anti-CDllb or anti-NKp46 antibody indicated oHSV-infected areas, presence of aCD47-Gl, distribution of macrophages or NK cells, respectively.
- the anti-human Fc staining showed that there was a measurable amount of aCD47-Gl detectable in the brains of the mice treated with OV-aCD47-Gl but no anti -human Fc staining was found in the brains of those that were i.c. treated with saline or OV-Q1 or in mice that received i.p. injections of aCD47-Gl (Figs. 15B and C).
- the anti-human Fc staining localized in the same area of the anti-HSV staining in the brains treated with OV-aCD47-Gl.
- CD1 lb(+) macrophage and NKp46(+) NK cell infiltration increased only in the tumor-bearing hemispheres compared to the non-tumor hemispheres.
- the macrophages and NK cells in the brains of saline- treated mice were mainly located at the surrounding area of the entire tumor but rarely infiltrated into the central area of the tumor.
- treatment with OV-Q1 or OV-aCD47-Gl substantially increased intratumoral infiltration of CD1 lb(+) macrophages and NKp46(+) NK cell (Figs. 15B and C).
- OV-Hu5F9-Gl- or OV-Hu5F9-G4-infected A2780 cells secrete a full-length anti-CD47 antibody.
- A2780 the human ovarian cancer cell line and observed that CD47 was expressed on the surface of A2780 cell line.
- A2780 cells were firstly incubated with aCD47-Gl or aCD47-G4 at gradient concentrations. Then the cells were stained with a BV786-conjugated anti-CD47 antibody. Results showed a similar dose-dependent decrease of BV786 signal when cells were preincubated with aCD47-Gl and aCD47-G4, indicating that aCD47-Gl and aCD47-G4 have a similar CD47 blocking capacity (Fig. 19).
- OV-aCD47-Gl- and OV-aCD47-G4 were constructed by inserting the coding genes of aCD47-Gl and aCD47-G4 into the oncolytic herpes virus backbone (OV-Q1) respectively.
- the inserted genes of anti-CD47 antibody were driven by the virus immediately early gene promoter IE4/5 to get a high-level expression after infection (Fig. 20).
- human ovarian cancer cells, A2780 cells were saturated infected by OV-aCD47-Gl and OV-aCD47-G4 at the MOI of 2.
- Anti-CD47 antibodies were detected in the supernatant of infected cells as soon as 6 hours after infection and the yield of anti-CD47 antibody reached over 5 ug/ml at 24 hours after infection. Then we tested if the insertion of anti-CD47 antibody coding gene affect the oncolytic effect of OV-aCD47-Gl and OV-aCD47-G4. A2780 cells were infected with different titers of OV-aCD47-Gl, OV-aCD47-G4 or the parental virus (OV-Q1). There was no obvious difference in cell death was observed among that caused by infection of OV-aCD47-Gl, OV-aCD47-G4 or OV-Q1. Therefore, the insertion of aCD47-Gl and aCD47-G4 coding genes does not affect the oncolytic ability of OV-aCD47-Gl and OV-aCD47-G4.
- aCD47-Gl activates the antitumor effect of macrophages
- human primary macrophages were isolated for using as effector cells.
- Human ovarian cancer cells A2780 were used as target cells.
- the target cells were cocultured with the human macrophages at the ratio of 2: 1 for 4 hours in the presence of purified aCD47-Gl or aCD47-G4.
- the phagocytosis results showed that compared to vehicle control, aCD47-Gl dramatically, while aCD47-G4 moderately enhanced the phagocytosis of human macrophages against A2780 cells (Fig. 21A).
- the supernatants from OV-aCD47-Gl-, OV-aCD47-G4- or OV-Q1 -infected A2780 cells were used to repeat this experiment.
- BMDMs Bone marrow derived macrophages isolated from BALB/c mice were used as effector cells.
- CFSE labeled human ovarian cancer cells A2780 were used as target cells.
- the target cells were cocultured with the BMDMs at the ratio of 2: 1 for 4 hours in the presence of purified aCD47-Gl or aCD47-G4.
- the phagocytosis results showed that compared to vehicle control, aCD47-Gl significantly activated the phagocytosis function of mouse BMDMs against A2780 cells.
- aCD47-G4 has moderate effect on mouse BMDM phagocytosis activation (Fig. 21C).
- the supernatants from OV-aCD47-Gl-, OV- aCD47-G4- or OV-Q1 -infected A2780 cells were used to repeat this experiment with mouse BMDMs.
- Both aCD47-Gl secreted by OV-aCD47-Gl -infected cells and aCD47-G4 secreted by OV-aCD47-G4-infected cells significantly enhanced the phagocytosis of mouse BMDMs against A2780 cells, although the effect of the former is more substantial than the latter due to aCD47- G1 having additional strong ADCP effect (Fig. 21D).
- aCD47-Gl and aCD47-G4 were also tested. Human macrophages were incubated with aCD47-Gl, aCD47-G4 or vehicle for 6 hours. Then the total RNA was isolated for measuring the gene transcription level by real time PCR. The results showed that aCD47-Gl dramatically activated the transcription of some typical macrophages cytokine genes such as IL6, IL10, iNOS and IL12 (Fig.22 A and 22B).
- OV-aCD47-Gl activates the antitumor effect of NK cells
- aCD47-Gl and aCD47-G4 were used freshly isolated human NK cells as effector cell and ovarian cancer cells as target cells to perform NK cell cytotoxicity assays. Chromium-51 pre-labeled target cells were incubated with purified aCD47-Gl or aCD47-G4. Then the effector NK cells were cocultured with the pretreated target cells at different ratios for 4 hours. The release of chromium-51 was measured for evaluating the cytotoxicity. The results showed that aCD47-Gl but not aCD47-G4 induced strong NK cell cytotoxicity against ovarian cancer cells (Fig. 23A).
- OV-aCD47-Gl improves the therapeutic efficacy against ovarian tumor
- OV-aCD47-Gl was significantly more effective than OV-aCD47-G4 at inhibiting the progression of tumors in vivo and both are superior to OV-Q1 (Fig. 24).
- OV-Q1 moderately slowed tumor progression as compared to vehicle control (Fig. 24).
- OV-aCD47-Gl enhances the therapeutic efficacy in an immunocompetent ovarian cancer mouse model
- Olaparib a poly (ADP-ribose) polymerase (PARP) inhibitor
- PARP poly (ADP-ribose) polymerase
- the PARP enzyme plays a role in DNA repair. Inhibiting this enzyme may contribute to cancer cell death and increased sensitivity to chemotherapy. By blocking this enzyme, DNA inside the cancerous cells is less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth.
- OV-aCD47-Gl enhanced olaparib function for treating ovarian cancer.
- A2780 cells were treated with olaparib overnight, and the pretreated cells were 51Cr-labeled and used as target cells. These cells were then incubated with the supernatant from OV-aCD47-Gl- or OV-Q1- infected cells. The effector NK cells and target cells were then co-cultured at the ratios of 40: 1, 20:1, and 10:1 for 4 hours and assayed for cytotoxicity. The results demonstrated that olaparib pre-treatment enhanced NK cell cytotoxicity.
- TME immune-evasive tumor microenvironment
- a platform was developed by using oncolytic virus as a locoregional delivery vehicle of the full-length anti-CD47 antibody.
- This novel reagent can be administered intratumorally or intracranially post-surgery.
- This two-in-one, economical, and effective reagent should be able to be administered intratumorally pre-, intra- or post-operatively.
- OV-aCD47- G1 leads to (1) direct tumor lysis by oHSV; (2) innate immune cell infiltration and activation at the TME by oHSV; (3) blockade of the “don’t eat me” signal normally mediated by the interaction between SIRP-a and CD47 expressed by macrophages and GBM, respectively; (4) aCD47-Gl- mediated ADCP via bridging Fey receptors on macrophages and CD47 on GBM; and (5) aCD47- G1 -mediated ADCC by NK cells.
- aCD47-G4 The systemic administration of the IgG4 anti-CD47 antibody (aCD47-G4) has shown significant anti-tumor activity in several types of malignancies in both preclinical and clinical studies (see, for example, Refs. 17-19).
- aCD47-G4 was constructed on a human IgG4 scaffold to minimize adverse effects resulting from Fc-dependent effector functions resulting from systemic administration of aCD47-Gl such as ADCC and ADCP.
- the aCD47-G4 mAh is largely limited to blocking the CD47-SIRPa axis while being unable to induce the FcR+ innate immune effector cell responses of ADCC and ADCP, which result from Fc portion of the IgGl mAh binding to the FcR on macrophages and NK cells.
- OV-aCD47-Gl and OV-aCD47-G4 released full length aCD47-Gl and aCD47- G4 mAbs, respectively, once GBM was infected, we found the anti -tumor efficacy of OV-aCD47- G1 to be significantly higher than OV-aCD47-G4 in vitro and in vivo.
- the data presented here suggest this is because aCD47-G4 can only block the CD47-SIRPa “don’t-eat-me” signal, while aCD47-Gl combines this effect with Fc-dependent effector functions that result from ADCC and ADCP.
- mAbs Monoclonal antibodies
- the intravenous (i.v.), subcutaneous (s.c.), or intramuscular (i.m.) routes of administration may be impeding their efficacy in solid tumors with challenging TMEs.
- s.c. and i.m. administration of mAbs require an additional absorption step, whereby mAbs are transported from the interstitial space into the lymphatic system prior to draining into the blood stream (see, for example, Ref. 34).
- the systemic delivery of mAbs is mainly distributed in plasma rather than the targeted tissue.
- a high systemic dose of mAh is required but can result in adverse side effects and excessive cost.
- traversing the blood-brain barrier (BBB) for mAh treatment of GBM is another challenge that largely precludes the systemic approach for mAh therapy in most GBM patients.
- oHSV re-engineered oHSV is an excellent platform to deliver mAbs in solid tumors such as GBM because the mAbs can be delivered beyond the BBB locoregionally by the GBM itself given the neurotropic properties of HSV.
- the infected GBM can produce the mAh continually within the TME, thereby achieving an effective local dose and improving the likelihood of an anti-tumor response as FcR+ innate immune effect cells migrate to the virally infected tumor site.
- the encoded anti-CD47 mAh gene is designed to be driven by a strong oHSV promoter, the promoter of the HSV-1 immediate early gene IE4/5.
- TAMs have been found to be the major immune cells that promote tumor development in the GBM microenvironment (see, for example, Ref. 35). Since modulating TAMs is considered to be a promising anti-tumor strategy, targeting the CD47-SIRPa axis in these cells should be a good approach for the treatment of GBM.
- CD47 is highly expressed on numerous types of tumors including GBM (see, for example, Refs. 16, 26, 36).
- CD47 acts as an anti-phagocytic “don't eat me” signal by binding to SIRPa on the surfaces of macrophages. Activation of SIRP-a results in the inhibition of phagocytosis (see, for example, Ref. 18).
- CD47 helps the tumor cells escape from elimination by macrophages and facilitates their metastasis (see, for example, Ref. 37). Disrupting this CD47-SIRPa axis using mAbs has been shown to increase the phagocytosis of cancer cells and inhibit the progression of some hematological malignancies as well as solid tumors (see, for example, Refs. 17, 19, 38, 39).
- aCD47-G4 (5F9-G4) is a humanized mAh whose construction was carried out by grafting its complementarity determining regions (CDRs) onto a human IgG4 scaffold to minimize Fc-dependent effector functions such as ADCC and ADCP.
- the aCD47-Gl antibody has identical CDRs but is grafted onto a human IgGl scaffold. Therefore, they should have a near-identical ability to interrupt the “don’t eat me” CD47-SIRPa interaction.
- our study suggests that when locoregional delivery is available for GBM via its infection with oHSV, the aCD47-Gl antibody should be considered instead of aCD47-G4.
- the aCD47- G1 antibody has superior in vitro anti-tumor efficacy compared to that of aCD47-G4.
- the aCD47-Gl antibody expressed by OV- aCD47-Gl can induce Fc-dependent ADCP mediated by macrophages and ADCC mediated by NK cells, while the aCD47-G4 antibody can only interrupt the “don’t-eat-me” signal.
- our in vivo efficacy data showed that OV-aCD47-Gl played a better role than OV- aCD47-G4 in impeding GBM growth and facilitating its eradication.
- Our data also suggest that both the Fc-dependent anti -tumor effect and the effect resulting from the interruption of the CD47- SIRPa axis are important in the experimental treatment of GBM.
- OV-aCD47-G4 When systemic delivery of oncolytic virus is considered for tumors outside of the CNS, OV-aCD47-G4 may prove to be effective. Considering that both the oHSV backbone and anti- CD47 antibody have been tested in the clinic, our novel oHSV expressing an anti-CD47 antibody should likely be considered for translation into the clinic for the treatment of systemic solid tumors.
- the full-length antibodies including both heavy and light chains are produced by a strong viral promoter, which can increase the locoregional delivery of antibodies in the TME but eliminate toxicities that could result from high dose systemic administration that would be required to achieve therapeutic levels in the CNS, however unlikely.
- Our therapeutic oHSV will not only activate the innate immune system but also continuously produce the mAh locally as long as the OV persists within the TME. In the ideal situation, once tumor cells are completely lysed by the OV, replicating virus dissipates and antibody production will cease thereby limiting the potential for long-term local tissue toxicity.
- our platform can be used to deliver other forms of mAbs such as single chain mAbs (scFv) or any mAh with diverse functions such as T cell checkpoint blockade including anti- PD1, anti-PD-Ll, anti-CTL4 or mAbs that directly target tumor cells, e.g., the anti-EGFR mAh (see, for example, Refs. 41-42).
- scFv single chain mAbs
- any mAh with diverse functions
- T cell checkpoint blockade including anti- PD1, anti-PD-Ll, anti-CTL4 or mAbs that directly target tumor cells, e.g., the anti-EGFR mAh (see, for example, Refs. 41-42).
- OV-aCD47- G1 could not only directly lysis tumor cell, but also activate NK cell ADCC and macrophages ADCP function in vitro.
- OV-aCD47-Gl also blockaded the “don’t eat me” signal normally mediated by the interaction between SIRP-a and CD47 expressed by macrophages and ovarian tumor cells, respectively. Therefore, OV-aCD47-Gl treatment significantly improved the virotherapy efficacy against ovarian tumor in vivo.
- OV-aCD47-Gl and OV-aCD47-G4 are designed to secret aCD47-Gl and aCD47-G4 respectively to the ovarian cancer tumor microenvironment after intratumoral administration.
- CD47 is highly expressed on numerous types of tumors including ovarian cancer cell. By binding to its receptor SIRPa on the surfaces of macrophages, CD47 that expressed on ovarian cancer cell can bring a “don’t eat me” signal to macrophages and protect the tumor cells from been phagocytized (see, for example, Ref. 51).
- Anti-CD47 antibodies have been used for blocking CD47-SIRPa axis to enhance the phagocytosis of ovarian cancer cells and have been proved effective by many clinical and preclinical trials (see, for example, Refs.
- aCD47-Gl induced much stronger phagocytosis of A2780 cells by both human and mouse macrophages, besides that, aCD47-Gl but not aCD47-G4 dramatically induced the cytotoxicity of A2780 cells by human NK cells. While aCD47-Gl and aCD47-G4 they shared identical CDRs, they should have a near-identical ability to interrupt the “don’t eat me” CD47-SIRPa interaction.
- aCD47-Gl and aCD47-G4 can block the CD47-SIRPa interaction
- the aCD47-Gl antibody can induce Fc- dependent ADCP mediated by macrophages and ADCC mediated by NK cells, while the aCD47-G4 antibody can only interrupt the “don’t-eat-me” signal. Consistent with these, the in vivo results compared to OV-aCD47-G4 treatment, OV-aCD47-Gl showed a stronger anti tumor therapy effect.
- GBM43 and GBM43-FFL cells were maintained as tumor spheres with basic neurobasal medium supplemented with 2% B27 (Gibco), human epidermal growth factor (EGF, 20 ng/ml) and fibroblast growth factor (FGF, 20 ng/ml) in low-attachment cell culture flasks.
- BT422 cells derived from a GBM patient were cultured with NS-A basal medium (StemCell) with EGF (20 ng/ml) and FGF (20 ng/ml) in low-attachment cell culture flasks.
- Human ovarian cancer cell line A2780, Chinese hamster ovary cell line CHO, sand monkey kidney epithelium-derived Vero cells were cultured with DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 pg/ml).
- Monkey kidney epithelium-derived Vero cells used for viral propagation and plaque-assay -based viral titration were maintained with the same media as the GBM cell lines.
- Gli36AEGFR and U251T2 cells were authenticated by the University of Arizona Genetics Core via STR profiling in January 2015, and LN229 in March 2018.
- GBM43 were authenticated by the Cell Line Characterization Core at MD Anderson Cancer Center in February 2019. Vero cells were not authenticated after receipt.
- GBM43 was developed at Mayo Clinic and other cell lines were originally developed by our group or obtained from ATCC. All cell lines were routinely tested for absence of mycoplasma using the MycoAlert Plus Mycoplasma Detection Kit from Lonza (Walkersville, MD).
- CHO cells were used to produce aCD47-Gl and aCD47-G4 for functionality tests.
- the light chain and heavy chain coding genes of aCD47-G4 were reconstructed as previously reported (see Ref. 20).
- aCD47-Gl used the same light chain coding gene as aCD47-G4, but a modified aCD47-G4 heavy chain coding gene that replaced the human IgG4 constant region with the human IgGl constant region as the heavy chain coding gene.
- Lentiviral vectors were used to transduce CHO cells to express aCD47-Gl or aCD47-G4.
- the light chain and heavy chain coding genes were carried by different lentiviral vectors with GFP and mCherry selection markers, respectively, for sorting the double positive CHO cells by using a FACS Aria II cell sorter (BD Biosciences, San Jose, CA, USA).
- the conditional supernatants of the lentivirus- infected CHO cells were used to purify aCD47-Gl and aCD47-G4 by using a protein G column (Thermo Fisher, 89927).
- the purified aCD47-Gl was desalted by fast protein liquid chromatography (FPLC).
- aCD47-Gl or aCD47-G4 antibodies purified for 30 min. Then the cells were washed twice and stained with APC-conjugated anti -human Fc (Jackson ImmunoResearch, 209-605-098) for 20 min. After that the cells were washed twice and stained with BV786-conjunaged anti-CD47 antibody (clone, B6H12, BD, 563758) for 20 min. The cells were analyzed by using Fortessa X20 flow cytometer (BD Biosciences). Median of mean fluorescence intensity (MFI) of APC and BV786 was used to determine CD47 binding and blocking capacity of aCD47-Gl and aCD47-G4.
- MFI mean fluorescence intensity
- A2780 cells were saturated infected with OV-Q1, OV- aCD47-Gl or OV-aCD47-G4 at a MOI of 2. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 6, 12, 24, 48 and 72 hpi to measure antibody concentration by ELISA. A series amount of aCD47-Gl and aCD47-G4 antibodies purified from CHO cells with known concentrations served as standards. The ELISA was performed as previously reported with slight modification (see Ref. 69). Briefly recombinant human CD47 protein (abeam, abl74029) was used as coating reagent. Anti-human Fc antibody (sigma, MAB1307) was used as detecting antibody.
- OV-aCD47-Gl and OV-aCD47-G4 were generated by using the fHsvQuik-1 system as previously described (see, for example, Refs. 4, 21).
- the light chain and heavy chain coding genes were linked with a DNA sequence encoding a T2A self-cleaving peptide.
- the linked aCD47-Gl and aCD47-G4 light chain and heavy sequences were inserted into pT-oriSIE4/5 following the HSV pIE4/5 promoter to construct pT-oriSIE4/5-aCD47-Gl or pT-oriSIE4/5- aCD47-G4.
- pT-oriSIE4/5-aCD47-Gl was recombined with fHsvQuik-1 for engineering OV-aCD47-Gl, OV-aCD47-G4 and OV-Q1, respectively.
- Vero cells were used for propagating and titrating the viruses. Virus titration was performed using plaque assays. Briefly, monolayer Vero cells were seeded in a 96-well plate. After 12h, these cells were infected with gradient-diluted viral solutions. The infection media were replaced with DMEM supplemented with 10% FBS, after two-hour infection.
- GFP-positive plaques were observed and counted with a Zeiss fluorescence microscope (AXIO observer 7) 2 days after infection to calculate the viral titer.
- AXIO observer 7 To concentrate and purify the viral particles of OV-Q1, OV-aCD47-Gl and OV-aCD47-G4, the culture media containing viruses were harvested and centrifugated at 3,000 g for 30 min. Then the supernatants were collected and ultra-centrifugated at 100,000 g for 1 hour. The pellets of virus were resuspended with saline as needed.
- CCK8 tetrazolium salt is reduced by cellular dehydrogenases to an orange formazan product that is soluble in tissue culture medium.
- the amount of formazan produced is directly proportional to the number of living cells and is measured by absorbance at 460 nm.
- Cell lysis and viral dose curves were established to evaluate the in vitro oncolytic efficacy of OV-aCD47-Gl and OV-aCD47-G4.
- the viral replication assay was performed as previously reported (see Ref. 4). Briefly, monolayers of U251T2 and Gli36AEGFR cells were seeded on 96-well plates and infected with OV-Q1, OV-aCD47-Gl or OV-aCD47-G4 at a MOI of 2. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 24, 48 and 72 hpi and viral titers were determined by plaque assays.
- mice were sacrificed at the time of bone marrow harvest. Bone marrow cells were extracted from the tibias and femurs by flushing with culture medium using a 25 G needle. The cells were then passed through a 70 pm nylon mesh (BD Bioscience) and washed three times with PBS. Extracted BM cells were implanted with 2.4 x 107/100 mm culture dish (BD Falcon) and cultured for 7 days in the presence of murine M-CSF (PeproTech, 315-02) medium (replacing culture medium on day 3 and day 5).
- murine M-CSF PeproTech, 315-02
- peripheral blood was collected from health donors.
- Human monocytes were isolated and enriched by using the RosetteSepTM Human Monocyte Enrichment Cocktail kit (Stemcell, Cat# 15068) from the peripheral blood.
- the enriched human monocytes were cultured with RPMI-1640 medium containing 20 ng/ml human M-CSF (PeproTech, Cat#300-25-50UG) and 2 % human serum for 7 days to induce the macrophage differentiation (replacing culture medium on day 3 and day 5).
- RPMI-1640 medium containing 20 ng/ml human M-CSF (PeproTech, Cat#300-25-50UG) and 2 % human serum for 7 days to induce the macrophage differentiation (replacing culture medium on day 3 and day 5).
- BMDM and target cells were cocultured at a ratio of 1:2 for 2 hours in the presence of vehicle control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml, in a humidified, 5% C02 incubator at 37 °C in ultra-low-attachment 96-well U-bottom plates (Coming) in serum-free 1640 (Life Technologies).
- BMDM were pre-incubated with 10 pg/ml isotype human IgGl (Biolegend, 403505) for 30 min. All flow cytometry data were collected using an Fortessa X20 flow cytometer (BD Biosciences). Phagocytosis was measured as the number of CD1 lb+CFSE+ macrophages, quantified as a percentage of the total CDllb+ macrophages.
- phagocytosis assay of human primary macrophage GBM43 cells stained with CFSE (Thermo fisher, C34554) were used as target cells.
- Human macrophages and target cells were cocultured at a ratio of 1 :2 for 4 hours in the presence of vehicle control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml, in a humidified, 5% C02 incubator at 37 °C in ultra-low- attachment 96-well U-bottom plates (Coming) in serum-free 1640 (Life Technologies).
- the cells were harvested by centrifuging at 400 g for 5 min at 4 °C and stained with anti-human CD1 lb (BD, 552850) to identify macrophages. All flow cytometry data were collected using an Fortessa X20 flow cytometer (BD Biosciences). Phagocytosis was measured as the number of CD1 lb+CFSE+ macrophages, quantified as a percentage of the total CD1 lb+ macrophages.
- ovarian cancer studies For the phagocytosis assay of human primary macrophage, A2780 cells stained with CFSE (Thermo fisher, C34554) were used as target cells human macrophages and target cells were cocultured at a ratio of 1:2 for 4 hours in the presence of vehicle control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml, in a humidified, 5% C02 incubator at 37 °C in ultra-low-attachment 96-well U-bottom plates (Coming) in serum-free 1640 (Life Technologies).
- CFSE Thermo fisher, C34554
- GBM43, BT422, U251T2, GBM30, LN229 and Gli36AEGFR cells were used as target cells.
- Primary human NK cells isolated from leukopaks of health donors using an NK cell isolation kit (MACSxpress Miltenyi Biotec, San Diego, CA) and an erythrocyte depletion kit (Miltenyi Biotec) were used as effector cells.
- the target cells were labeled with 51 Cr for 1 h.
- GBM43, BT422, U251T2, GBM30 and LN229 cells were cocultured with 1 pg/ml aCD47-Gl or aCD47-G4 antibodies or vehicle for 30 min.
- Gli36AEGFR cells were cocultured with gradient doses of aCD47-Gl or aCD47-G4 antibodies or vehicle for 30 min. Then the target cells were cocultured with isolated human primary NK cells at different effectortarget ratios at 37 °C for 4 h. Release of 51 Cr was measured with a MicroBeta2 microplate radiometric counters (Perkin Elmer, Waltham, MA). Target cells incubated in complete media were for spontaneous and in 1% SDS media were used for maximal 51 Cr release control. The cell lysis percentages were calculated using the standard formula: 100 c (cpm experimental release - cpm spontaneous release) / (cpm maximal release - cpm spontaneous release).
- the assays were performed in at least three technical replicates with NK cells from different donors.
- the expression of CD69, an NK cell activation marker, was measured after 4 hours coculture of NK cells and GBM43, GBM30 or U251T2 cells at a ratio of 1:1 with flow cytometer by using the anti-CD56 (BD, 557919) and anti-CD69 (BD, 562883) antibodies.
- A2780 cells were used as target cells.
- Primary human NK cells isolated from leukopaks of health donors using an NK cell isolation kit (MACSxpress Miltenyi Biotec, San Diego, CA) and an erythrocyte depletion kit (Miltenyi Biotec) were used as effector cells.
- the target cells were labeled with 51 Cr for 1 h.
- A2780 cells were cocultured with 1 pg/ml aCD47-Gl or aCD47-G4 antibodies or vehicle for 30 min. Then the target cells were cocultured with isolated human primary NK cells at different effector: target ratios at 37 °C for 4 h.
- CD69 and granzyme B, NK cell activation markers were measured after 12 hours coculture of NK cells and A2780 cells at the ratio of 1: 1 with flow cytometer by using the anti-CD56 antibody (BD, 557919) , anti-granzyme B antibody and anti-CD69 (BD, 562883) antibody.
- Anti-human IgG heavy chain (sigma, MAB1307), anti-human kappa chain (Thermo fisher, MA5-12117) and the corresponding secondary antibodies (LI-COR, 925-32210) were used to detect the heavy chain and light chain.
- mouse BMDM and GBM43 were cocultured at a ratio of 1:1 for 6 hours with or without the presence of 5 pg/ml aCD47-Gl or aCD47-G4. Then the total RNA was extracted for measuring the relative transcription of murine Argl, Ccl2, Ccl4, Illb, 116, 1110, 1112b and Nos2 genes with the corresponding primers. 18s rRNA was used as internal control.
- aCD47-Gl and aCD47-G4 were cocultured at a ratio of 1: 1 for 6 hours with or without the presence of 5 pg/ml aCD47-Gl or aCD47-G4. Then the total RNA was extracted for measuring the relative transcription of human IL1B, IL6, IL10, IL12A and NOS2 genes with the corresponding primers. 18s rRNA was used as internal control.
- aCD47-Gl and aCD47-G4 were cocultured at the ratio of 1 : 1 for 6 hours with or without the presence of 5 pg/ml aCD47-Gl or aCD47-G4. Then human macrophages were sorted by staining with anti- CD45 antibody. The total RNA was extracted for measuring the relative transcription of human IL1B, IL6, IL10, IL12A and NOS2 genes with the corresponding primers. 18s rRNA was used as internal control.
- mice Six- to eight-week-old female athymic nude mice were purchased from Jackson Laboratories (Bar Harbor, Maine). For the survival studies, the mice were anesthetized and stereotactically injected with 1 c 10 5 GBM43-FFL cells, which express a firefly luciferase (FFL) gene, into the right frontal lobe of the brain (2 mm lateral and 1 mm anterior to bregma at a depth of 3 mm). The cells grew for 7 d, and animals were subsequently randomly divided into groups that were i.c.
- FTL firefly luciferase
- mice were injected either with 2 c 10 5 PFU oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-G4) in 3 pi of saline or with saline as control. Mice were subsequently monitored and weighed frequently for GBM disease progression. Luciferase-based in vivo images were taken from 15 days after tumor implantation to evaluate the tumor development. The mice were euthanized when they became moribund, with neurologic impairments and obvious weight loss.
- nude mice were stereotactically injected with 1 c 10 5 GBM43 into the same site of the brain mentioned above.
- the GBM cells were allowed to grow for 21 days, and the mice were randomly divided to four groups: Group 1, saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus i.p. delivery of aCD47-Gl and Group 4, OV-aCD47-Gl.
- Group 1 received saline as control.
- Groups 2, 3, and 4 with OV treatment were i.c. injected with 2 c 10 5 PFU oHSV (OV-Q1 or OV-aCD47-Gl) on day 21.
- Group 3 received i.p.
- mice For establishing the immunocompetent mouse GBM model, six- to eight-week-old female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). The mice were anesthetized and stereotactically injected with 1 c 10 5 CT2A-hCD47 cells, which express a human CD47 gene, into the right frontal lobe of the brain (2 mm lateral and 1 mm anterior to bregma at a depth of 3 mm). The cells grew for 3 d, and animals were subsequently randomly divided into groups that were i.c.
- mice were injected either with 2 c 10 5 PFU oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-G4) in 3 pi of saline or with saline as control. Mice were subsequently monitored and weighed frequently for GBM disease progression. Luciferase-based in vivo images were taken from 15 days after tumor implantation to evaluate the tumor development. The mice were euthanized when they became moribund, with neurologic impairments and obvious weight loss.
- osmotic pumps (Alzet, Cat#1003D) were filled with 100 pi of desalted and concentrated aCD47-Gl at the concentration of 1.0 pg/m ⁇ .
- the pumps were connected with the brain infusion kit (Alzet, Cat#0008851) and implanted into the mice for continuous delivery aCD47-Gl to the tumor site.
- mice Six- to eight-week-old female athymic nude mice were purchased from Jackson Laboratories (Bar Harbor, Maine). For the survival studies, the mice were anesthetized and s.c. injected with 5 c 10 6 A2780 cells over the flank. 1 day after A2780 cells injection, animals were subsequently randomly divided into groups that were injected intratumorally either with 1 c 10 5 pfu oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-G4) in 10 m ⁇ of saline or with saline as control. Mice were subsequently monitored for ovarian cancer progression. The mice were euthanized when the tumor diameter was over 30 mm.
- mice were implanted with patient derived tumor fragments.
- the mice were randomly divided to 3 groups: Group 1: OV- Ql; Group 2: OV-aCD47-Gl; and Group 3: OV-aCD47-G4. All groups with OV treatment were intratumorally injected with 2 c 10 5 PFU oHSV on day 5. Mice were euthanized on day 7 for harvesting the tumor fragments. Tumor fragments isolated from the experimental mice were used for histologic study.
- mice For establishing the immunocompetent mouse ovarian tumor model, six- to eight-week- old female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). The mice were anesthetized and i.p injected with 1 c 10 6 ID8-hCD47 cells, which express a human CD47 gene, The cells grew for 3 d, and animals were subsequently randomly divided into groups that were i.p injected either with 2 c 10 5 PFU oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47- G4) in 10 m ⁇ of saline or with saline as control. Mice were subsequently monitored and weighed frequently for ovarian cancer disease progression. Luciferase-based in vivo images were taken from 15 days after tumor implantation to evaluate the tumor development. The mice were euthanized when they became moribund and obvious weight increased.
- gliablastoma studies Brains isolated from the experimental mice were placed in 10% neutral buffered formalin for a minimum of 72 h. After paraffin embedding, 4-pm-thick sections were cut from the blocks. H&E staining and immunohistochemical staining with anti- HSV (Cell marque, 361A-15-ASR), anti-human Fc (Jackson ImmunoResearch, 109-005-098), anti-CDllb (abeam, abl33357) antibodies were performed by the Pathology Core of Shared Resources at City of Hope Beckman Research Institute and National Medical Center. Stained slides were mounted and scanned for observation.
- Descriptive statistics (means, standard deviations, median, counts, etc.) were used to summarize data. Continuous endpoints that are normally distributed with or without prior log transformation were compared between two or more independent conditions by Student’s t test or one-way ANOVA, respectively. For data with repeated measures from the same subject/donor, a linear mixed model was used to compare matched groups by accounting for the underlying variance and covariance structure. For survival data, survival functions were estimated by the Kaplan-Meier method and compared by log rank test. All tests were two-sided. P values were adjusted for multiple comparisons by Holm’s procedure or the Bonferroni method and a P value of 0.05 or less was defined as statistically significant. Statistical software GraphPad, R.3.6.3. and SAS 9.4 were used for the statistical analysis.
- Embodiments disclosed herein include embodiments PI to P25 following.
- Embodiment PI A recombinant oncolytic herpes simplex virus (HSV) comprising: an expression cassette encoding a CD47 antibody.
- HSV herpes simplex virus
- Embodiment P2 The recombinant oncolytic virus of Embodiment PI, wherein the CD47 antibody comprises an IgG scaffold.
- Embodiment P3 The recombinant oncolytic virus of Embodiment P2, wherein the IgG scaffold is selected from IgGl, IgG2, IgG3, and IgG4 scaffold.
- Embodiment P4 The recombinant oncolytic virus of Embodiment P3 wherein the IgG scaffold is an IgGl scaffold.
- Embodiment P5. The recombinant oncolytic virus of Embodiment P3, wherein the IgG scaffold is an IgG4 scaffold.
- Embodiment P6 The recombinant oncolytic virus of any one of Embodiment P1-P5, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding ay34.5 gene.
- Embodiment P7 The recombinant oncolytic virus of any one of Embodiment P1-P6, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional ICP6 gene.
- Embodiment P8 The recombinant oncolytic virus of any of the preceding Embodiments, wherein the nucleic acid encoding the CD47 antibody is under the control of a viral or tumor specific promoter.
- Embodiment P9. The recombinant virus of any of the preceding Embodiments, wherein the viral promoter is a herpes simplex virus (HSV) immediate early (IE) promoter.
- HSV herpes simplex virus
- IE immediate early
- Embodiment P10 The recombinant oncolytic virus of Embodiment P9, wherein the HSV IE promoter is the IE 4/5 promoter.
- Embodiment PI 1. The recombinant oncolytic virus of any of the preceding Embodiments, wherein the recombinant oncolytic virus comprises a nucleic acid encoding a marker within an ICP6 gene.
- Embodiment PI A pharmaceutical composition comprising: the recombinant oncolytic virus of any of the preceding Embodiments, and a pharmaceutically acceptable carrier.
- Embodiment PI 3 A method for killing tumor cells in a subject comprising: administering to a subject an effective amount of the recombinant oncolytic virus of any of Embodiments P 1 -P 11.
- Embodiment P14 A method of treating a patient having cancer comprising administering to the patient an effective amount of the pharmaceutical composition of Embodiment P12 or the recombinant oncolytic virus of any of Embodiments Pl-Pll.
- Embodiment P15 The method of Embodiment P14, wherein the cancer is a chronic cancer.
- Embodiment PI 6 The method of any one of Embodiments P14-P15, wherein the cancer is an inflammatory chronic cancer.
- Embodiment P17 The method of Embodiment P14, wherein the cancer is a CD47 expressing cancer.
- Embodiment PI 8 The method of Embodiment P17, wherein the CD47 expressing cancer is selected from glioblastoma, ovarian cancer, pancreatic cancer, leukemia, and lymphoma.
- Embodiment P19 The method of any of Embodiments P14-P18, wherein administering is by intratumoral, systemic, or intracavitary administration.
- Embodiment P20 A method for immune modulation in a subject, comprising administering an effective amount of the recombinant oncolytic virus of any of Embodiments Pl-Pll.
- Embodiment P21 The method of Embodiment P20, wherein immune modulation comprises activating natural killer (NK) cells.
- NK natural killer
- Embodiment P22 The method of Embodiment P21, wherein activation ofNK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity.
- Embodiment P23 The method of Embodiment P21, wherein activation ofNK cells is measured as expression of CD69 on NK cells.
- Embodiment P24 The method of any of Embodiments P21-P22, wherein activation is measured as increased NK cell cytotoxicity.
- Embodiment P25 The method of any of Embodiments P21-P24, wherein administering is by intratumoral, systemic, or intracavitary administration.
- Embodiments disclosed herein include Embodiments 1 to 38 following.
- Embodiment 1 A recombinant oncolytic herpes simplex virus (HSV) comprising a nucleic acid encoding an anti-CD47 antibody.
- HSV herpes simplex virus
- Embodiment 2 The recombinant oncolytic virus of Embodiment 1 wherein the anti- CD47 antibody is an IgGl isotype.
- Embodiment 3 The recombinant oncolytic virus of Embodiment 1 or 2, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional g34.5 gene.
- Embodiment 4 The recombinant oncolytic virus of any one of Embodiments 1 to 3, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional ICP6 gene.
- Embodiment 5 The recombinant oncolytic virus of any one of Embodiments 1 to 4, wherein the nucleic acid encoding the anti-CD47 antibody is under the control of a viral or tumor specific promoter.
- Embodiment 6. The recombinant virus of Embodiment 5, wherein the viral promoter is a herpes simplex virus (HSV) immediate early (IE) promoter.
- HSV herpes simplex virus
- IE immediate early
- Embodiment 7 The recombinant oncolytic virus of Embodiment 6, wherein the HSV IE promoter is the IE 4/5 promoter.
- Embodiment 8 The recombinant oncolytic virus of any one of Embodiments 1 to 7, wherein the recombinant oncolytic virus comprises a nucleic acid encoding a marker within an ICP6 gene.
- Embodiment 9 A pharmaceutical composition comprising: the recombinant oncolytic virus of any one of Embodiments 1 to 8, and a pharmaceutically acceptable carrier.
- Embodiment 10 A pharmaceutical composition comprising: the recombinant oncolytic virus of any one of Embodiments 1 to 9, an anti-cancer agent, and a pharmaceutically acceptable carrier.
- Embodiment 11 The pharmaceutical composition of Embodiment 10, wherein the anti cancer agent is a checkpoint inhibitor.
- Embodiment 12 The pharmaceutical composition of Embodiment 10, wherein the anti cancer agent is a PARP inhibitor.
- Embodiment 13 The pharmaceutical composition of Embodiment 12, wherein the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3-aminobenzamide.
- the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3-aminobenzamide.
- Embodiment 14 A method for killing tumor cells in a subject comprising: administering to a subject an effective amount of the recombinant oncolytic virus of any one of Embodiments 1 to 8.
- Embodiment 15 A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the pharmaceutical composition of Embodiment 10 to 13 or the recombinant oncolytic virus of any one of Embodiments 1 to 8.
- Embodiment 16 The method of Embodiment 15, wherein the cancer is a chronic cancer.
- Embodiment 17 The method of Embodiment 16, wherein the cancer is an inflammatory chronic cancer.
- Embodiment 18 The method of Embodiment 15, wherein the cancer is a CD47 expressing cancer.
- Embodiment 19 The method of Embodiment 18, wherein the CD47 expressing cancer is selected from glioblastoma, ovarian cancer, pancreatic cancer, leukemia, and lymphoma.
- Embodiment 20 The method of any of Embodiments 15-19, wherein administering is by intratumoral, systemic, or intracavitary administration.
- Embodiment 21 A method for immune modulation in a subject, comprising administering an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
- Embodiment 22 The method of Embodiment 21, wherein immune modulation comprises activating natural killer (NK) cells.
- NK natural killer
- Embodiment 23 The method of Embodiment 22, wherein activation of NK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity.
- Embodiment 24 The method of Embodiment 22, wherein activation of NK cells is measured as expression of CD69 on NK cells.
- Embodiment 25 The method of Embodiment 22 or 23, wherein activation is measured as increased NK cell cytotoxicity.
- Embodiment 26 The method of any one of Embodiments 21 to 25, wherein administering is by intratumoral, systemic, or intracavitary administration.
- Embodiment 27 A method of treating an overactive immune reaction in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
- Embodiment 28 The method of Embodiment 27, wherein said overactive immune reaction is asthma, eczema, or allergic rhinitis.
- Embodiment 29 A method of treating an autoimmune disease in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
- Embodiment 30 The method of Embodiment 29, wherein said autoimmune disease is arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison’
- Embodiment 31 A method of treating an infectious disease in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
- Embodiment 32 The method of Embodiment 31, wherein the infectious disease is human immunodeficiency virus (HIV), COVID-19, influenza, pneumonia, syphilis, anthrax, gonorrhea, HPV, mononucleosis, West Nile fever, Zika, malaria, or plague
- HIV human immunodeficiency virus
- COVID-19 the infectious disease
- influenza influenza
- pneumonia syphilis
- anthrax gonorrhea
- HPV mononucleosis
- West Nile fever Zika, malaria, or plague
- Embodiment 33 A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9 in a first dosage form and an anti-cancer agent in a second dosage form.
- Embodiment 34 The method of Embodiment 33, wherein the anti-cancer agent is a checkpoint inhibitor.
- Embodiment 35 The method of Embodiment 33, wherein the anti-cancer agent is a PARP inhibitor.
- Embodiment 36 The method of Embodiment 35, wherein the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3- aminobenzamide.
- Embodiment 37 A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9 and an anti cancer therapy.
- Embodiment 38 The method of Embodiment 37, wherein the anti-cancer therapy is chemotherapy, radiation therapy, surgery, targeted therapy, immunotherapy, or cell therapy.
- CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109, 6662-6667, doi : 10.1073/pnas.1121623109 (2012).
- Microglia are effector cells of CD47-SIRPalpha antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci USA 116, 997-1006, doi : 10.1073/pnas.1721434116 (2019).
- trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
- CTGCAAGAGACTTCCATCCAG SEQ ID NO: 14
- CTCCAAGCCAAAGTCCTTAGAG SEQ ID NO: 16
- mNos2 forward sequence: TGACGGCAAACATGACTTCAG (SEQ ID NO:22)
- mil 10 forward sequence: CAGTACAGCCGGGAA GACAATAA (SEQ ID NO:24) [0360] mil 10, reverse sequence: CCGCAGCTCTAGGAGCATGT (SEQ ID NO:25)
- mil 12b forward s equence : CCTGAAGTGTGAAGCACCAAATT (SEQ ID NO: 26)
- mI112b reverse sequence:
- CTTCAAGTCCATGTTTCTTTGCA (SEQ ID NO: 27) [0363] mlllb, forward sequence: GAAATGCCACCTTTTGACAGTG (SEQ ID NO:28) [0364] mlllb, reverse sequence: TGGATGCTCTCATCAGGACAG (SEQ ID NO: 29) [0365] hILIB, forward sequence:
- hILIB reverse sequence: TTTTTGCTGTGAGTCCCGGAG (SEQ ID NO:31) [0367] hIL6, forward sequence: CCTGAACCTTCCAAAGATGGC (SEQ ID NO:32) [0368] hIL6, reverse sequence: TTCACCAGGCAAGTCTCCTCA (SEQ ID NO:33) [0369] ML12A, forward sequence: ATGGCCCTGTGCCTTAGTAGT (SEQ ID NO: 34) [0370] ML12A, reverse sequence: AGCTTTGCATTCATGGTCTTGA (SEQ ID NO:35) [0371] hNOS2, forward sequence: AGGGACAAGCCTACCCCTC (SEQ ID NO:36)
- hNOS2 reverse sequence: CTCATCTCCCGTCAGTTGGT (SEQ ID NO: 37)
- hILlO forward sequence: GACTTTAAGGGTTACCTGGGTTG (SEQ ID NO:38)
- hILlO reverse sequence: TCACATGCGCCTTGATGTCTG (SEQ ID NO:39)
- 18s rRNA forward sequence:
- GTAACCCGTTGAACCCCATT (SEQ ID NO:40) [0376] 18s rRNA, reverse sequence:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing CD47 antibody for the treatment of diseases including cancer, immune disorders, and infectious disease.
Description
Oncolytic Virus Compositions and Methods for the Treatment of Cancer
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 62/971,768, filed February 7, 2020, which is hereby incorporated by reference in its entirety and for all purposes.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0002] This invention was made with government support under grant nos. R01 NS106170 and P01 CA163205 awarded by the National Institutes of Health. The government has certain rights in the invention.
REFERENCE TO A SEQUENCE LISTING, A TABLE OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE
[0003] The Sequence Listing written in file 048440-748001WO-
SEQUENCE_LISTING_ST25.TXT, created on February 5, 2021, 11,491 bytes, machine format IBM-PC, MS Windows operating system, is hereby incorporated by reference.
BACKGROUND
[0004] Oncolytic viral (OV) therapy has been recognized as a promising approach for cancer treatment. It differs from traditional gene therapy where a viral vector serves for delivery of a specific gene. OV therapy utilizes the virus itself as an immune stimulatory agent that can also selectively replicate in tumor cells resulting in their lysis without harming normal tissues. The concept of OV therapy has existed for decades. OV therapy is effective at treating preclinical models of brain tumors with a genetically engineered herpes simplex virus type I (HSV-1) containing a mutation in the thymidine kinase (ΊK) gene. This encouraged researchers to further modify the viral genome to design an oncolytic HSV-1 (oHSV). Over the past two decades, it has been established that oHSV can boost systemic immunity and therefore the anti-tumor immune response.
[0005] Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. GBM patients who undergo the standard of care, including surgical resection,
chemotherapy and radiotherapy, have a median survival of only approximately 15 months. Due to the early infiltrative nature of the disease, a complete surgical resection of GBM is largely unachievable. The intrinsic resistance of GBM to the chemo- and radiotherapy also contributes to the poor clinical outcomes. Given these attributes, new therapeutic agents are urgently needed for to improve the median survival. (See, for example, Ref. 1). Provided herein are solutions to these and other problems in the art.
[0006] Ovarian cancer is the most lethal gynecological malignancies (see, for example, Refs. 44-47). Although a lot of efforts have been made for improving the treatment of ovarian cancer by more aggressive surgical approaches and the introduction of more effective chemotherapy, the 5-year overall survival for the advanced ovarian cancer is approximately 30%. Increasing evidence, from preclinical and clinical data, indicates that immunotherapy approaches that harness and enhance antitumor effector cells, such as immune checkpoint blockade therapy and tumor specific monoclonal antibody therapy, have led to clinical benefits for ovarian cancer (see, for example, Ref. 48).
[0007] CD47 was first identified as a tumor antigen on human ovarian cancer in the 1980s (see, for example, Refs. 49-50). CD47 overexpression is found to be associated with poor prognosis in ovarian cancer (see, for example, Refs. 51-52). CD47 provides a “do not eat” signal by binding to its receptor, signal regulatory protein alpha (SIRPa) on macrophages and suppresses the phagocytosis (see, for example, Refs. 53-54). Targeting CD47 therapy has been proven as an effective treatment for ovarian cancer, with several clinical trials (see, for example, Refs. 51, 55, 56).
[0008] However, the traditional delivery methods of antibody drugs such as intravenous (i.v.), subcutaneous (s.c.), or intramuscular (i.m.) administration result in limited tumor tissue distribution of the antibodies, but leave most of the administrated antibodies remaining in the peripheral circulatory system that leads to side effects (see, for example, Refs. 57-58).
BRIEF SUMMARY OF THE INVENTION
[0009] In an aspect, provided herein is a recombinant oncolytic virus including an expression cassette encoding an anti-CD47 antibody. In an aspect, provided herein is a recombinant oncolytic virus including a nucleic acid encoding an anti-CD47 antibody.
[0010] In an aspect, provided herein is a pharmaceutical composition including a recombinant oncolytic virus as described herein, and a pharmaceutically acceptable carrier. In an aspect, the pharmaceutical composition further includes an anti-cancer agent.
[0011] In an aspect, provided herein is a combination therapy including a pharmaceutical composition that includes a recombinant oncolytic herpes simplex virus as described herein and an anticancer agent. In an aspect, the anti-cancer agent is a checkpoint inhibitor.
[0012] In an aspect, provided herein is a method for killing tumor cells in a subject including administering to a subject an effective amount of the recombinant oncolytic virus according to any embodiment as described herein. In an aspect, the method further includes administering to a subject an anti-cancer agent.
[0013] In an aspect, provided herein is a method of treating cancer to a subject in need including administering to the subject an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein. In an aspect, the method further includes administering to a subject an anti cancer agent.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] FIGS. 1A-1E depict construction and characterization of OV-Q1, OV-Hu5F9-Gl and OV-Hu5F9-G4 (Hu5F9 also known as aCD47 (alpha-CD47) throughout this specification). FIG. 1A shows a schematic map of oncolytic viruses used in this study. Top: genetic map of wild type HSV-1. Second: genetic map of control oHSV, OV-Q1, with deletion of two copies of g34.5, dysfunction of ICP6, and insertion of the GFP gene. Third: genetic map of OV-Hu5F9-Gl showing the inserted coding gene of IgGl version of anti-CD47 (aCD47-Gl) that is constructed on human IgGl scaffold. The light chain and heavy chain coding genes of aCD47-Gl are linked by a T2A sequences and are driven by the viral pIE4/5 promoter. Fourth: The genetic map of OV-aCD47- G4 demonstrating the inserted coding gene of the IgG4 version of anti-CD47 (aCD47-G4) that is constructed on the scaffold of human IgG4 instead of IgGl. FIG. IB shows immunoblotting performed with concentrated supernatants of engineered CHO cells and oHSV-infected U251T2
cells. Lentiviral-infected CHO cells (CHO-aCD47-Gl and CHO-aCD47-G4) were used to produce pure aCD47-Gl and aCD47-G4. 10 ml supernatants were collected from cultured CHO- EV (empty vector), CHO- aCD47-Gl and CHO-aCD47-G4 cells, as well as OV-Q1 -infected, OV- aCD47-Gl -infected and OV-aCD47-G4-infected U251T2 cells at 24 hours after infection. FIG. 1C shows that human CD47 binding affinity of aCD47-Gl and aCD47-G4 were tested by flow cytometry assay. Stained cells were tested on flow cytometry, aCD47-Gl and aCD47-G4 both showed dose-dependent increase on APC signal. FIG. ID shows that the human CD47 neutralizing activity of aCD47-Gl and aCD47-G4 were also tested by flow cytometry assay. Stained cells were tested by flow cytometry. aCD47-Gl and aCD47-G4 both showed a dose-dependent decrease of BV786 signal. FIG. IE shows that aCD47-Gl and aCD47-G4 yields of OV-aCD47-Gl- and OV- aCD47-G4-infected GBM cells were tested by ELISA assay.
[0015] FIGS. 2A-2D demonstrate viral production and infectivity of OV-aCD47-Gl and OV- aCD47-G4. FIG. 2A shows that U251T2 and Gli36AEGFR cells were infected with OV-Q1, OV- aCD47-Gl or OV-aCD47-G4 at the indicated MOIs. Cell survival was analyzed at 5 days after infection by CCK8 assay. The dose response curves were established for each virus to calculate the viral Lethal Dose 50 (LD50, pfu/mL). FIG. 2B shows that U251T2 and Gli36AEGFR cells were infected with OV-Q1, OV-aCD47-Gl or OV-aCD47-G4 at a MOI of 3. The supernatants were harvested at indicated time points and checked for viral reproduction using a plaque assay in Vero cells. FIG. 2C shows that OV-aCD47-Gl and OV-aCD47-G4-infected U251T2 GBM cells (Fig. 2C) produce similar amounts of oHSV when compared to the same GBM cells infected with the parental oHSV OV-Q1. FIG. 2D shows that OV-aCD47-Gl and OV-aCD47-G4-infected Gli36 GBM cells (FIG. 2D) produce similar amounts of oHSV when compared to the same GBM cells infected with the parental oHSV OV-Q1. Therefore, engineering oHSV to infect GBM with Hu5F9-Gl or Hu5F9-G4 did not affect their oncolysis or viral production.
[0016] FIGS. 3A-3H demonstrate aCD47-Gl and aCD47-G4 induce phagocytosis of GMB cells by macrophages. FIGS. 3A-3D show examination of the effect of aCD47-Gl and aCD47- G4 purified from CHO cells on phagocytosis of GBM cells by bone-marrow-derived-macrophages (BMDM). GBM43 (FIG. 3A and FIG.3B) and BT422 (FIG. 3C and FIG. 3D) cells were labeled with CFSE and co-cultured with BMDM at the ratio of 1:2 in the presence of control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml. Percentage of BMDM uptake of labeled tumor cells (CD1 lb+
and CFSE+) were measured by flow cytometry assay to evaluate the phagocytosis rates. FIGS. 3E-3F show conditional media of OV-aCD47-Gl- and OV- OV-aCD47-G4-infected GBM cells induce phagocytosis of GBM cells by BMDM. GBM43 and BT422 cells were labeled with CFSE and co-cultured with BMDM at the ratio of 1:2 in the presence of supernatants from OV-Q1, OV- aCD47-Gl- or OV-aCD47-G4 infected U251T2 cells that were collected at 24 hours after infection. Percentage of BMDM uptake of labeled tumor cells (CDllb+ and CFSE+) were measured by flow cytometry assay to evaluate the phagocytosis rates. FIG. 3G shows results from phagocytosis assay performed with Fc receptor blocking. FIG. 3H shows cytokine gene transcription assay results.
[0017] FIGS. 4A-4E demonstrate aCD47-Gl but not aCD47-G4 induces cytotoxicity of human NK cells against GBM cells. FIGS. 4A-4B show cytotoxicity of human primary NK cells against aCD47-Gl- and aCD47-G4-treated GBM43 (FIG. 4A) and BT422 (FIG. 4B) cells at the effectortarget ratios of 40:1, 20:1 and 10:1. FIG. 4C shows cytotoxicity of human primary NK cells against GBM43 cells that were treated with conditional medium from OV-Q1-, OV-aCD47- Gl- or OV-aCD47-G4-infected U251T2 cells. FIG. 4D shows that aCD47-Gl but not aCD47-G4 induces expression of the NK cell activation marker CD69 when co-cultured with GBM43 cells that were pretreated with aCD47-Gl or aCD47-G4. FIG. 4E is a graphical representation of the data in Fig. 4D.
[0018] FIGS. 5A-5E shows a comparison of the effectiveness of OV-aCD47-Gl versus OV- aCD47-G4 to improve in vivo oncolytic virotherapy of GBM in an orthotopic model of human GBM. FIG. 5A shows experimental timeline for in vivo studies. An orthotopic model of human GBM was established by i.c. injection of 1 x 105 GBM43-FFL human GBM cells into athymic nude mice. Seven days later, mice were intratumorally injected with a vehicle control or 2 c 105 PFU of OV-Q1, OV-aCD47-Gl, or OV-aCD47-G4. Mice were weighed every other day and luciferase-based images were takenl 5 days post tumor implantation to evaluate tumor progression. FIG. 5B shows time-lapse luciferase imaging of GBM43-FLL GMB mice with indicated treatments. FIG. 5C shows survival of GBM43 tumor-bearing mice treated with OV-Q1, OV- aCD47-Gl, OV-aCD47-G4 or vehicle control. P < 0.01 for the primary hypothesis of OV-aCD47- G1 vs. OV-aCD47-G4. In secondary hypothesis testing, P < 0.01 for OV-aCD47-Gl vs. OV-Q1 and P < 0.001 for OV-aCD47-Gl vs. control. Survival was estimated by the Kaplan-Meier method
and compared by log rank test (n = 9 animals). *Two mice in the OV-Q1 control group died accidently after i.p. injection of luciferin on days 16 and 27 without obvious GBM symptoms. FIG. 5D shows individual body weights recorded in mice treated on the experimental study. FIG. 5E shows the luciferase intensity of the experimental mice shown in FIG. 5B measured at 35 days post tumor implantation. Data presented are for individual mice (n = 7 for OV-Q1 and 9 for other groups). Error bars represent standard deviations of all individual mice.
[0019] FIGS. 6A-6D demonstrate OV-aCD47-Gl is safer and more effective than the combination of OV-Q1 and i.p. administrated aCD47-Gl. FIG. 6A shows experimental timeline for in vivo studies. Xenograft GBM mouse models were established by intracranially injecting 1 c 105 GBM43-FLL cells to athymic nude mice. Fourteen days later, mice were intratumorally injected with 2 c 105 PFU of OV-Q1, OV-aCD47-Gl or vehicle. The group of OV-Ql-plus- Hu5F9-Gl received i.p. administrated aCD47-Gl twice on day 15 and day 17 at the dose of 150 pg/mouse. The mice were monitored and the survival data were recorded. FIG. 6B shows survival of GBM43 tumor-bearing mice treated with OV-Q1, OV-Q1 plus aCD47-Gl, OV-aCD47-Gl, or vehicle control as indicated in FIG. 6A. FIG. 6C shows experimental timeline for in vivo studies. Xenograft GBM mouse models were established by intracranially injecting 1 c 105 GBM43 cells to athymic nude mice. Twenty-one days later, mice were intratumorally injected with 2 c 105 PFU of OV-Q1, OV-aCD47-Gl or vehicle. The group of OV-Ql-plus- aCD47-Gl received i.p. administrated aCD47-Gl twice on day 22 and day 24 at the dose of 150 pg/mouse. The mice were euthanized on day 23 and day 25 to harvest tissue. FIG. 6D shows that the plasma concentration of aCD47-Gl in different groups were measured by ELISA assay.
[0020] FIGS. 7A-7B are graphs showing dose-dependent binding. FIG. 7A show IgGl and IgG4 versions of anti-CD47 (aCD47) both exhibit dose-dependent binding affinity to CD47 positive cells. FIG. 7B shows that IgGl and IgG4 versions of anti-CD47 (aCD47) both block the binding sites of CD47 in a dose-dependent manner.
[0021] FIGS. 8A-8D show that aCD47-Gl but not aCD47-G4 induces cytotoxicity of human NK cells against GBM cells. FIG. 8A shows cytotoxicity of human primary NK cells against Gli36AEGFR human GBM cells pretreated with different doses of aCD47-Gl or aCD47-G4 for 20 min. The NK cells were added to the pre-treated GBM cells without washing at the effectortarget ratios of 40: 1, 20: 1 and 10:1 in a 51Cr release assay. FIG. 8B shows cytotoxicity of
primary human NK cells against aCD47-Gl- and aCD47-G4-pretreated three human GBM lines: GBM30, U251T2 and LN229. A linear mixed model was used to account for the underlying variance and covariance structure (n = 4 donors). FIG. 8C shows aCD47-Gl but not aCD47-G4 induced the expression of the NK cell activation marker CD69. GBM30 or U251T2 human GBM cells that were pretreated with aCD47-Gl or aCD47-G4 at the concentration of 1 pg/ml and then co-cultured with primary human NK cells at a ratio of 1 : 1 for 4 hours. No wash of GBM cells was applied before NK cells were added. CD69 expression on NK cells was measured by flow cytometry to quantify the level of NK cell activation. FIG. 8D shows a statistic summary of the data provided in FIG. 8C. The bars left to right in top panel are NK + GBM30, NK + GBM30 + aCD47-Gl, NK+ GBM30 + aCD47-G4. The bars left to right in bottom panel areNK + U251T2, NK + U251T2 + oCD47-Gl, NK + U251T2 + aCD47-G4. One-way ANOVA with Bonferroni's multiple comparisons test (n = 4 donors). Experiments in FIG. 8C and FIG. 8D were repeated with primary NK cells isolated from 4 different donors with similar results. All experiments were performed with four donors in triplicate. Error bars represent standard deviations of means of four donors.
[0022] FIG. 9 shows percentage of BMDM phagocytosis of GBM43 cells (CDllb+CFSE+) assayed by flow cytometry. BMDM were incubated with vehicle control or human IgGl at the dose of 10 pg/ml for 30 min prior to co-culture with GBM43 cells in the presence of increasing aCD47-Gl for 2 hours.
[0023] FIG. 10 shows expression levels of Argl, Ccl2, Illb, 116, 1110, 1112b, and Nos2 where BMDM were cocultured with GBM43 cells at a ratio of 1 : 1 with or without aCD47-Gl or aCD47-G4 for 6 hours.
[0024] FIG. 11 shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of GBM43 cells by primary human macrophages.
[0025] FIG. 12 shows shows the effect of conditioned media from OV-aCD47-Gl- and OV- aCD47-G4-infected U251T2 human GBM cells on phagocytosis of GBM43 cells by primary human macrophages.
[0026] FIGS. 13A-13B show the effect of coculturing primary human macrophages with GBM43 cells at a ratio of 1 : 1 with or without aCD47-Gl or aCD47-G4 (bars left to right for
each indicated transcript is without antibody, with aCD47-Gl, or with aCD47-G4, correspondingly) for 6 hours on transcription of IL1B, IL6, IL10, NOS2 (FIG. 13A) and IL12A (FIG. 13B).
[0027] FIG. 14 shows an experimental timeline for in vivo studies using an orthotopic model of human GBM. Group 1, saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus i.p. administration of aCD47-Gl; and Group 4, OV-aCD47-Gl. After tumor implantation, Groups 2, 3 and 4 received intracranial injection of oHSV (OV-Q1 or OV-aCD47-Gl) at a dose of 2 c 105 PFU per mouse on day 21. Group 1 received saline as control. On day 22, Group 3 received i.p. injection of purified aCD47-Gl at the dose of 150 pg per mouse. Groups 1, 2, and 4 received i.p. injection of saline as control. All mice were euthanized on day 23 for blood and brain harvesting.
[0028] FIGS. 15A-15C shows OV-aCD47-Gl is effective for locoregional delivery of the anti-CD47 antibody, while systemic administration of aCD47-Gl is not effective. FIG. 15A shows the concentration of aCD47-Gl in plasma was measured by ELISA in mice from different treatments. The columns left to right are saline, OV-Q1, OV-Q1 plus aCD47-Gl, and OV- aCD47-Gl. FIG 15B and FIG. 15C shows slides from the brain tissues isolated from experimental mice were subjected to H&E and immunohistochemical staining, the latter with anti-HSV, anti-human Fc, which identifies IgG, anti-CDllb or anti-NKp46 antibodies. Images with high and low magnifications are shown in FIG. 15B and FIG. 15C, respectively. The boxed images in FIG. 15B are shown in higher power in FIG. 15C. Data presented are represented of one (FIG. 15B and FIG. 15C) or three (FIG. 15A) mice of at least three mice in total with similar data. Error bars (FIG. 15A) represent standard deviations of means of three mice.
[0029] FIG. 16 shows an experimental timeline for in vivo studies using an orthotopic model of human GBM. There were four treatment groups: Group 1, saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus i.p. administration of aCD47-Gl; and Group 4, OV-aCD47-Gl.
On day 0, the mice were implanted with 1 c 105 GBM43 cells i.c.. After tumor implantation, Groups 2, 3 and 4 received intratumoral injection of oHSV (OV-Q1 or OV-aCD47-Gl) at a dose of 2 x 105 PFU per mouse on day 21. Group 1 received saline as control. On days 22 and 24, Group 3 received i.p. injection of purified aCD47-Gl at the dose of 150 pg per mouse per day.
Groups 1, 2, and 4 received i.p. injections of saline as control. All mice were euthanized on day 25 for blood and brain harvesting.
[0030] FIGS. 17A-17C shows that OV-aCD47-Gl infection continuously delivers anti-CD47 antibody to the tumor microenvironment, while systemic infusion of aCD47-Gl does not. The concentration of aCD47-Gl in plasma was measured by ELISA in mice from different treatments (FIG. 17A). The columns left to right are saline, OV-Q1, OV-Q1 plus aCD47-Gl, and OV-aCD47-Gl. One-way ANOVA with P values corrected for multiple comparisons by Bonferroni method multiple comparisons test (n = 3 mice). (FIGS. 17B and 17C) Slides from the brains isolated from experimental mice were subjected to H&E staining and immunohistochemical staining, the latter with anti-HSV, anti -human Fc, which identifies IgG, anti-CDllb or anti-NKp46 antibodies. High and low magnifications of brain H&E and IHC with anti-HSV, anti-human Fc, anti-CDl lb and anti-Nkp46 staining at the tumor implantation site are shown in C and D, respectively. The images in FIG. 17B are exactly represent high magnification of the boxed area in FIG. 17C. Data presented are represented of one (FIGS. 17B and 17C) or three (B) mice of at least three mice in total with similar data. Error bars (FIG.
17A) represent standard deviations of means of three mice.
[0031] FIGS. 18A-18E show a comparison of the effectiveness of OV-aCD47-Gl versus OV- aCD47-G4 as well as combined locoregional deliveries of OV-Q1 and aCD47-Gl in an immunocompetent mouse GBM model. FIG. 18A shows an experimental timeline for in vivo studies. An immunocompetent mouse GBM model was established by i.c. injection of 1 x 105
CT2A-hCD47 mouse GBM cells (expressing human CD47) into C57BL/6 mice. Three days later, mice were intratumorally injected with a vehicle control or 2 c 105 PFU of OV-Q1, OV- aCD47-Gl or OV-aCD47-G4. Mice were weighed every other day, and luciferase-based images were taken from 11 days post tumor implantation to evaluate tumor progression. FIG. 18 B
Survival of CT2A-hCD47 tumor-bearing mice as described in (A). P < 0.01 for OV-aCD47-Gl vs. OV-aCD47-G4. P < 0.01 for OV-aCD47-Gl vs. OV-Q1; and P < 0.001 for OV-aCD47-Gl vs. control. Survival was estimated by the Kaplan-Meier method and compared by log rank test
(n = 9 animals). FIG. 18C shows individual body weights recorded in mice treated on the experimental study. FIG. 18D shows an experimental timeline for the survival study. An immunocompetent mouse GBM model was established by i.c. injection of 1 x 105 CT2A-hCD47 mouse GBM cells (expressing human CD47) into C57BL/6 mice. Three days later, mice were
intratumorally injected with vehicle control or 2 c 105 PFU of OV-Q1, or OV-aCD47-Gl. Osmotic pumps were implanted on day 4 to the mice for continuous administration of aCD47- G1 until day 7. Mice were monitored twice a day to evaluate for tumor development. FIG. 18E shows survival of CT2A-hCD47 tumor-bearing mice treated with OV-Q1, aCD47-Gl, OV-Q1 plus aCD47-Gl, OV-aCD47-Gl, or vehicle control. Survival was estimated by the Kaplan- Meier method and compared by log rank test (n = 9 or 10 animals per group).
[0032] FIG. 19 shows characterization of OV-Q1, OV-aCD47-Gl and OV-aCD47-G4. A2780 cells were incubated with different concentrations of unlabeled aCD47-Gl or aCD47-G4 mAh followed by incubation with a conjugated anti-human CD47 and assessed by flow cytometry.
[0033] FIG. 20 shows aCD47-Gl and aCD47-G4 yields from supernatants of OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells as determined by ELISA assay.
[0034] FIGS. 21A-21D shows aCD47-Gl and aCD47-G4 induce phagocytosis of A2780 ovarian cells. FIG. 21A shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of A2780 cells by primary human macrophages. FIG. 21B shows conditional media from OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells induce phagocytosis against A2780 cells by primary human macrophages. Phagocytosis was assayed by flow cytometry. FIG. 21C shows the effect of 5 pg/ml of aCD47-Gl and aCD47-G4 purified from CHO cells on phagocytosis of A2780 cells by BMDMs. Percentage of BMDM phagocytosis of A2780 cells (CDllb+CFSE+) was assayed by flow cytometry. FIG. 21D shows conditional media from OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells induce phagocytosis against A2780 cells by BMDMs. Phagocytosis was assayed by flow cytometry.
[0035] FIGS. 22A-22B show transcription assays. Primary human macrophages were cocultured with A2780 cells at a ratio of 1 : 1 with or without aCD47-Gl or aCD47-G4 for 6 hours after which gene transcripts were quantified. FIG. 22A shows expression levels of ILlb, IL6, IL10, and INOS. FIG. 22B shows expression levels of IL12. All experiments were performed at least with three human donors or mice. Error bars represent standard deviations of triplicates.
[0036] FIGS. 23A-23E show that aCD47-Gl but not aCD47-G4 induces cytotoxicity of human NK cells against ovarian cells. FIG. 23 A shows cytotoxicity of human primary NK cells
against aCD47-Gl- and aCD47-G4-treated A2780 human ovarian cells. FIG. 23B shows cytotoxicity of human primary NK cells against A2780 cells that were treated with conditional media from OV-Q1-, OV-aCD47-Gl- or OV-aCD47-G4-infected A2780 cells. FIG. 23 C shows CD69 expression of NK cells when co-cultured with A2780 cells that were pretreated with aCD47-Gl or aCD47-G4 detected by flow cytometry (columns left to right are control, aCD47- Gl, and aCD47-G4). FIG. 23 D shows CD69 expression of NK cells when co-cultured with A2780 cells with conditional media from uninfected, OV-Q1-, OV-aCD47-Gl- or OV-aCD47- G4-infected A2780 cells detected by flow cytometry (columns left to right are uninfected, OV- Q1 -infected, OV-aCD47-Gl -infected, and OV-aCD47-G4-infected). FIG. 23E shows Granzyme b production by NK cells when co-cultured with A2780 cells that were pretreated with aCD47-Gl or aCD47-G4 detected by flow cytometry. All experiments were performed with three donors in triplicate. Error bars represent standard deviations of means of three donors.
[0037] FIG. 24 shows OV-aCD47-Gl improves the therapeutic efficacy against ovarian tumor. An orthotopic model of human ovarian tumor was established by s.c. injection of 5 c 106 A2780 cells. One day later, mice were intratumorally injected with a vehicle control or 1 c 105 PFU of OV-Q1, OV-aCD47-Gl, or OV-aCD47-G4. FIG. 24 shows tumor volume of ovarian tumor growth in mice with indicated treatments. X-axis shows days post-implantation.
[0038] FIG. 25 shows OV-aCD47-Gl enhances the therapeutic efficacy (percent survival) in an immunocompetent ovarian cancer mouse model. X-axis shows days post tumor implantation.
[0039] FIG. 26 shows an enhanced effect in vitro and in vivo for the combination of OV- aCD47-Gl with olaparib.
DETAILED DESCRIPTION
[0040] Provided herein are, inter alia, recombinant oncolytic viruses expressing an anti-CD47 antibody and methods for the treatment of cancer, immune disorders, and infectious disease.
I. Definitions
[0041] Before the present invention is further described, it is to be understood that this invention is not strictly limited to particular embodiments described, and as such may of course vary. It is also to be understood that the terminology used herein is for the purpose of describing
particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the claims.
[0042] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It should further be understood that as used herein, the term “a” entity or “an” entity refers to one or more of that entity. For example, a nucleic acid molecule refers to one or more nucleic acid molecules. As such, the terms “a”, “an”, “one or more” and “at least one” can be used interchangeably. Similarly the terms “comprising”, “including” and “having” can be used interchangeably.
[0043] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.
[0044] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub combination. All combinations of the embodiments are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.
[0045] It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
[0046] As used herein, the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/- 10% of the specified value. In embodiments, about means the specified value.
[0047] The terms “virus” or “virus particle” are used according to its plain ordinary meaning within virology and refers to a virion including the viral genome (e.g. DNA, RNA, single strand, double strand), viral capsid and associated proteins, and in the case of enveloped viruses (e.g. herpesvirus), an envelope including lipids and optionally components of host cell membranes, and/or viral proteins.
[0048] The term “replicate” is used in accordance with its plain ordinary meaning and refers to the ability of a cell or virus to produce progeny. A person of ordinary skill in the art will immediately understand that the term replicate when used in connection with DNA, refers to the biological process of producing two identical replicas of DNA from one original DNA molecule. In the context of a virus, the term “replicate” includes the ability of a virus to replicate (duplicate the viral genome and packaging said genome into viral particles) in a host cell and subsequently release progeny viruses from the host cell, which results in the lysis of the host cell. A “replication-competent” virus as provided herein refers to a virus (herpes virus) that is capable of replicating in a cell (e.g., a cancer cell).
[0049] As used herein, the term “oncolytic virus” is used in accordance with its plain ordinary meaning and refers to a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis (directly lysing cells), they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic viruses are thought not only to cause direct destruction of the tumor cells, but also to stimulate host anti-tumor immune
system responses. Oncolytic viruses include adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, vaccinia, and the senecavirus.
[0050] As used herein, the term “recombinant virus” is a virus produced by recombining pieces of nucleic acid (e.g. DNA) using recombinant nucleic acid technology. A “recombinant oncolytic virus” is an concolytic virus produced by recombining pieces of nucleic acid (e.g. DNA) using recombinant nucleic acid technology.
[0051] As used herein, the term “herpes simplex virus” or “HSV” refers to members of the Herpesviridae family. Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known by their taxonomical names Human alphaherpesvirus 1 and Human alphaherpesvirus 2, are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans.
[0052] As used herein, the term “g34.5 gene” or “gamma-34.5 gene” is used in accordance with its plain ordinary meaning and refers to a herpes simplex virus neurovirulence gene.
[0053] As used herein, the term “ICP6” or “ICP6 gene” is used in accordance with its plain ordinary meaning and refers to a gene that encodes a viral ribonucleotide reductase (vRR).
[0054] As used herein, the term "cancer" is used in accordance with its plain ordinary meaning and refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemias, lymphomas, carcinomas and sarcomas. Examples of cancers that may be treated with a compound, composition, or method provided herein include brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, Medulloblastoma, melanoma, cervical cancer, gastric cancer, ovarian cancer, lung cancer, cancer of the head, Hodgkin's Disease, and Non-Hodgkin's Lymphomas. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung carcinoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors,
malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer. In embodiments, the cancer is glioblastoma, ovarian cancer, pancreatic cancer, myeloma, leukemia, or lymphoma.
[0055] The term "leukemia" is used in accordance with its plain ordinary meaning and refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Examples of leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia. In embodiments, the cancer is acute myeloid leukemia.
[0056] The term “chronic inflammatory cancer” is used in accordance with its plain ordinary meaning and refers broadly to as used herein, relates to its usual an customary meaning of a
cancer related to a chronic inflammatory condition. Chronic inflammatory conditions related to cancers include, but are not limited to, those provided in the table below.
Table 1
[0057] An “overactive immune system” is used in accordance with its plain ordinary meaning and refers to an immune system that reacts to allergen in the environment that are normally harmless. Conditions related to an overactive immune system include asthma, eczema, and allergic rhinitis.
[0058] An "autoimmune disease" as used herein refers to a disease or disorder that arises from altered immune reactions by the immune system of a subject, e.g., against substances tissues and/or cells normally present in the body of the subject. Autoimmune diseases include, but are not limited to, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves
ophthalmopathy, inflammatory bowel disease, Addison’s disease, Vitiligo, asthma, and allergic asthma.
[0059] The term “infection” or “infectious disease” is used in accordance with its plain ordinary meaning and refers to a disease or condition that can be caused by organisms such as a bacterium, virus, fungi or any other pathogenic microbial agents. In embodiments, the infectious disease is caused by a pathogenic bacteria. Pathogenic bacteria are bacteria which cause diseases (e.g., in humans). In embodiments, the infectious disease is a bacteria associated disease (e.g., tuberculosis, which is caused by Mycobacterium tuberculosis). Non-limiting bacteria associated diseases include pneumonia, which may be caused by bacteria such as Streptococcus and Pseudomonas; or foodbome illnesses, which can be caused by bacteria such as Shigella, Campylobacter, and Salmonella. Bacteria associated diseases also includes tetanus, typhoid fever, diphtheria, syphilis, and leprosy. In embodiments, the disease is Bacterial vaginosis (i.e. bacteria that change the vaginal microbiota caused by an overgrowth of bacteria that crowd out the Lactobacilli species that maintain healthy vaginal microbial populations) (e.g., yeast infection, or Trichomonas vaginalis); Bacterial meningitis (i.e. a bacterial inflammation of the meninges); Bacterial pneumonia (i.e. a bacterial infection of the lungs); Urinary tract infection; Bacterial gastroenteritis; or Bacterial skin infections (e.g. impetigo, or cellulitis). In embodiments, the infectious disease is human immunodeficiency virus (HIV), COVID-19, West Nile fever, Zika, malaria, Japanese encephalitis, tularemia, Chagas, sandfly fever, plague, rickettsiosis, influenza, cervicovaginal infections, and decubitus ulcers.
[0060] The term “patient” or “subject in need thereof’ is used in accordance with its plain ordinary meaning and refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a composition, compound, or method as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human. In embodiments, the subject has, had, or is suspected of having cancer.
[0061] As used herein, the terms “control” or “control experiment” are used in accordance with its plain ordinary meaning and refer to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure,
reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).
[0062] As used herein, the terms “treating” or “treatment” are used in accordance with its plain ordinary meaning and refer to to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. The term "treating" and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating includes preventing. In embodiments, treating does not include preventing.
[0063] As used herein, the term “prevent” is used in accordance with its plain ordinary meaning and refers to a decrease in the occurrence of disease symptoms in a patient. The prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.
[0064] By "therapeutically effective dose or amount" is intended an amount of cells, agents, or compounds described herein that brings about a positive therapeutic response in a subject in need of, such as an amount that restores function and/or results in the elimination and/or reduction of tumor and/or cancer cells. The exact amount (of cells or agents) required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, mode of administration, and the like. An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein. A “combined therapeutically effective dose or amount dose” refers a combination of therapies that together brings about a positive therapeutic response in a subject in need of, such as an amount that restores function and/or results in the elimination and/or reduction of tumor and/or cancer cells.
[0065] As used herein, the term “immune response” is used in accordance with its plain ordinary meaning and refers to a response by an organism that protects against disease. The response can be mounted by the innate immune system or by the adaptive immune system, as well known in the art.
[0066] As used herein, the term “cytotoxicity” is used in accordance with its plain ordinary meaning and refers to quality of being toxic to cells.
|0067] As used herein, the terms “antibody-dependent cellular cytotoxicity”, “ADCC”, and “antibody-dependent cell-mediated cytotoxicity” are used in accordance with their plain ordinary meanings and refer to an immune mechanism through which Fc receptor-bearing effector cells can recognize and kill antibody-coated target cells expressing tumor- or pathogen-derived antigens on their surface.
|0068| As used herein, the terms “antibody-dependent cellular phagocytosis” and “ADCP” are used in accordance with their plain ordinary meanings and refer to the mechanism by which antibody-opsonized target cells activate the Fc receptors on the surface of macrophages to induce phagocytosis, resulting the ingestion and degradation of the target cell. The macrophage Fc receptors refer to all classes of Fey receptors.
|0069] As used herein, the terms “adaptive immune response”, “acquired immune system”, and “specific immune system” are used in accordance with their plain ordinary meanings and refer to a subsystem of the overall immune system that is composed of specialized, systemic cells and processes that eliminate designated targets. The targets are designated by identification via immunological memory. Immunological memory is created when the immune system had previously encountered the immune assault, and retained a record of it.
[0070] As used herein, the terms “natural killer cells” and “NK cells” are used in accordance with their plain ordinary meaning and refer to a type of cytotoxic lymphocyte involved in the innate immune system. The role NK cells play is typically analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells may provide rapid responses to virus- infected cells, acting at around 3 days after infection, and respond to tumor formation.
Typically, immune cells detect major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells typically have the
ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction.
[0071] As used herein, the term “T cells” or “T lymphocytes” are used in accordance with their plain ordinary meaning and refer to a type of lymphocyte (a subtype of white blood cell) inolved in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells, by the presence of a T-cell receptor on the cell surface. T cells include, for example, natural killer T (NKT) cells, cytotoxic T lymphocytes (CTLs), regulatory T (Treg) cells, and T helper cells. Different types of T cells can be distinguished by use of T cell detection agents.
[0072] As used herein, the terms “tumor microenvironment”, “TME”, and “cancer microenvironment” are used in accordance with its plain ordinary meaning and refer to the non neoplastic cellular environment of a tumor, including blood vessels, immune cells, fibroblasts, cytokines, chemokines, non-cancerous cells present in the tumor, and proteins produced.
[0073] As defined herein, the terms “activation”, “activate”, “activating”, “activator” and the like are used in accordance with its plain ordinary meaning and refer to an interaction that positively affects (e.g. increasing) the activity or function of a protein or cell relative to the activity or function of the protein or cell in the absence of the activator. In embodiments activation means positively affecting (e.g. increasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the activator. The terms may reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease. Thus, activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein associated with a disease (e.g., a protein that is decreased in a disease relative to a non-diseased control). Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein
[0074] As used herein, the terms “agonist,” “activator,” “upregulator,” etc. are used in accordance with its plain ordinary meaning and refer to a substance capable of detectably
increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
[0075] As used herein, the terms “inhibition”, “inhibit”, “inhibiting” and the like are used in accordance with its plain ordinary meaning and refer to an interaction that negatively affecting (e.g. decreasing) the activity or function of the protein or cell relative to the activity or function of the protein or cell in the absence of the inhibitor. In embodiments, inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments, inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein or cell from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation or cell activations).
[0076] As used herein, the terms “inhibitor,” “repressor” or “antagonist” or “downregulator” are used in accordance with its plain ordinary meaning and refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
[0077] As may be used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid oligomer,” “oligonucleotide,” “nucleic acid sequence,” “nucleic acid fragment” and
“polynucleotide” are used interchangeably and are intended to include, but are not limited to, a
polymeric form of nucleotides covalently linked together that may have various lengths, either deoxyribonucleotides or ribonucleotides, or analogs, derivatives or modifications thereof. Different polynucleotides may have different three-dimensional structures, and may perform various functions, known or unknown. Non-limiting examples of polynucleotides include a gene, a gene fragment, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, a ribozyme, cDNA, a recombinant polynucleotide, a branched polynucleotide, a plasmid, a vector, isolated DNA of a sequence, isolated RNA of a sequence, a nucleic acid probe, and a primer. Polynucleotides useful in the methods of the disclosure may comprise natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or a combination of such sequences.
[0078] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.
[0079] As used herein, the term "expression" is used in accordance with its plain ordinary meaning and refers to any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for
detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
[0080] As used herein, the term “expression cassette” refers to a distinct component of vector DNA consisting of a gene and regulatory sequence to be expressed by a transfected cell. In each successful transformation, the expression cassette directs the cell's machinery to make RNA and protein(s). Some expression cassettes are designed for modular cloning of protein-encoding sequences so that the same cassette can easily be altered to make different proteins. An expression cassette is composed of one or more genes and the sequences controlling their expression. An expression cassette comprises three components: a promoter sequence, an open reading frame, and a 3' untranslated region that, in eukaryotes, usually contains a polyadenylation site. Different expression cassettes can be transfected into different organisms including bacteria, yeast, plants, and mammalian cells as long as the correct regulatory sequences are used.
[0081] As used herein, the term “cytokine” is used in accordance with its plain ordinary meaning and refers to a broad category of small proteins (-5-20 kDa) that are important in cell signaling. Cytokines are peptides, and cannot cross the lipid bilayer of cells to enter the cytoplasm. Cytokines are involved in autocrine signaling, paracrine signaling and endocrine signaling as immunomodulating agents. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors. Cytokines are produced by a broad range of cells, including immune cells like macrophages, B lymphocytes, T lymphocytes and mast cells, as well as endothelial cells, fibroblasts, and various stromal cells; a given cytokine may be produced by more than one type of cell.
[0082] The term "antibody" refers to a polypeptide encoded by an immunoglobulin gene or functional fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
[0083] The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, often in a heterogeneous population of proteins and other biologies. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies can be selected to obtain only a subset of antibodies that are specifically immunoreactive with the selected antigen and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
[0084] As used herein, the terms “immunoglobulin domain” or “Ig-domain” are used in accordance with their plain and ordinary meanings and refer to any of the recombinant or naturally-occurring forms of the Ig-domain or variants or homologs thereof that maintain the Ig- domain fold or three-dimensional structure. The Ig-domain belongs to a family of protein folds that consist of a 2-layer sandwich of 7-9 antiparallel beta-strands arranged in two beta-sheets with a Greek-key topology. The folding pattern typically consists of (N-terminal beta-hairpin-in sheet l)-(beta-hari pin-in sheet 2)-(beta-strand in sheet l)-(C-terminal beta-hairpin in sheet 2) linkages. Immunoglobulin domains are the primary components of antibodies, and a large set of extracellular surface receptors, including receptor tyrosine kinases.
[0085] An example of an immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms “variable heavy chain,” “VH,” or “VH” refer to the variable region of an immunoglobulin heavy chain, including an Fv, scFv, dsFv or Fab; while
the terms “variable light chain,” “VL” or “VL” refer to the variable region of an immunoglobulin light chain, including of an Fv, scFv, dsFv or Fab.
[0086] Examples of antibody functional fragments include, but are not limited to, complete antibody molecules, antibody fragments, such as Fv, single chain Fv (scFv), complementarity determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), Fab, F(ab)2' and any combination of those or any other functional portion of an immunoglobulin peptide capable of binding to target antigen (see, e.g., FUNDAMENTAL IMMUNOLOGY (Paul ed., 4th ed. 2001). As appreciated by one of skill in the art, various antibody fragments can be obtained by a variety of methods, for example, digestion of an intact antibody with an enzyme, such as pepsin; or de novo synthesis. Antibody fragments are often synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries.
[0087] As used herein, the term “chimeric antibody” is used in accordance with its plain ordinary meaning and refers to an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity. The preferred antibodies of, and for use according to the invention include humanized and/or chimeric monoclonal antibodies.
[0088] As used herein, the terms "Immunoglobulin G" or “IgG” are used in accordance with their plain and ordinary meanings and refer to any of the recombinant or naturally-occurring forms of the IgG antibody protein or variants or homologs thereof that maintain IgG activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to IgG). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring IgG
2/
polypeptide. IgG antibodies are composed of four separate chains (two identical light chains and two identical heavy chains) that form a homodimer (via inter-heavy chain disulfide) of heterodimers (one light chain and one heavy chain interchain disulfide) in a canonical Y-shaped quaternary structure. The light chain includes a variable immunoglobulin domain (VL) and a constant immunoglobulin domain (CL). The heavy chain includes one variable immunoglobulin domain (VH) and three constant immunoglobulin domains (CHI, CH2, CH3). The variable domains form the antigen-recognition surface of an IgG antibody. There are four subclasses of IgG, IgGl, IgG2, IgG3, and IgG4.
[0089] As used herein, the terms “CD47” and “Cluster of Differentiation 47” and integrin associated protein” or “IAP” refer to a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamilyand partners with membrane integrins and also binds the ligands thrombospondin- 1 (TSP-1) and signal-regulatory protein alpha (SIRPa). CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers, and more recently, for the treatment of pulmonary fibrosis. CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is ubiquitously expressed in human cells and has been found to be overexpressed in many different tumor cells. Expression in equine cutaneous tumors has been reported as well.
[0090] As used herein, the terms “anti-CD47 antibody” or “aCD47”refers to a protein capable of binding CD47 protein. Examples includes Hu5F9 (also known as 5F9). An anti-CD47 monoclonal antibody with an IgGl isotype is referred to as aCD47-Gl (or Hu5F9-Gl or 5 F9- Gl). An anti-CD47 monoclonal antibody with an IgG4 isotype is referred to as aCD47-G4 (or Hu5F9-G4 or 5fp-G4).
[0091] As used herein, the term “Signal regulatory protein a” or “SIRPa” refers to a regulatory membrane glycoprotein from SIRP family. SIRPa acts as inhibitory receptor and interacts with a broadly expressed transmembrane protein CD47 also called the "don't eat me" signal. This interaction negatively controls effector function of innate immune cells such as host cell phagocytosis.
[0092] For specific proteins described herein, the named protein includes any of the protein’s naturally occurring forms, variants or homologs that maintain the protein transcription factor activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the native protein). In some embodiments, variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring form. In other embodiments, the protein is the protein as identified by its NCBI sequence reference. In other embodiments, the protein is the protein as identified by its NCBI sequence reference, homolog or functional fragment thereof.
[0093] As used herein, the term “immunotherapy” and “immunotherapeutic agent” are used in accordance with their plain ordinary meaning and refer to the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Such immunotherapeutic agents include antibodies and cell therapy.
[0094] As used herein, the term “checkpoint inhibitor” is used in accordance with its plain ordinary meaning and refers to a drug, often made of antibodies, that unleashes an immune system attack on cancer cells. An important part of the immune system is its ability to tell between normal cells in the body and those it sees as “foreign.” This lets the immune system attack the foreign cells while leaving the normal cells alone. To do this, it uses “checkpoints” which are molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system. Drugs that target these checkpoints are known as checkpoint inhibitors.
[0095] As used herein, the term “PD-1” is used in accordance with its plain ordinary meaning and refers to a checkpoint protein on immune cells called T cells. It acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body. It does this when it attaches to PD-L1, a protein on some normal (and cancer) cells. When PD-1 binds to PD-L1, the signal notifies the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps them evade immune attack.
[0096] As used herein, the term “PD-L1” or “programmed death-ligand 1 (PD-L1)” refers to a 40kDa type 1 transmembrane protein that plays a role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states. It appears that upregulation of PD-L1 may allow cancers to evade the host immune system.
[0097] As used herein, the term “CLTA-4”, “CTLA4” and “cytotoxic T-lymphocyte- associated protein 4)”, also known as CD 152 (cluster of differentiation 152), refer to a protein receptor that functions as an immune checkpoint and downregulates immune responses.
[0098] As used herein, the term “anticancer agent” and “anticancer therapy” are used in accordance with their plain ordinary meaning and refer to a molecule or composition (e.g. compound, peptide, protein, nucleic acid, drug, antagonist, inhibitor, modulator) or regimen used to treat cancer through destruction or inhibition of cancer cells or tissues. Anticancer therapy includes chemotherapy, radiation therapy, surgery, targeted therapy, immunotherapy, and cell therapy. Anticancer agents and/or anticancer therapy may be selective for certain cancers or certain tissues. In some embodiments, an anti-cancer therapy is an immunotherapy. In embodiments, anticancer agent or therapy may include a checkpoint inhibitor. In embodiments, the anti-cancer agent or therapy is a cell therapy.
[0099] In some embodiments, an anti-cancer agent is an agent identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/ AZD6244,
GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti -metabolites (e.g., 5- azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic
acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, pacbtaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, pbcamycin, etc. ), platinum-based compounds (e.g. cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43- 9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans -retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-l, 25 dihydroxy vitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrebde; anastrozole; andrographobde; angiogenesis inhibitors; antagonist D; antagonist G; antarebx; anti-dorsabzing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicobn glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole;
CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis- porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregubn; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinobde; kahalabde F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprobde+estrogen+progesterone; leuprorebn; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene
inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinabne; N-substituted benzamides; nafarebn; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxabplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelbptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenyl acetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras famesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelbptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safmgol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem cell division inhibitors; stipiamide; stromelysin inhibitors; sulfmosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfm; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem
cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfm; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefmgol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-la; interferon gamma-lb; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane;
porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safmgol; safmgol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfm; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfm; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g. Taxol.TM (i.e. paclitaxel), Taxotere.TM, compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS- 10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g. Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e. LU-103793 andNSC-D-669356), Epothilones (e.g. Epothilone A, Epothilone B, Epothilone C (i.e. desoxy epothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone AN-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e. BMS-310705), 21- hydroxy epothilone D (i.e. Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663), Soblidotin (i.e. TZT-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS- 164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, CS-39-L- Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-
106969), T-138067 (Tularik, i.e. T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (i.e. BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asia Medica), A-l 05972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, lnanocine (i.e. NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e. T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asia Medica), D-68144 (Asia Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (i.e. NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e. SPA- 110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti- CD20 monoclonal antibody conjugated to mIn, 90Y, or 131I, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5- nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal
growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa ™), erlotinib (Tarceva ™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP- 724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib, vebparib, pamiparib, CEP 9722, E7016, and 3- aminobenzamide), sorafenib, imatinib, sunitinib, dasatinib, pembrobzumab nivolumab, atezobzumab, avelumab, durvalumab or the like.
[0100] As used herein, the term "administering" means oral administration, administration as a suppository, topical contact, intravenous, systemic, intracavitary, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. In embodiments, the administering does not include administration of any active agent other than the recited active agent. As used herein, “systemic administration” refers to a route of administration into the circulatory system so that the entire body of a subject is affected. Systemic administration incldes enteral and parenteral administrion. As used herein, the term “intracavitary administration” refers to a route of administration within any natural, non-pathologic cavity.
[0101] “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose,
amylose or starch, fatty acid esters, hydroxymethy cellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure.
[0102] As used herein, the term "co-administer" refers to a composition described herein that is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds provided herein can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
[0103] As used herein, the term "about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/- 10% of the specified value. In embodiments, about includes the specified value.
[0104] A “synergistic amount” as used herein refers to the sum of a first amount (e.g., an amount of a compound provided herein) and a second amount (e.g., a therapeutic agent) that results in a synergistic effect (i.e. an effect greater than an additive effect). Therefore, the terms "synergy", "synergism", "synergistic", "combined synergistic amount", and "synergistic therapeutic effect" which are used herein interchangeably, refer to a measured effect of the compound administered in combination where the measured effect is greater than the sum of the individual effects of each of the compounds provided herein administered alone as a single agent.
II. Compositions
[0105] In an aspect, provided herein is a recombinant oncolytic virus including an expression cassette encoding an anti-CD47 antibody. In an aspect, provided herein is a recombinant oncolytic virus including a nucleic acid encoding an anti-CD47 antibody.
[0106] An oncolytic virus is defined by its ability to selectivity replicate and kill dividing cells as compared to non-dividing cells. It may be a native virus that is naturally oncolytic or may be engineered by modifying one or more viral genes so as to increase tumor selectivity and/or preferential replication in dividing cells, such as those involved in DNA replication, nucleic acid metabolism, host tropism, surface atachment, virulence, lysis and spread (see for example Kim et al., 2001, Nat. Med. 7: 781; Wong et al., 2010, Viruses 2: 78-106). One may also envisage placing one or more viral gene(s) under the control of event or tissue-specific regulatory elements (e.g. promoter).
[0107] Exemplary oncolytic viruses include without limitation reovirus, Seneca Valley virus (SVV), vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), herpes simplex virus (HSV), morbillivirus virus, retrovirus, influenza virus, Sin bis virus, poxvirus, adenovirus, or the like.
[0108] In an aspect, the oncolytic virus is a herpes virus. The Herpesviridae are a large family of DNA viruses that all share a common structure and are composed of relatively large double- stranded, linear DNA genomes encoding 100-200 genes encapsided within an icosahedral capsid which is enveloped in a lipid bilayer membrane. The oncolytic herpes virus can be derived from different types of HSV. In aspects, the oncolytic herpes virus is HSV1. In aspects, the oncolytic herpes virus is HSV2. The herpes virus may be genetically modified so as to restrict viral replication in tumors or reduce its cytotoxicity in non-dividing cells. For example, any viral gene involved in nucleic acid metabolism may be inactivated, such as thymidine kinase (Martuza et al., 1991, Science 252: 854-6), ribonucleotide reductase (RR) (Boviatsis et al., Gene Ther. 1: 323-31; Mineta et al., 1994, Cancer Res. 54: 3363-66), or uracil-N-glycosylase (Pyles et al.,
1994, J. Virol. 68: 4963-72). Another aspect involves viral mutants with defects in the function of genes encoding virulence factors such as the ICP34.5 gene (Chambers et al., 1995, Proc. Natl. Acad. Sci. USA 92: 1411-5). Representative examples of oncolytic herpes virus include NV1020
(e.g. Geevarghese et al., 2010, Hum. Gene Ther. 21(9): 1119-28) and T-VEC (Andtbacka et al., 2013, J. Clin. Oncol. 31, abstract number LBA9008).
[0109] In an aspect, the oncolytic virus is a reovirus. A representative example includes Reolysin (under development by Oncolytics Biotech; NCT01166542).
[0110] In an aspect, the oncolytic virus is a Seneca Valley virus. A representative example includes NTX-010 (Rudin et al., 2011, Clin. Cancer. Res. 17(4): 888-95).
[0111] In an aspect, the oncolytic virus is a vesicular stomatitis virus (VSV). Representative examples are described (e.g. Stojdl et al., 2000, Nat. Med. 6(7): 821-5; Stojdl et al., 2003, Cancer Cell 4(4): 263-75).
[0112] In an aspect, the oncolytic virus is a Newcastle disease virus. Representative examples include without limitation the 73-T PV701 and HDV-HUJ strains as well as those described (e.g. Phuangsab et al., 2001, Cancer Lett. 172(1): 27-36; Lorence et al., 2007, Curr. Cancer Drug Targets 7(2): 157-67; Freeman et al., 2006, Mol. Ther. 13(1): 221-8).
[0113] In an aspect, the oncolytic virus is a morbillivirus which can be obtained from the paramyxoviridae family. In an aspect, the oncolytic virus is a measles virus. Representative examples of oncolytic measles viruses include without limitation MV-Edm (McDonald et al., 2006; Breast Cancer Treat. 99(2): 177-84) and HMWMAA (Kaufmann et al., 2013, J. Invest. Dermatol. 133(4): 1034-42)
[0114] In an aspect, the oncolytic virus is an adenovirus. Methods are available in the art to engineer oncolytic adenoviruses. Various aspects include the replacement of viral promoters with tumor-selective promoters or modifications of the El adenoviral gene product(s) to inactivate its/their binding function with p53 or retinoblastoma (Rb) protein that are altered in tumor cells. In the natural context, the adenovirus E1B55 kDa gene cooperates with another adenoviral product to inactivate p53 (p53 is frequently dysregulated in cancer cells), thus preventing apoptosis. Representative examples of oncolytic adenovirus include ONYX-015 (e.g. Khuri et al., 2000, Nat. Med 6(8): 879-85) and H101 also named Oncorine (Xia et al., 2004, Ai Zheng 23(12): 1666-70).
[0115] In an aspect, the oncolytic virus is a poxvirus. As used herein the term “poxvirus” refers to a virus belonging to the Poxviridae family. The poxvirus can be of the
Chordopoxviridae subfamily and can be of the Orthopoxvirus genus. Sequences of the genome of various poxviruses, for example, the vaccinia virus, cowpox virus, Canarypox virus, Ectromelia virus, Myxoma virus genomes are available in the art and specialized databases such as Genbank (accession number NC_006998, NC_003663, NC_005309, NC_004105,
NC_001132 respectively). The oncolytic poxvirus can be an oncolytic vaccinia virus. Vaccinia viruses are members of the poxvirus family characterized by a 200 kb double-stranded DNA genome that encodes numerous viral enzymes and factors that enable the virus to replicate independently from the host cell machinery. The majority of vaccinia virus particles is intracellular (IMV for intracellular mature virion) with a single lipid envelop and remains in the cytosol of infected cells until lysis. The other infectious form is a double enveloped particle (EEV for extracellular enveloped virion) that buds out from the infected cell without lysing it.
[0116] The anti-CD47 antibody can be a humanized antibody. The phrase “humanized antibodies” refers to monoclonal antibodies and antigen binding fragments thereof, including the nucleic acids encoding an antibody disclosed herein, that have binding and functional properties according to the disclosure similar to those disclosed herein, and that have framework and constant regions that are substantially human or fully human surrounding CDRs derived from a non-human antibody. “Framework region” or “framework sequence” refers to any one of framework regions 1 to 4. Humanized antibodies and antigen binding fragments encompassed by the present disclosure include molecules wherein any one or more of framework regions 1 to 4 is substantially or fully human, i.e., wherein any of the possible combinations of individual substantially or fully human framework regions 1 to 4, is present. For example, this includes molecules in which framework region 1 and framework region 2, framework region 1 and framework region 3, framework region 1, 2, and 3, etc., are substantially or fully human Substantially human frameworks are those that have at least 80% sequence identity to a known human germline framework sequence. Preferably, the substantially human frameworks have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, to a framework sequence disclosed herein, or to a known human germline framework sequence.
[0117] CDRs encompassed by the present disclosure include not only those specifically disclosed herein, but also CDR sequences having sequence identities of at least 80%, at least
85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to a CDR sequence disclosed herein. Alternatively, CDRs encompassed by the present disclosure include not only those specifically disclosed herein, but also CDR sequences having 1, 2, 3, 4, 5, or 6 amino acid changes at corresponding positions compared to CDR sequences disclosed herein. Such sequence identical, or amino acid modified, CDRs preferably bind to the antigen recognized by the intact antibody.
[0118] As used herein, the phrase “sequence identity” means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Identity can be readily calculated by known methods, including but not limited to those described in: Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G, Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs.
[0119] Optimal alignment of sequences for comparison can be conducted, for example, by the local homology algorithm of Smith & Waterman, by the homology alignment algorithms, by the search for similarity method or, by computerized implementations of these algorithms (GAP, BESTFIT, PASTA, and TFASTA in the GCG Wisconsin Package, available from Accelrys, Inc., San Diego, Calif., United States of America), or by visual inspection. See generally, (Altschul, S. F. et al., J. Mol. Biol. 215: 403-410 (1990) and Altschul et al. Nucl. Acids Res. 25: 3389-3402 (1997)).
[0120] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in (Altschul, S., et al., NCBI NLMNIH Bethesda, Md. 20894; & Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990).
Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold.
[0121] These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always; 0) and N (penalty score for mismatching residues; always; 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix.
[0122] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is in one embodiment less than about 0.1, in another embodiment less than about 0.01, and in still another embodiment less than about 0.001.
[0123] Fully human frameworks are those that are identical to a known human germline framework sequence. Human framework germline sequences can be obtained from ImMunoGeneTics (IMGT) via their website or from The Immunoglobulin FactsBook by Marie-
Paule Lefranc and Gerard Lefranc, Academic Press, 2001, ISBN 012441351. For example, germline light chain frameworks can be selected from the group consisting of: A11, A17, A18, A19, A20, A27, A30, LI, L1I, L12, L2, L5, L15, L6, L8, 012, 02, and 08, and germline heavy chain framework regions can be selected from the group consisting of: VH2-5, VH2-26, VH2- 70, VH3-20, VH3-72, VHI-46, VH3-9, VH3-66, VH3-74, VH4-31, VHI-18, VHI-69, VI-13-7, VH3-11, VH3-15, VH3-21, VH3-23, VH3-30, VH3-48, VH4-39, VH4-59, and VH5-5I.
[0124] Humanized antibodies in addition to those disclosed herein exhibiting similar functional properties according to the present disclosure can be generated using several different methods. In one approach, the parent antibody compound CDRs are grafted into a human framework that has a high sequence identity with the parent antibody compound framework. The sequence identity of the new framework will generally be at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identical to the sequence of the corresponding framework in the parent antibody compound. In the case of frameworks having fewer than 100 amino acid residues, one, two, three, four, five, six, seven, eight, nine, or ten amino acid residues can be changed. This grafting may result in a reduction in binding affinity compared to that of the parent antibody. If this is the case, the framework can be back-mutated to the parent framework at certain positions based on specific criteria disclosed by Queen et al. (1991) Proc. Natl. Acad. Sci. USA 88:2869. Additional references describing methods useful in humanizing mouse antibodies include U.S. Pat. Nos. 4,816,397; 5,225,539; and 5,693,761; computer programs ABMOD and ENCAD as described in Levitt (1983) J. Mol. Biol. 168:595-620; and the method of Winter and co-workers (Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; and Verhoeyen et al. (1988) Science 239:1534-1536.
[0125] The identification of residues to consider for back-mutation can be carried out as follows: When an amino acid falls under the following category, the framework amino acid of the human germ-line sequence that is being used (the “acceptor framework”) is replaced by a framework amino acid from a framework of the parent antibody compound (the “donor framework”): (a) the amino acid in the human framework region of the acceptor framework is unusual for human frameworks at that position, whereas the corresponding amino acid in the donor immunoglobulin is typical for human frameworks at that position; (b) the position of the
amino acid is immediately adjacent to one of the CDRs; or (c) any side chain atom of a framework amino acid is within about 5-6 angstroms (center-to-center) of any atom of a CDR amino acid in a three dimensional immunoglobulin model.
[0126] When each of the amino acids in the human framework region of the acceptor framework and a corresponding amino acid in the donor framework is generally unusual for human frameworks at that position, such amino acid can be replaced by an amino acid typical for human frameworks at that position. This back-mutation criterion enables one to recover the activity of the parent antibody compound.
[0127] Another approach to generating human engineered antibodies exhibiting similar functional properties to the antibody compounds disclosed herein involves randomly mutating amino acids within the grafted CDRs without changing the framework, and screening the resultant molecules for binding affinity and other functional properties that are as good as or better than those of the parent antibody compounds. Single mutations can also be introduced at each amino acid position within each CDR, followed by assessing the effects of such mutations on binding affinity and other functional properties. Single mutations producing improved properties can be combined to assess their effects in combination with one another.
[0128] Further, a combination of both of the foregoing approaches is possible. After CDR grafting, one can back-mutate specific framework regions in addition to introducing amino acid changes in the CDRs. This methodology is described in Wu et al. (1999) J. Mol. Biol. 294: 151- 162.
[0129] A person skilled in the art can use common techniques, e.g., site-directed mutagenesis, to substitute amino acids within the presently disclosed CDR and framework sequences and thereby generate further variable region amino acid sequences derived from the present sequences. Up to all naturally occurring amino acids can be introduced at a specific substitution site, including conservative amino acid substitutions as are well known to those of ordinary skill in the art. The methods disclosed herein can then be used to screen these additional variable region amino acid sequences to identify sequences having the indicated in vitro and/or in vivo functions. In this way, further sequences suitable for preparing human engineered antibodies and antigen-binding portions thereof in accordance with the present disclosure can be identified. In some embodiments, amino acid substitution within the frameworks can include one, two, three,
four, five, six, seven, eight, nine, or ten positions within any one or more of the 4 light chain and/or heavy chain framework regions disclosed herein. In some embodiments, amino acid substitution within the CDRs is restricted to one, two, three, four, or five positions within any one or more of the 3 light chain and/or heavy chain CDRs. Combinations of the various changes within these framework regions and CDRs described above are also possible.
[0130] In embodiments, the recombinant oncolytic virus includes a nucleic acid sequence encoding an anti-CD47 antibody. The antibody encoded by the oncolytic virus of the invention can be of any origin, e.g. human, humanized, animal (e.g. rodent or camelid antibody) or chimeric. It may be of any isotype (e.g. IgGl, IgG2, IgG3, IgG4). In addition, it may be glycosylated, partially glycosylated or non-glycosylated (e.g. by mutating one or more residue(s) within the site(s) of glycosylation). The term antibody also includes bispecific or multispecific antibodies so long as they exhibit the binding specificity described herein.
[0131] The nucleic acid sequence encoding an anti-CD47 antibody can include a nucleic acid encoding a light chain signal peptide. In aspects, the nucleic acid sequence encoding a light chain signal peptide is SEQ ID NO. :2. The nucleic acid sequence encoding an anti-CD47 antibody can include a nucleic acid encoding a light chain variable region. In aspects, the nucleic acid sequence encoding a light chain variable region is SEQ ID NO.: 3. The nucleic acid sequence encoding an anti-CD47 antibody can include a nucleic acid encoding a light chain constant region. In aspects, the nucleic acid sequence encoding a light chain constant region is SEQ ID NO.:4.
[0132] The nucleic acid sequence encoding an anti-CD47 antibody can encode an anti-CD47 (aCD47) IgG antibody utilizing the techniques of CDR grafting described above to provide a scaffold of an IgG (an antibody that incorporates portions of heavy chains of an IgG). In embodiments, the IgG is selected from IgGl, IgG2, IgG3, and IgG4. The nucleic acid sequence encoding an anti-CD47 IgG antibody (e.g. IgGl or IgG4) can include a nucleic acid encoding a heavy chain signal peptide. In aspects, the nucleic acid sequence encoding a heavy chain signal peptide is SEQ ID NO.:5. The nucleic acid sequence encoding an anti-CD47 IgG antibody can include a nucleic acid encoding a heavy chain variable region. In aspects, the nucleic acid sequence encoding a heavy chain variable region is SEQ ID NO.: 6.
[0133] The nucleic acid sequence encoding an anti-CD47 antibody can encode an anti-CD47 (aCD47) IgGl antibody. The nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain constant region CHi. In aspects, the nucleic acid sequence encoding a IgGl heavy chain constant region CHi is SEQ ID NO.: 7. The nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain hinge. In aspects, the nucleic acid sequence encoding a IgGl heavy chain hinge is SEQ ID NO.: 8. The nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain constant region CEE. In aspects, the nucleic acid sequence encoding a IgGl heavy chain constant region CEE is SEQ ID NO.: 9. The nucleic acid sequence encoding an anti-CD47 IgGl antibody can include a nucleic acid encoding IgGl heavy chain constant region CEE. In aspects, the nucleic acid sequence encoding a IgGl heavy chain constant region CEE is SEQ ID NO.: 10.
[0134] In embodiments, the recombinant oncolytic virus includes a nucleic acid sequence encoding an aCD47 IgG2 antibody. In embodiments, the recombinant oncolytic virus includes a nucleic acid sequence encoding an aCD47 IgG3 antibody.
[0135] In embodiments, the recombinant oncolytic virus includes a nucleic acid sequence encoding an aCD47 IgG4 antibody. The nucleic acid sequence encoding an anti-CD47 IgG4 antibody can include a nucleic acid encoding IgG4 heavy chain constant region CEE. In aspects, the nucleic acid sequence encoding an IgG4 heavy chain constant region CEE is SEQ ID NO. : 11. The nucleic acid sequence encoding an anti-CD47 IgG4 antibody can include a nucleic acid encoding IgG4 heavy chain constant region CEE. In aspects, the nucleic acid sequence encoding a IgGl heavy chain constant region CEE is SEQ ID NO.: 12.
[0136] In embodiments, the oncolytic virus includes a nucleic acid sequence encoding an aCD47 ScFv.
[0137] The terminal 1 kb of the long repeat region (RL) of the HSV-1 and HSV-2 genomes contain a gene (11-13), that confers neuro virulence. Deletion or mutation of this gene results in variants that grow as well as wild type virus on dividing cells of many established cell lines, but show impaired replication on non-dividing cells. The oncolytic virus provided herein can lack a functional g34.5 gene. In embodiments, the recombinant oncolytic virus does not include nucleic acid encoding a g34.5 gene. In embodiments, the oncolytic herpes simplex virus does not include
nucleic acid encoding ay34.5 gene. In embodiments, the oncolytic herpes simplex 1 virus does not include nucleic acid encoding a g34.5 gene. In embodiments, the oncolytic herpes simplex 2 virus does not include nucleic acid encoding a g34.5 gene. In embodiments, the oncolytic herpes simplex virus does not include nucleic acid encoding a functional g34.5 gene. In embodiments, the oncolytic herpes simplex 1 virus does not include nucleic acid encoding a functional g34.5 gene. In embodiments, the oncolytic herpes simplex 2 virus does not include nucleic acid encoding a functional g34.5 gene.
[0138] The ICP6 gene is a gene encoding the large subunit of ribonucleotide reductase (RR). RR is an enzyme necessary for virus DNA synthesis. Inactivation of this gene prevents virus replication in non-dividing cells. Only in cells which divide actively and have increased RR activity, the deficiency of the RR activity due to deletion of the ICP6 gene is compensated, enabling virus replication. The oncolytic virus provided herein can lack a functional IP6 gene. In embodiments, the recombinant oncolytic virus does not include nucleic acid encoding a functional ICP6 gene. In embodiments, the oncolytic herpes simplex virus does not include nucleic acid encoding a functional ICP6 gene. In embodiments, the oncolytic herpes simplex 1 virus does not include nucleic acid encoding a functional ICP6 gene. In embodiments, the oncolytic herpes simplex 2 virus does not include nucleic acid encoding a functional ICP6 gene.
[0139] The nucleic acid encoding an anti-CD47 antibody operably linked to elements for transcription and translation. The term “operably linked” means that the nucleotide sequence of interest is linked to regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence. The regulatory sequence may include, for example, promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are well known in the art and are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells, and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the target cell, the level of expression desired, and the like. In some examples, a vector has one or more transcription and/or translation control elements.
[0140] Non-limiting examples of suitable eukaryotic promoters (i.e., promoters functional in a eukaryotic cell) include those from cytomegalovirus (CMV) immediate early, HI, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retrovirus, human elongation factor- 1 promoter (EF1), a hybrid construct having the cytomegalovirus (CMV) enhancer fused to the chicken beta-actin promoter (CAG), murine stem cell virus promoter (MSCV), phosphogly cerate kinase- 1 locus promoter (PGK), and mouse metallothionein-I. The promoter can be a constitutive promoter (e.g., CMV promoter, UBC promoter). In some cases, the promoter can be a spatially restricted and/or temporally restricted promoter (e.g., a tissue specific promoter, a cell type specific promoter, etc.).
[0141] In embodiments, the recombinant oncolytic virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter. In embodiments, the oncolytic herpes simplex virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter. In embodiments, the oncolytic herpes simplex 1 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter. In embodiments, the oncolytic herpes simplex 2 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter.
[0142] In embodiments, the recombinant oncolytic virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter. In embodiments, the oncolytic herpes simplex virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter. In embodiments, the oncolytic herpes simplex 1 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter. In embodiments, the oncolytic herpes simplex 2 virus includes nucleic acid encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter. In embodiments, the HSV promoter is an immediate early (IE) promoter. In embodiments, the HSV IE promoter is an IE 4/5 promoter.
[0143] The recombinant oncolytic virus can include a nucleic acid encoding a marker that can be used to determine whether the virus is present in the cell. The marker can be a selectable marker. A selectable marker is a gene introduced into a cell that confers a trait suitable for artificial selection. In embodiments, the recombinant oncolytic virus includes a nucleic acid
encoding a marker within an ICP6 gene. In embodiments, the oncolytic herpes simplex virus includes a nucleic acid encoding a marker within an ICP6 gene. In embodiments, the oncolytic herpes simplex 1 virus includes a nucleic acid encoding a marker within an ICP6 gene. In embodiments, the oncolytic herpes simplex 2 virus includes a nucleic acid encoding a marker within an ICP6 gene. In embodiments, the marker is a selectable marker.
[0144] In embodiments, the pharmaceutical composition has one or more compounds of the present disclosure and one or more pharmaceutically acceptable excipients. In embodiments, the pharmaceutical compositions, the compound, or pharmaceutically acceptable salt thereof, is included in a therapeutically effective amount. In an aspect, provided herein is a pharmaceutical composition including a recombinant oncolytic virus as described herein, and a pharmaceutically acceptable carrier.
[0145] The pharmaceutical composition of the present disclosure can be prepared and administered in a wide variety of dosage formulations. Compounds described can be administered orally, rectally, or by injection (e.g. intratumorally, intracavitary, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally). For example, the compositions disclosed herein can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. The compositions of the present disclosure can additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions disclosed herein can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci.
Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). In another embodiment, the formulations of the compositions of the present disclosure can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i. e.. by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present disclosure into the target cells in vivo. (See, e.g., Al- Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989). The compositions can also be delivered as nanoparticles.
[0146] In embodiments, provided herein is a pharmaceutical composition including a recombinant oncolytic virus encoding an anti-CD47 antibody, and a pharmaceutically acceptable carrier. In embodiments, provided herein is a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody, and a pharmaceutically acceptable carrier. In embodiments, provided herein is a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a viral or tumor specific gene promoter, and a pharmaceutically acceptable carrier. In embodiments, provided herein is a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) promoter, and a pharmaceutically acceptable carrier. In embodiments, provided herein is a pharmaceutical composition including an oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) immediate early (IE) promoter, and a pharmaceutically acceptable carrier. In embodiments, provided herein is a pharmaceutical composition including a oncolytic herpes simplex virus encoding an anti-CD47 antibody under the control of a herpes simplex virus (HSV) immediate an IE 4/5 promoter promoter, and a pharmaceutically acceptable carrier. In embodiments, the pharmaceutical composition further includes an anti-cancer agent.
III. Methods of use
[0147] In an aspect, provided herein is a method for killing tumor cells in a subject including administering to a subject an effective amount of the recombinant oncolytic virus according to any embodiment as described herein. The compositions provided herein are oncolytic viruses that express an anti-CD47 antibody. While not wishing to be held to theory, the oncolytic virus replicates preferentially in the tumor cell and and the anti-CD47 antibody binds to the CD47 receptor that helps the tumor evade the host immune system. In aspects, the composition is administered directly to the tumor location. Methods for tumor location and access are known in the art. Compositions can be administered to a subject in need by any of the methods further described below. Progress in tumor killing can be monitored by any of the methods of imaging tumors or measuring tumor markers known in the art.
[0148] In an aspect, provided herein are methods of treating cancer in a subject in need including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein. In embodiments, the pharmaceutical composition is co-admininstered with an anti-cancer therapy. The anti-cancer therapy can include, but is not limited to, chemotherapy (anti-cancer agents), radiation therapy, surgery, targeted therapy, immunotherapy, or cell therapy. Anticancer agents can include, but are not limited to, checkpoint inhibitors and PARP inhibitors (see “anticancer agents” in Definitions). The pharmaceutical composition and anti cancer agent can be in separate dosage formats. The pharmaceutical composition and anti-cancer agent can be in different types of dosage formats. The pharmaceutical composition and anti cancer agent can be administered by different routes of administration.
[0149] In embodiments, the cancer is a chronic cancer. Chronic cancer is cancer that cannot be cured but that ongoing treatment, also called extended treatment, can control for months or years. As with other chronic disease, the goal of extended treatment for cancer is to help patients live as well as possible for as long as possible. Cancer progression can be monitored by methods known in the art.
[0150] In embodiments, the cancer is a solid tumor. Solid tumors include, but are not limited to, histiocytic lymphoma, cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung. In embodiments, the cancer an inflammatory chronic cancer. Markers of inflammation, such at cytokine expression, can be monitored.
[0151] In embodiments, the cancer is a CD47 expressing cancer. Because the recombinant oncolytic viruses disclosed herein express an anti-CD47 antibody, it would be expected that the compositions would be particularly effective in such cancers. A tumor type can be tested for the expression of CD47 by methods known in the art, such as by ELISA or FACS detection using an anti-CD47 antibody. Gliablastomas and ovarian cancers are demonstrated herein to express CD47. In embodiments, the cancer is glioblastoma, ovarian cancer, pancreatic cancer, leukemia, myeloma, or lymphoma. In embodiments, cancer is glioblastoma. In embodiments, cancer is ovarian cancer. In embodiments, cancer is pancreatic cancer. In embodiments, cancer is leukemia. In embodiments, cancer is myeloma. In embodiments, cancer is lymphoma.
[0152] In an aspect, provided herein is a method of treating a subject with an overactive immune system, including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
[0153] In embodiments of methods of treating a subject with an overactive immune system, the subject has asthma or eczema. In embodiments, the subject has asthma. In embodiments, the subject has eczema. In embodiments of methods of treating a subject with an overactive immune system, the subject has allergic rhinitis.
[0154] In an aspect, provided herein is a method of treating a subject with an autoimmune disease, including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
[0155] In embodiments, the autoimmune disease is arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis,
systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison’s disease, Vitiligo, asthma, and allergic asthma. In embodiments, the autoimmune disease is arthritis. In embodiments, the autoimmune disease is rheumatoid arthritis. In embodiments, the autoimmune disease is psoriatic arthritis. In embodiments, the autoimmune disease is juvenile idiopathic arthritis. In embodiments, the autoimmune disease is scleroderma In embodiments, the autoimmune disease is systemic scleroderma. In embodiments, the autoimmune disease is multiple sclerosis. In embodiments, the autoimmune disease is systemic lupus erythematosus (SLE). In embodiments, the autoimmune disease is myasthenia gravis. In embodiments, the autoimmune disease is juvenile onset diabetes. In embodiments, the autoimmune disease is diabetes mellitus type 1. In embodiments, the autoimmune disease is Guillain-Barre syndrome. In embodiments, the autoimmune disease is Hashimoto’s encephalitis. In embodiments, the autoimmune disease is Hashimoto’s thyroiditis. In embodiments, the autoimmune disease is ankylosing spondylitis. In embodiments, the autoimmune disease is psoriasis. In embodiments, the autoimmune disease is Sjogren’s syndrome. In embodiments, the autoimmune disease is vasculitis. In embodiments, the autoimmune disease is glomerulonephritis. In embodiments, the autoimmune disease is auto-immune thyroiditis. In embodiments, the autoimmune disease is Behcet’s disease. In embodiments, the autoimmune disease is Crohn’s disease. In embodiments, the autoimmune disease is ulcerative colitis. In embodiments, the autoimmune disease is bullous pemphigoid. In embodiments, the autoimmune disease is sarcoidosis. In embodiments, the autoimmune disease is ichthyosis. In embodiments, the autoimmune disease is Graves ophthalmopathy. In embodiments, the autoimmune disease is inflammatory bowel disease. In embodiments, the autoimmune disease is Addison’s disease. In embodiments, the autoimmune disease is Vitiligo. In embodiments, the autoimmune disease is asthma. In embodiments, the autoimmune disease is allergic asthma.
[0156] In an aspect, provided herein is a method of treating a subject with an infectious disease, including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically
acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein. The recombinant oncolytic virus compositions disclosed herein can boost a subject’s immune system to fight off an infection. In embodiments infectious disease is human immunodeficiency virus (HIV). In embodiments infectious disease is COVID-19. In embodiments infectious disease is influenza. In embodiments infectious disease is pneumonia.
In embodiments infectious disease is syphilis. In embodiments infectious disease is anthrax. In embodiments infectious disease is gonorrhea. In embodiments infectious disease is HPV. In embodiments infectious disease is mononucleosis. In embodiments infectious disease is West Nile fever. In embodiments infectious disease is Zika. In embodiments infectious disease is malaria. In embodiments infectious disease is plague.
[0157] In embodiments, immune modulation includes activating natural killer (NK) cells. NK cells can play a critical anti-tumor activity in cancers including GBM via natural cytotoxicity and ADCC, especially in combination with antibody therapy (see, for example, Ref. 31). Oncolytic virus compositions provided herein induce activation of NK cells. NK cell activation induction can be confirmed by cytotoxicity assays and by measuring the expression of the activation marker CD69 on NK cells, such as by flow cytometry (see Examples). In embodiments, activation of NK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity. In embodiments, activation of NK cells is measured as expression of CD69 on NK cells. In embodiments, activation of NK cells is measured as increased NK cell cytotoxicity.
[0158] In an aspect, provided herein is a method for increasing cytotoxicity of natural killer (NK) cells and/or CD8 T cells in a subject, including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
[0159] In an aspect, provided herein is a method for increasing survival and/or proliferation of immune cells in a subject, including administering to the patient an effective amount of a pharmaceutical composition including a recombinant oncolytic virus as described above, and a pharmaceutically acceptable carrier as described herein or the recombinant oncolytic virus according to any embodiment as described herein.
[0160] In embodiments, the immune cell is a natural killer (NK) cell. In embodiments, the immune cell is a CD8 T-cell.
[0161] The compositions may be administered in a single dose (e.g. bolus injection) or multiple doses. If multiple administrations, they may be performed by the same or different routes and may take place at the same site or at alternative sites. It is also possible to proceed via sequential cycles of administrations that are repeated after a rest period. Intervals between each administration can be from several hours to one year (e.g. 24 h, 48 h, 72 h, weekly, every two weeks, monthly or yearly). Intervals can also be irregular (e.g. following tumor progression).
The doses can vary for each administration within the range described above.
[0162] Any of the conventional administration routes are applicable including parenteral, topical or mucosal routes. Parenteral routes are intended for administration as an injection or infusion. Common parenteral injection types are intravenous (into a vein), intra-arterial (into an artery), intradermal (into the dermis), subcutaneous (under the skin), intramuscular (into muscle) and intratumoral (into tumor or at its close proximity). Infusions typically are given by intravenous route. Mucosal administrations include without limitation oral/alimentary, intranasal, intratracheal, intrapulmonary, intravaginal or intra-rectal route. Topical administration can also be performed using transdermal means (e.g. patch and the like). Administrations may use conventional syringes and needles (e.g. Quadrafuse injection needles) or any compound or device available in the art capable of facilitating or improving delivery of the active agent(s) in the subject. Routes of administration for the oncolytic virus include intravenous and intratumoral routes.
[0163] In embodiments, administering includes intratumoral, systemic, or intracavitary administration. In embodiments, administering is intratumoral administration. In embodiments, administering is systemic administration. In embodiments, administering is intracavitary administration.
[0164] The compositions may be administered once or several time (e.g. 2, 3, 4, 5, 6, 7 or 8 times etc) at a dose within the range of from 107 to 5xl09 pfu. The time interval between each administration can vary from approximately 1 day to approximately 8 weeks, advantageously from approximately 2 days to approximately 6 weeks, preferably from approximately 3 days to
approximately 4 weeks and even more preferably from approximately 1 week to approximately 3 weeks (e.g. every two weeks for example).
[0165] In an embodiment the method of the invention provides a higher therapeutic efficacy than the one obtained in the same conditions with a similar oncolytic virus (without immune checkpoint modulator) or the immune checkpoint modulator either individually or even in co administration. In the context of the invention, the method of the invention provides at least 5%, at least 10%, at least 15%, at least 20%, or at least 25% more therapeutic efficacy than either the virus or the immune check point modulator alone or in co-administration. A higher therapeutic efficacy could be evidenced as described above in connection with the term “therapeutically effective amount” with a specific preference for a longer survival.
[0166] The present invention also provides kits including a different container (e.g., a sterile glass or plastic vial) for each virus dose to be administered. Optionally, the kit can include a device for performing the administration of the active agents. The kit can also include a package insert including information concerning the compositions or individual component and dosage forms in the kit.
[0167] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
EXAMPLES
[0168] Example 1: Experimental background
[0169] Oncolytic virus (OV) provides a therapeutic approach for glioblastoma (GBM) as its mechanism of action is completely different from the standard approaches for the treatment of GBM. Oncolytic herpes simplex virus (oHSV), one of the most widely investigated oncolytic viruses, is genetically engineered so that it can selectively lyse cancer cells while leaving normal cells intact. Like many other OVs, oHSV can also alert the patients’ immune system to attack tumor cells. Talimogene laherparepvec (Imlygic), the first FDA-approved oncolytic viral therapy,
consists of an oHSV (see, for example, Ref. 2). oHSV has proven relatively safe and has shown some activity in treating GBM (see, for example, Ref. 3). In previous studies, data showed that oHSV treatment dramatically increased the intratumoral infiltration of immune cells (see, for example, Refs. 4-8) However, most tumor cells have evolved to engage the immune checkpoints and down-modulate the immune cells, thereby evading the anti-tumor immune response (see, for example, Refs. 9-10). Thus, engineering oHSV to express a transgene(s) that could enhance immune responses and/or block engagement of immune checkpoints could be an effective approach to improve the overall efficacy of oHSV against GBM.
[0170] Tumor-associated macrophages (TAM) and microglia are the major tumor-promoting immune cells in the GBM microenvironment (see, for example, Refs. 11-12) Hence, re-education of TAM and tumor-associated microglia in GBM is a promising antitumor strategy (See, for example, Refs. 13-14). The signal-regulatory protein (SIRP)a-CD47 pathway is one of the most studied phagocytosis checkpoints in macrophages and microglia (see, for example, Ref. 15). CD47-SIRPa myeloid checkpoint blockade has been shown to effectively enhance tumor phagocytosis and hence reduce tumor burden (see, for example, Refs. 16-18). A humanized anti- CD47 antibody, which directly inhibits the CD47-SIRPa interaction, is currently in clinical trials showing strong activity against GBM (see, for example, Refs. 17, 19). For safety concerns, this antibody was engineered on a human IgG4 scaffold to minimize Fc-dependent effector functions of innate immunity such as antibody-dependent cellular cytotoxicity (ADCC) and complement- dependent cytotoxicity (CDC) (see, for example, Ref. 20). However, infusion toxicities and difficulty in passing through the blood brain barrier are challenges when the monoclonal antibody are administrated systemically to treat GBM.
[0171] In experiments described herein, oHSV was engineered to express a full length, soluble anti-CD47 antibody with an IgGl scaffold (OV- H5F9-G1) and this was compared to another version that was engineered with an IgG4 scaffold (OV- H5F9-G4) in order to assess for locoregional treatment of glioblastoma (GBM), a devastating brain tumor without curative treatment options. Once it infects the GBM cell, the oHSV encodes a full-length anti-CD47 antibody that is secreted by the GBM and blocks the “don’t eat me” signal normally mediated by the interaction of the innate immune cell’s SIRP-a (a receptor) and its ligand, CD47, expressed by the tumor cell. Blocking this “don’t eat me” signal allows for cytotoxicity against the tumor
cell by antibody-dependent cellular phagocytosis (ADCP). In vitro, both versions of secreted antibodies blocked the CD47-SIRP-a axis, thereby enhancing phagocytosis of tumor cells by macrophages, with a stronger effect against GBM cells seen with the IgGl version due to: (1) an additional ADCP effect via binding with macrophage FcyRIIIA (CD 16) and (2) a strong antibody-dependent cellular cytotoxicity (ADCC) by CD16(+) natural killer (NK) cells. Interestingly, data showed that the Fc-FcR-dependent cytotoxic effect was much stronger than the effect of blocking the CD47-SIRPa axis, i.e., the former contributes most to the overall cytotoxic effect of OV-H5F9-G1 against GBM. In vivo, following locoregional oncolytic virotherapy of GBM, these multifaceted functions of OV-H5F9-G1 and OV-H5F9-G4 led to improvement of survival in orthotopic xenograft animal models, compared to control oHSV alone, with a superior effect seen with the OV-H5F9-G1 construct compared to the OV-H5F9- G4 construct. Data showed that both OV-H5F9-G1 and OV-H5F9-G4, each encoding a secretable full length antibody, could be administered safely without apparent toxicity. Collectively, data herein demonstrated that an oncolytic herpes virus encoding a full length anti- CD47 antibody, especially an IgGl version, is a promising approach for improving the treatment of GBM via its novel enhancement of FcR(+) innate immune cell function.
[0172] Example 2: Results
[0173] OV-Hu5F9-Gl- or OV-Hu5F9-G4-infected GBM cells secrete a full-length anti-CD47 antibody.
[0174] First, we assessed six human GBM cell lines, including patient-derived stem-like
GBM30, GBM43 and BT422, and observed that each uniformly expressed CD47 on the cell surface. Next, constructs of aCD47-Gl (IgGl version) and OV- aCD47-G4 (IgG4 version) were generated, that express an IgGl or IgG4 version of humanized anti -human CD47 antibody coding genes including a full-length of both heavy chain and light chain, driven by the promoter of the
HSV-1 immediate early gene IE4/5. aCD47-G4 was re-constructed as previously reported (see, for example, Ref. 20). aCD47-Gl was constructed by replacing the human IgG4 constant region of aCD47-G4 with the human IgGl constant region. For both versions of anti-CD47, the light chain and heavy chains were linked with a T2A self-cleaving peptide as illustrated in Fig. 1 A. The top line of Fig. 1A is the genetic map of wild type HSV-1. The second line is a genetic map of control oHSV, OV-Q1, with deletion of two copies of g34.5, dysfunction of ICP6, and insertion
of the GFP gene. The third line is a genetic map of OV- aCD47-Gl showing the inserted coding gene of IgGl version of anti-CD47 (Hu5F9-Gl) that is constructed on human IgGl scaffold. The light chain and heavy chain coding genes of Hu5F9-Gl are linked by a T2A sequences and are driven by the viral pIE4/5 promoter. The fourth line is the genetic map of OV-aCD47-G4 demonstrating the inserted coding gene of the IgG4 version of anti-CD47 (aCD47-G4) that is constructed on the scaffold of human IgG4 instead of IgGl.
[0175] The CD47 binding affinity and blocking activity of aCD47-Gl and aCD47-G4 were tested by a flow cytometric assay, using the antibodies purified from supernatants of cultured CHO cells lentivirally transduced with the corresponding coding vector. For this, CD47(+) U251T2 cells were incubated with aCD47-Gl or aCD47-G4 at gradient concentrations. Results showed dose- dependent binding of aCD47-Gl and aCD47-G4 to CD47(+) U251T2 GBM cells, demonstrating that the two antibodies have almost equal binding affinity to the CD47(+) U251T2 cells (Fig. 7A). For the blocking assay, U251T2 cells were incubated with Hu5F9-Gl or Hu5F9-G4 at gradient concentrations, followed by staining with a commercially available anti-CD47 (clone, B6H12). Results showed a similar dose-dependent decrease of BV786 signal when Hu5F9-Gl and Hu5F9- G4 were added, indicating that Hu5F9-Gl and Hu5F9-G4 have a similar CD47 blocking capacity (Fig. 7B).
[0176] After demonstrating the two antibody constructs worked in a lentiviral vector, experiments were performed to generate oHSV expressing each version of the antibodies, using the parental oHSV named OV-Q1, which was double-attenuated with an inactivated ribonucleotide reductase gene (ICP6) and deletions of both copies of the neurovirulence gene (ICP34.5) that limits its replication only in tumor cells and reduces its neuro virulence (see, for example, Refs. 21-22). The two oHSVs were generated in a manner that was previously reported (see, for example, Ref. 4) and are termed OV-aCD47-Gl and OV-aCD47-G4. The genetic maps of wild-type human HSV-1, OV-Q1, OV-aCD47-Gl and OV-aCD47-G4 are illustrated in Fig. 1A. Infection of GBM cells with OV-aCD47-Gl or OV-aCD47-G4 enabled the infected cells to secrete IgGl or IgG4 versions of anti-CD47, respectively. The supernatants from OV-aCD47-Gl-, OV-aCD47-G4- or OV -Q 1 -infected U251 T2 GBM cells were concentrated with protein G columns twenty-four hours after saturated infection (MOI = 3) to obtain the requisite amount required for detection by immunoblot. An immunoblot was undertaken with the concentrated supernatants and
demonstrated that human IgG heavy chain and light chain existed within the supernatants from OV-aCD47-Gl- and OV-aCD47-G4-infected U251T2 GBM cells (Fig. ID). The light chain expressed by OV-aCD47-Gl and OV-aCD47-G4 displayed a larger molecular size, likely due to remaining of the 17 amino acid N-terminus residues of the T2A peptide left in light chain resulting from the self-cleavage of T2A between glycine (G) and proline (P) at its C-terminus (see, for example, Ref. 23) (Fig. ID). The yield of anti-CD47 from OV-aCD47-Gl- and OV-aCD47-G4- infected U251T2 GBM cells were quantified by flow cytometry assay, using corresponding antibodies purified from CHO cells with known concentrations as standards. The OV-5F9-G1- and OV-5F9-G4-infected U251T2 GBM cells released appreciable amount of anti-CD47 as early as 12 hours post infection, and the yields reached peak levels > 6 pg/ml in culture at 24 hours post infection (Fig. IE).
[0177] OV-5F9-G1 and OV-5F9-G4 retain oncolytic potency and virus production.
[0178] To test the oncolytic effect of OV-aCD47-Gl and OV-aCD47-G4, the GBM cell lines U251T2 (Fig. 2A) and Gli36dEGFR (Fig. 2B) were infected with the corresponding viruses. There were no significant difference in cell death among GBM cells infected with OV-5F9-G1, OV-5F9- G4, or the parental oHSV named OV-Q1.
[0179] Next, the viral production capacities of OV-aCD47-Gl and OV-aCD47-G4 were evaluated. Results showed that OV-aCD47-Gl and OV-aCD47-G4-infected U251T2 GBM cells (Fig. 2C) or Gli36 GBM cells (FIG. 2D) produce similar amounts of oHSV when compared to the same GBM cells infected with the parental oHSV OV-Q1. Therefore, engineering oHSV to infect GBM with Hu5F9-Gl or Hu5F9-G4 did not affect their oncolysis or viral production.
[0180] The enhancement of macrophage-mediated phagocytosis by aCD47-Gl is largely mediated by antibody dependent cellular phagocytosis (ADCP). not via blockade of CD47
[0181] Next, the ability of aCD47-Gl and aCD47-G4 to modulate phagocytosis of GBM cells by macrophages was compared. For this purpose, mouse bone marrow derived-macrophages were used as effector cells, as performed by many other groups22. Patient-derived GBM cells GBM43 and BT422 were used as target cells and were labeled with CFSE and pre-incubated with aCD47- G1 or aCD47-G4 purified from lentivirally infected CHO cells. Flow cytometry results showed
that both aCD47-Gl and aCD47-G4 induced a significantly higher level of phagocytosis against GBM43 and BT422 cells compared to the corresponding OV-Q1 -infected GBM cells. Notably, the effect of aCD47-Gl on macrophage phagocytosis against GBM43 or BT422 cells was significantly higher than that observed for aCD47-G4 (Fig. 3A-D). IgG4-based antibodies have the effect of blocking CD47-SIRPa yet have a weak ADCP effect while IgGl-based antibodies block CD47-SIRPa and have a strong ADCP effect due to the difference between IgGl and IgG4 antibodies. Consistent with this, the overall effect of aCD47-Gl was significantly higher than that of aCD47-G4. Compared to control derived from OV-Q1 -infected GBM cells, the effect of the purified aCD47-Gl had a dramatic increase while the effect of the purified aCD47-G4 had a moderate increase (Fig. 3A-D). These data suggest that the phagocytosis increased by aCD47-Gl was mainly from ADCP and blocking CD47-SIRPa contributed substantially less. The phagocytosis assays were also repeated with the supernatants from OV-aCD47-Gl, OV-aCD47- G4 or OV-Q1 infected U251T2 GBM cells. Consistent with the above results, the effect of OV- aCD47-Gl on ADCP was higher than that of OV-aCD47-G4. The effect of OV-aCD47-Gl is approximately three-fold of the effect of OV-aCD47-G4 (Fig. 3E, 3F). FIG. 3G shows phagocytosis assay performed with Fc receptor blocking. For blocking the Fc receptors, BMDM cells were incubated with isotype human IgGl at the dose of 10 mg/ml for 30 min in advance. FIG. 3H shows cytokine gene transcription assay. BMDM were cocultured with GBM43 at the ratio of 1:1 with or without the presence of aCD47-Gl or aCD47-G4 for 6 hours. Then, total RNA was extracted and reverse-transcribed for detecting the transcription level of the indicated genes by real time PCR.
[0182] aCD47-Gl induces potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against GBM
[0183] NK cells play a critical anti-tumor activity in cancers including GBM via natural cytotoxicity and ADCC, especially in combination with antibody therapy (see, for example, Ref. 31). In order to determine how Hu5F9-Gl or Hu5F9-G4 affects NK cell anti-tumor activity, freshly isolated human NK cells were used to measure the effect of the two antibodies on ADCC. Human GBM patients-derived tumor cells GBM43 and BT422 were used as target cells. The target cells were labeled with Chromium-51 (51Cr) for 1 hour, and were then incubated with aCD47-Gl, aCD47-G4 purified from supernatants of lentivirus-infected CHO cells or vehicle for 30 min. The
effector NK cells and the target cells were then co-cultured at the ratios of 40: 1, 20: 1 and 10: 1 for 4 hours. Released 51Cr was measured for evaluating the levels of NK cell cytotoxicity. The results showed that when GBM43 and BT422 were used as target cells, aCD47-Gl but not aCD47-G4 induced strong NK cell cytotoxicity (Fig. 4A, 4B). This experiment was repeated with the supernatants from OV-aCD47-Gl- and OV-aCD47-G4-infected U251T2 GBM cells. The GBM43 cells incubated with the conditioned medium from OV-aCD47-Gl -infected U251T2 GBM cells underwent substantially more cytolysis than those incubated with the medium from OV-Q1- infected U251T2 cells. However, no difference was found between conditioned media from OV- Ql- and OV-aCD47-G4-infected U251T2 GBM cells (Fig. 4C). NK cell activation induced by Hu5F9-Gl was also confirmed by measuring the expression of the activation marker CD69 on NK cells by flow cytometry. The results showed that aCD47-Gl but not aCD47-G4 dramatically increased the surface expression of CD69 on NK cells (Fig. 4D, 4E, 8C, 8D). To confirm that the effect of OV-aCD47-Gl was mediated by Fc receptor, blocking of the Fc receptors was found to reduce antitumor activity of aCD47-Gl secreted from GBM cells.
[0184] While both OV-aCD47-Gl and OV-aCD47-G4 improve oncolytic virotheranv. OV- aCD47-Gl shows a superior effect.
[0185] To evaluate the efficacy of OV-aCD47-Gl and OV-aCD47-G4 for the in vivo treatment of GBM, previously described xenograft GBM mouse models were utilized by intracranially (i.c.) injecting luciferase-expressing GBM43 cells into athymic nude mice (see, for example, Ref. 32). Seven days after tumor implantation, animals received an i.c. injection with OV-aCD47-Gl, OV- aCD47-G4 or OV-Q1 at the dose of 2 c 105 PFU per mouse, or saline as a placebo control. Tumor progression was monitored by luciferase-based imaging every five days from day 15 post tumor implantation (Fig. 5 A). Xenograft GBM mouse models were established by intracranially injecting 1 x 105 GBM43-FLL cells to athymic nude mice. Seven days later, mice were intratumorally injected with 2 c 105 PFU of OV-Q1, OV-aCD47-Gl, OV-aCD47-G4 or vehicle. Mice were weighed every day, and luciferase-based image were taken every 5 day from day 15 post tumor implantation to evaluate tumor progression. OV-aCD47-Gl was significantly more effective than OV-aCD47-G4 at inhibiting the progression of GBM tumors in vivo and both were superior to OV-Q1 (Fig. 5B-D). OV-Q1 slowed GBM progression moderately as compared to vehicle control and prolonged the median survival from 43 days to 51 days. OV-aCD47-G4 treatment prolonged
median survival time of the GBM mice compared to both saline control and OV-Q1 treatment. Eight out of nine mice from the OV-aCD47-Gl group and two out of nine mice from the OV- aCD47-G4 group survived over 125 days without GBM symptoms and exhibited no detectable luciferase signal (Fig. 5B, C and E). Body weight recording of the experimental mice further indicated that the mice treated with OV-aCD47-Gl were healthier compared to mice in other groups at the late stage of the study with continuously increasing body weights (Fig. 5D)
[0186] OV-aCD47-Gl is superior to OV-aCD47-G4 and to separate intracranial delivery of OV and systemic aCD47-Gl in improving outcome in an immunocompetent GBM model
[0187] We next sought to evaluate the efficacy of OV-aCD47-Gl in an immunocompetent GBM mouse model. A modified CT2A mouse GBM model was used for this purpose. The mouse CT2A GBM cells were modified to express human CD47 for generating the CT2A- hCD47 cells. The purpose for this modification is allow the aCD47-Gl antibody to bind to the human CD47 expressed on CT2A-hCD47 GBM cells. By i.c. injection of CT2A-hCD47 cells into immunocompetent wild-type C57BL/6 mice, we established a GBM immunocompetent mouse model and repeated the survival study in Figure 5 with slight modification (Fig. 18A).
The treatment of these mice with OV-aCD47-Gl significantly prolonged their median survival when compared to those mice treated with OV-aCD47-G4, OV-Q1 or vehicle control (Fig. 18B). However, in contrast to the xenograft model, we did not see a significant difference from the mice treated with OV-aCD47-G4 and either OV-Q1 or vehicle control (Fig. 18B). Possible explanations for this include: (1) the human-CD47-mediated “don’t eat me” signal may not function well in the immunocompetent C57BL/6 mice; (2) the murine macrophages still receive the murine-CD47-mediated “don’t eat me” signal from the CT2A-hCD47 GBM that cannot be blocked by human aCD47-Gl or aCD47-G4; (3) human aCD47-Gl can still bind to a murine Fc receptor to induce ADCP or ADCC but aCD47-G4 cannot, as shown for other antibodies33.
Body weight recordings of the mice in the study supported the findings that OV- aCD47-Gl was the only effective treatment for the immune competent mouse GBM model (Fig. 18C).
[0188] Next, we repeated the survival study with the CT2A-hCD47 GBM mouse model to compare the effectiveness of i.c. administration of OV-aCD47-Gl against the combination of i.c. administration of OV-Q1 combined with continuous release of aCD47-Gl mAh into the GBM environment by an osmotic pump. For the purpose, we set up 5 different treatment groups of i.c.
administration: Group 1, saline; Group 2, OV-Q1; Group 3, osmotic pump delivery of aCD47- Gl; Group 4, a combination of OV-Q1 plus osmotic pump delivery of aCD47-Gl mAb and Group 5, OV-aCD47-Gl. Three days post tumor implantation (day 3), the two groups with OV- Q1 injection (Groups 2 and 4) and the group with OV-aCD47-Gl injection (Group 5) received 2 x 105 PFU corresponding virus per mouse. On days 4 to 7, the two groups with an osmotic pump delivery of aCD47-Gl received the i.c. delivery of the antibody by the pump at the rate of 1.0 pg per hour for 72 hours, i.e. 24 pg per day, which is about 2-3 times of the amount produced by the injected virus, based the data from Figure IF. Mice in other groups received i.c. saline as control (Fig. 18D). As a single agent, compared to saline, both OV-Q1 and aCD47-Gl delivery by the pump showed a modest but not statistically significant improvement in mouse survival (Fig. IE). The combination of OV-Q1 and aCD47-Gl delivery by the pump seems to be better than aCD47-Gl alone and the P value is on the boarder of significance ( P = 0.0737) but was not significantly different when compared to OV-Q1 alone. Consistent with other two animal models (Figs. 5C and 21B), OV-aCD47-Gl significantly prolonged the survival of the GBM mice when compared to OV-Q1 (Fig. 18E). OV-aCD47-Gl is the best among all the tested groups and in particular is statistically superior to the combination of i.c. OV-Q1 and aCD47-Gl delivery by the pump. As the OV-aCD47-Gl therapeutic combines OV-Q1 and aCD47-Gl into a single agent, and the single agent shows therapeutic survival outcomes superior to aCD47-Gl alone, OV-Q1 alone, and their combination, the two-in-one single agent, i.e., an oncolytic virus expressing a full-length IgGl anti-CD47 antibody is an innovative, convenient, and effective approach for the treatment of experimental GBM.
[0189] To prove that aCD47-Gl induces GBM phagocytosis via ADCP, we repeated the phagocytosis assay with Fc receptor blockade. Preincubating BMDM with high-dose (10 pg/ml) isotype human IgGl, which competes with aCD47-Gl to bind to Fc receptors, significantly inhibited aCD47-Gl -induced GBM phagocytosis by BMDM (Fig. 9). We also found that aCD47- G1 but not aCD47-G4 dramatically activated transcription of typical macrophage cytokine genes of mouse BMDM that have been reported to response to IgGl antibody (see, for example, Ref. 28), such as II lb, 116, 1110, III 2b and Nos2 (Fig. 10).
[0190] The effects of aCD47-Gl and aCD47-G4 on inducing the human macrophage phagocytosis were also determined. For this purpose, primary human donor-derived
macrophages were used as effector cells, as previously reported by other groups (see, for example, Ref. 29). Patient-derived GBM43 GBM cells labeled with CFSE were used as target cells. Target cells were cocultured with the human primary macrophages at a ratio of 2: 1 for 4 hours in the presence of aCD47-Gl or aCD47-G4 that purified from lentivirus-infected CHO cells. Similar to the results as we collected using mouse BMDM, compared to vehicle control, both aCD47-Gl and aCD47-G4 significantly enhanced the phagocytosis of GBM43 cells by human macrophages, although the effect of the former is more substantial than the latter due to having additional strong ADCP effect (Fig. 11). Similar results were found by using the unconcentrated supernatants from OV-aCD47-Gl-, OV-aCD47-G4- or OV-Q1 -infected U251T2 GBM cells. Both aCD47-Gl secreted by OV-aCD47-Gl -infected cells and aCD47-G4 secreted by OV-aCD47-G4-infected cells significantly enhanced the phagocytosis of GBM43 cells by human macrophages, although the effect of the former is more substantial than the latter (Fig.
12). aCD47-Gl also activated the transcription of typical macrophage cytokine genes of human macrophages, such as IL1B, IL6, IL10, NOS2 (Fig. 13A) and IL12A (Fig. 13B).
[0191] For both murine and human macrophages, the increased phagocytosis effect of aCD47- G1 above vehicle control should be from both blockade of “don’t eat me” signaling and ADCP while the effect above aCD47-G4 should be from ADCP only, as IgGl rather than IgG4 antibodies can induce substantial ADCP via an Fc receptor-mediated effect, likely due to the distinct physical properties of IgGl and IgG4 antibodies (see, for example, Ref. 30).
[0192] Comparison of systemic i.v. injection versus locoregional OV delivery of the anti- CD47 antibody
[0193] To evaluate the efficacy of delivering aCD47-Gl antibody to the GBM microenvironment by i.c. OV-aCD47-Gl versus systemic i.v. administration, we modified a previously described xenograft GBM mouse model by i.c. injecting 1 c 105 GBM43 cells into athymic nude mice (Fig. 14) (see, for example, Ref. 32). Twenty-one days after tumor implantation (day 0), mice were divided to four groups for i.c. administration: Group 1, saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus intraperitoneal (i.p.) delivery of aCD47-Gl; and Group 4, OV-aCD47-Gl. The viral dose for the two groups receiving an i.c. injection of OV-Q1 and the group receiving i.c. injection of OV-aCD47-Gl on day 21 was 2 c 105 plaque-forming unit (PFU) per mouse. Group 3 received i.p. aCD47-Gl at a dose of 150 pg
per mouse on day 22. Mice in other groups received i.p. saline on day 22 as control. All mice were sacrificed on day 23 to determine the levels of the antibody in plasma by ELISA and in the central nervous system (CNS) by IHC (Fig. 14).
[0194] Mice with i.p. injection of aCD47-Gl (150 pg/mouse) had approximately 10 pg/ml of aCD47-Gl detected in the plasma, while Groups 1, 2 and 4 had no or little aCD47-Gl detected in the plasma (Fig. 15 A). Brains isolated from the experimental mice were used for histologic study. H&E staining was performed to distinguish GBM tissues from normal brain tissues (Figs. 15B and C). The immunohistochemical staining with an anti-HSV antibody, anti-human Fc antibody, anti-CDllb or anti-NKp46 antibody indicated oHSV-infected areas, presence of aCD47-Gl, distribution of macrophages or NK cells, respectively. The anti-human Fc staining showed that there was a measurable amount of aCD47-Gl detectable in the brains of the mice treated with OV-aCD47-Gl but no anti -human Fc staining was found in the brains of those that were i.c. treated with saline or OV-Q1 or in mice that received i.p. injections of aCD47-Gl (Figs. 15B and C). The anti-human Fc staining localized in the same area of the anti-HSV staining in the brains treated with OV-aCD47-Gl. The results showed that CD1 lb(+) macrophage and NKp46(+) NK cell infiltration increased only in the tumor-bearing hemispheres compared to the non-tumor hemispheres. The macrophages and NK cells in the brains of saline- treated mice were mainly located at the surrounding area of the entire tumor but rarely infiltrated into the central area of the tumor. However, treatment with OV-Q1 or OV-aCD47-Gl substantially increased intratumoral infiltration of CD1 lb(+) macrophages and NKp46(+) NK cell (Figs. 15B and C).
[0195] To confirm our findings, we repeated this experiment with some modifications: performing i.p. administration of aCD47-Gl or saline twice (once on day 22 and another on day 24) and sacrificing the mice on day 25 without other modifications to the treatment protocol (Fig. 16). Similar results were observed. Plasma aCD47-Gl (approximately 10 pg/ml) was only detectable after i.p. administration of aCD47-Gl (Fig. 17A). The enhancement of intratumoral infiltration of CD1 lb (+) macrophages and NKp46(+) NK cells induced by oHSV treatment was somewhat more obvious compared to the experiment performed in Figs. 15B and C (see Figs. 17B and C). Our data demonstrate that aCD47-Gl was not only detectable at 2 but also 4 days post OV-aCD47-Gl treatment in the OV-aCD47-Gl treated brains rather than the other groups
(Figs. 15B and C), suggesting continuous releasing of aCD47-Gl from OV-aCD47-Gl -infected GBM cells.
[0196] OV-Hu5F9-Gl- or OV-Hu5F9-G4-infected A2780 cells secrete a full-length anti-CD47 antibody.
[0197] Firstly, we detected CD47 expression on A2780, the human ovarian cancer cell line and observed that CD47 was expressed on the surface of A2780 cell line. For the blocking assay, A2780 cells were firstly incubated with aCD47-Gl or aCD47-G4 at gradient concentrations. Then the cells were stained with a BV786-conjugated anti-CD47 antibody. Results showed a similar dose-dependent decrease of BV786 signal when cells were preincubated with aCD47-Gl and aCD47-G4, indicating that aCD47-Gl and aCD47-G4 have a similar CD47 blocking capacity (Fig. 19). OV-aCD47-Gl- and OV-aCD47-G4 were constructed by inserting the coding genes of aCD47-Gl and aCD47-G4 into the oncolytic herpes virus backbone (OV-Q1) respectively. The inserted genes of anti-CD47 antibody were driven by the virus immediately early gene promoter IE4/5 to get a high-level expression after infection (Fig. 20). For testing the anti-CD47 antibody yield of OV-aCD47-Gl- and OV-aCD47-G4-infected cells, human ovarian cancer cells, A2780 cells, were saturated infected by OV-aCD47-Gl and OV-aCD47-G4 at the MOI of 2. Anti-CD47 antibodies were detected in the supernatant of infected cells as soon as 6 hours after infection and the yield of anti-CD47 antibody reached over 5 ug/ml at 24 hours after infection. Then we tested if the insertion of anti-CD47 antibody coding gene affect the oncolytic effect of OV-aCD47-Gl and OV-aCD47-G4. A2780 cells were infected with different titers of OV-aCD47-Gl, OV-aCD47-G4 or the parental virus (OV-Q1). There was no obvious difference in cell death was observed among that caused by infection of OV-aCD47-Gl, OV-aCD47-G4 or OV-Q1. Therefore, the insertion of aCD47-Gl and aCD47-G4 coding genes does not affect the oncolytic ability of OV-aCD47-Gl and OV-aCD47-G4.
[0198] aCD47-Gl activates the antitumor effect of macrophages
[0199] For testing the macrophage phagocytosis activation effects of aCD47-Gl and aCD47- G4, human primary macrophages were isolated for using as effector cells. Human ovarian cancer cells A2780 were used as target cells. The target cells were cocultured with the human macrophages at the ratio of 2: 1 for 4 hours in the presence of purified aCD47-Gl or aCD47-G4.
The phagocytosis results showed that compared to vehicle control, aCD47-Gl dramatically,
while aCD47-G4 moderately enhanced the phagocytosis of human macrophages against A2780 cells (Fig. 21A). The supernatants from OV-aCD47-Gl-, OV-aCD47-G4- or OV-Q1 -infected A2780 cells were used to repeat this experiment. Similar results were observed that compared to the supernatant from OV-Q-infected cells, the supernatant from OV-aCD47-Gl -cells significantly supernatant enhanced the phagocytosis effect of human macrophages against A2780 cells , while that from OV-aCD47-G4-infected cells showed moderate function (Fig. 21B).
[0200] We also tested the effect of aCD47-Gl and aCD47-G4 on mouse macrophage phagocytosis activation. Bone marrow derived macrophages (BMDMs) isolated from BALB/c mice were used as effector cells. CFSE labeled human ovarian cancer cells A2780 were used as target cells. The target cells were cocultured with the BMDMs at the ratio of 2: 1 for 4 hours in the presence of purified aCD47-Gl or aCD47-G4. The phagocytosis results showed that compared to vehicle control, aCD47-Gl significantly activated the phagocytosis function of mouse BMDMs against A2780 cells. However, aCD47-G4 has moderate effect on mouse BMDM phagocytosis activation (Fig. 21C). The supernatants from OV-aCD47-Gl-, OV- aCD47-G4- or OV-Q1 -infected A2780 cells were used to repeat this experiment with mouse BMDMs. Both aCD47-Gl secreted by OV-aCD47-Gl -infected cells and aCD47-G4 secreted by OV-aCD47-G4-infected cells significantly enhanced the phagocytosis of mouse BMDMs against A2780 cells, although the effect of the former is more substantial than the latter due to aCD47- G1 having additional strong ADCP effect (Fig. 21D).
[0201] The effect of aCD47-Gl and aCD47-G4 on regulating the cytokine release of human macrophages were also tested. Human macrophages were incubated with aCD47-Gl, aCD47-G4 or vehicle for 6 hours. Then the total RNA was isolated for measuring the gene transcription level by real time PCR. The results showed that aCD47-Gl dramatically activated the transcription of some typical macrophages cytokine genes such as IL6, IL10, iNOS and IL12 (Fig.22 A and 22B).
[0202] OV-aCD47-Gl activates the antitumor effect of NK cells
[0203] To determine the effect of aCD47-Gl and aCD47-G4 on NK cell anti -tumor activity, we used freshly isolated human NK cells as effector cell and ovarian cancer cells as target cells to perform NK cell cytotoxicity assays. Chromium-51 pre-labeled target cells were incubated with purified aCD47-Gl or aCD47-G4. Then the effector NK cells were cocultured with the
pretreated target cells at different ratios for 4 hours. The release of chromium-51 was measured for evaluating the cytotoxicity. The results showed that aCD47-Gl but not aCD47-G4 induced strong NK cell cytotoxicity against ovarian cancer cells (Fig. 23A). Then the supernatants from OV-Q1-, OV-aCD47-Gl- and OV-aCD47-G4-infected A2780 cells were used to repeat this experiment. Consistent results were observed. Only the supernatant from OV-aCD47-Gl- but not that from OV-aCD47-G4-infected A2780 cells induced strong NK cell cytotoxicity compared to the OV-Q1 supernatant (Fig. 23B). The NK cell activation effect of aCD47-Gl was also confirmed by measuring the expression of the NK cell activation marker CD69 with flow cytometry. The results showed that with the presence of tumor cells, aCD47-Gl but not aCD47- G4 significantly increased the surface expression of CD69 on NK cells (Fig. 23C). The similar results were also found when using the supernatants from OV-Q1-, OV-aCD47-Gl- and OV- aCD47-G4-infected A2780 cells. Only the supernatant from OV-aCD47-Gl- but not OV- aCD47-G4-infected cells significantly increased the surface expression of CD69 on NK cells (Fig. 23D). We also measured the granzyme B production of NK cells. Our data showed that with the presence of A2780 cells, aCD47-Gl significantly promoted the granzyme B production of NK cells compared to control group, while aCD47-G4 showed slightly effect on that (Fig. 23E).
[0204] OV-aCD47-Gl improves the therapeutic efficacy against ovarian tumor
[0205] To evaluate the efficacy of OV-aCD47-Gl and OV-aCD47-G4 for the in vivo treatment of ovarian cancer, we utilized a previously described xenograft model of ovarian cancer by s.c. injecting 5 c 106 A2780 cells into nude mice (see Ref. 60). 1 day after tumor implantation, animals received an intratumoral injection with OV-aCD47-Gl, OV-aCD47-G4 or OV-Q1 at the dose of 1 c 105 plaque-forming unit (pfu) per mouse, or saline as a placebo control. Tumor progression was monitored by measuring the tumor size. OV-aCD47-Gl was significantly more effective than OV-aCD47-G4 at inhibiting the progression of tumors in vivo and both are superior to OV-Q1 (Fig. 24). OV-Q1 moderately slowed tumor progression as compared to vehicle control (Fig. 24).
[0206] We also detected the distribution of anti-CD47 antibody after OV-aCD47-Gl or OV- aCD47-G4 treatment. NOD-scid IL2Rgammanu11 (NSG) mice were implanted with patient derived ovarian tumor fragments. 5 days after the implantation, animals received an intratumoral
injection with OV-aCD47-Gl, OV-aCD47-G4 or OV-Q1 at the dose of 1 x 106 plaque-forming unit (pfu) per mouse. 2 days after injection, the tumor fragments were isolated for immunohistochemical staining with an anti-HSV antibody and anti-human Fc antibody.
[0207] OV-aCD47-Gl enhances the therapeutic efficacy in an immunocompetent ovarian cancer mouse model
[0208] We next sought to evaluate the efficacy of OV-aCD47-Gl in an immunocompetent ovarian cancer mouse model. The mouse ID8 ovarian cancer cells were modified to express human CD47 for generating the ID8-hCD47 cells. The purpose for this modification is to make the aCD47-Gl antibody be able to bind to the human CD47 expressed on ID8-hCD47 cells. By intraperitoneal (i.p.) injection of ID8-hCD47 cells into immunocompetent wild-type C57BL/6 mice, we established an ovarian cancer immunocompetent mouse model and repeated the survival study with slight modification (Fig. 25). The treatment of these mice with OV-aCD47- G1 significantly prolonged their median survival when compared to those mice treated with OV- Q1 (Fig. 25).
[0209] The combination of OV-aCD47-Gl with olaparib demonstrates an enhanced effect in vitro and in vivo
[0210] Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was the first PARP inhibitor approved for treating ovarian cancer. The PARP enzyme plays a role in DNA repair. Inhibiting this enzyme may contribute to cancer cell death and increased sensitivity to chemotherapy. By blocking this enzyme, DNA inside the cancerous cells is less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth. To detect whether OV-aCD47-Gl enhanced olaparib function for treating ovarian cancer, we performed the combination therapy with OV-aCD47-Gl and olaparib in vivo and in vitro. A2780 cells were treated with olaparib overnight, and the pretreated cells were 51Cr-labeled and used as target cells. These cells were then incubated with the supernatant from OV-aCD47-Gl- or OV-Q1- infected cells. The effector NK cells and target cells were then co-cultured at the ratios of 40: 1, 20:1, and 10:1 for 4 hours and assayed for cytotoxicity. The results demonstrated that olaparib pre-treatment enhanced NK cell cytotoxicity. In addition, we found that when olaparib was given with the supernatant from OV-aCD47-Gl -infected cells, a significantly higher degree of NK cell cytotoxicity was observed as compared to either treatment alone (Fig. 26).
[0211] Discussion
[0212] In this study, oncolytic virotherapy and antibody therapy were combined into a single therapeutic agent, aiming to destroy tumor cells directly by oncolysis and indirectly by converting the “cold” immune-evasive tumor microenvironment (TME) to a “hot” TME. A platform was developed by using oncolytic virus as a locoregional delivery vehicle of the full-length anti-CD47 antibody. This novel reagent can be administered intratumorally or intracranially post-surgery. This two-in-one, economical, and effective reagent should be able to be administered intratumorally pre-, intra- or post-operatively. Experimentally, the local delivery of OV-aCD47- G1 leads to (1) direct tumor lysis by oHSV; (2) innate immune cell infiltration and activation at the TME by oHSV; (3) blockade of the “don’t eat me” signal normally mediated by the interaction between SIRP-a and CD47 expressed by macrophages and GBM, respectively; (4) aCD47-Gl- mediated ADCP via bridging Fey receptors on macrophages and CD47 on GBM; and (5) aCD47- G1 -mediated ADCC by NK cells. These multifaceted oncolysis and immunomodulatory roles collectively halt the spread of the GBM.
[0213] The systemic administration of the IgG4 anti-CD47 antibody (aCD47-G4) has shown significant anti-tumor activity in several types of malignancies in both preclinical and clinical studies (see, for example, Refs. 17-19). aCD47-G4 was constructed on a human IgG4 scaffold to minimize adverse effects resulting from Fc-dependent effector functions resulting from systemic administration of aCD47-Gl such as ADCC and ADCP. Using this approach, the aCD47-G4 mAh is largely limited to blocking the CD47-SIRPa axis while being unable to induce the FcR+ innate immune effector cell responses of ADCC and ADCP, which result from Fc portion of the IgGl mAh binding to the FcR on macrophages and NK cells. We therefore generated OV-aCD47-Gl as well as OV-aCD47-G4 to understand the importance of the Fc-FcR interaction in tumor clearance. While OV-aCD47-Gl and OV-aCD47-G4 released full length aCD47-Gl and aCD47- G4 mAbs, respectively, once GBM was infected, we found the anti -tumor efficacy of OV-aCD47- G1 to be significantly higher than OV-aCD47-G4 in vitro and in vivo. The data presented here suggest this is because aCD47-G4 can only block the CD47-SIRPa “don’t-eat-me” signal, while aCD47-Gl combines this effect with Fc-dependent effector functions that result from ADCC and ADCP. Our antibody distribution data comparing systemic to locoregional delivery of the aCD47- G1 molecule suggest that the locoregional delivery of aCD47-Gl to the TME by OV-aCD47-Gl
is an effective approach, even when compared to delivering the combination of oHSV and aCD47- G1 locoregionally but delivering them as two separate therapeutics.
[0214] Monoclonal antibodies (mAbs) have been widely and successfully used as targeted therapies in many cancers. However, the intravenous (i.v.), subcutaneous (s.c.), or intramuscular (i.m.) routes of administration may be impeding their efficacy in solid tumors with challenging TMEs. Because of large molecular sizes, s.c. and i.m. administration of mAbs require an additional absorption step, whereby mAbs are transported from the interstitial space into the lymphatic system prior to draining into the blood stream (see, for example, Ref. 34). However, regardless of the route of administration, the systemic delivery of mAbs is mainly distributed in plasma rather than the targeted tissue. To achieve an effective local dose in targeted tissues such as solid tumors, a high systemic dose of mAh is required but can result in adverse side effects and excessive cost. Moreover, traversing the blood-brain barrier (BBB) for mAh treatment of GBM is another challenge that largely precludes the systemic approach for mAh therapy in most GBM patients.
[0215] The current study suggests that re-engineered oHSV is an excellent platform to deliver mAbs in solid tumors such as GBM because the mAbs can be delivered beyond the BBB locoregionally by the GBM itself given the neurotropic properties of HSV. Further, the infected GBM can produce the mAh continually within the TME, thereby achieving an effective local dose and improving the likelihood of an anti-tumor response as FcR+ innate immune effect cells migrate to the virally infected tumor site. To achieve effective dose at the GBM microenvironment, the encoded anti-CD47 mAh gene is designed to be driven by a strong oHSV promoter, the promoter of the HSV-1 immediate early gene IE4/5.
[0216] TAMs have been found to be the major immune cells that promote tumor development in the GBM microenvironment (see, for example, Ref. 35). Since modulating TAMs is considered to be a promising anti-tumor strategy, targeting the CD47-SIRPa axis in these cells should be a good approach for the treatment of GBM. CD47 is highly expressed on numerous types of tumors including GBM (see, for example, Refs. 16, 26, 36). CD47 acts as an anti-phagocytic “don't eat me” signal by binding to SIRPa on the surfaces of macrophages. Activation of SIRP-a results in the inhibition of phagocytosis (see, for example, Ref. 18). Expression of CD47 helps the tumor cells escape from elimination by macrophages and facilitates their metastasis (see, for example,
Ref. 37). Disrupting this CD47-SIRPa axis using mAbs has been shown to increase the phagocytosis of cancer cells and inhibit the progression of some hematological malignancies as well as solid tumors (see, for example, Refs. 17, 19, 38, 39).
[0217] aCD47-G4 (5F9-G4) is a humanized mAh whose construction was carried out by grafting its complementarity determining regions (CDRs) onto a human IgG4 scaffold to minimize Fc-dependent effector functions such as ADCC and ADCP. The aCD47-Gl antibody has identical CDRs but is grafted onto a human IgGl scaffold. Therefore, they should have a near-identical ability to interrupt the “don’t eat me” CD47-SIRPa interaction. Despite this, our study suggests that when locoregional delivery is available for GBM via its infection with oHSV, the aCD47-Gl antibody should be considered instead of aCD47-G4. This is because we show that the aCD47- G1 antibody has superior in vitro anti-tumor efficacy compared to that of aCD47-G4. Indeed, while both can block the CD47-SIRPa interaction, the aCD47-Gl antibody expressed by OV- aCD47-Gl can induce Fc-dependent ADCP mediated by macrophages and ADCC mediated by NK cells, while the aCD47-G4 antibody can only interrupt the “don’t-eat-me” signal. Consistent with these data, our in vivo efficacy data showed that OV-aCD47-Gl played a better role than OV- aCD47-G4 in impeding GBM growth and facilitating its eradication. Our data also suggest that both the Fc-dependent anti -tumor effect and the effect resulting from the interruption of the CD47- SIRPa axis are important in the experimental treatment of GBM.
[0218] When systemic delivery of oncolytic virus is considered for tumors outside of the CNS, OV-aCD47-G4 may prove to be effective. Considering that both the oHSV backbone and anti- CD47 antibody have been tested in the clinic, our novel oHSV expressing an anti-CD47 antibody should likely be considered for translation into the clinic for the treatment of systemic solid tumors.
[0219] As aCD47-Gl and aCD47-G4 have an identical Fab recognizing CD47, any differences that we observed in phagocytosis must be attributable to the Fc portion of these two antibodies instead of the “don’t eat signal”. Our in vitro data show that IgG4-based antibodies have a weak phagocytosis effect, while IgGl -based antibodies induce a strong phagocytosis effect likely due to the distinct physical properties of IgGl and IgG4 antibodies (see, for example, Ref. 30). When we used murine macrophages as effector cells and human GBM as target cells, the phagocytotic effect of the purified aCD47-Gl was dramatic while the same
effect when using purified aCD47-G4 was relatively very moderate. These data suggest that the overall phagocytosis increased by aCD47-Gl was largely due to ADCP, while the phagocytosis from blocking CD47-SIRPa interaction was substantially less compared to ADCP. We may conclude that the Fc receptor-mediated ADCP effect is stronger than CD47-mediated “don’t eat me” signaling. However, this could be due to a low binding affinity between murine SIRPa and human CD47, thus resulting in a low level of “don’t eat me” signaling40. In fact, when we used human macrophages as effector cells against human GBM cells, we observed a significant but not dramatic difference between aCD47-Gl and aCD47-G4 as shown for murine macrophages against human GBM cells.
[0220] As provided herein, the full-length antibodies including both heavy and light chains are produced by a strong viral promoter, which can increase the locoregional delivery of antibodies in the TME but eliminate toxicities that could result from high dose systemic administration that would be required to achieve therapeutic levels in the CNS, however unlikely. Our therapeutic oHSV will not only activate the innate immune system but also continuously produce the mAh locally as long as the OV persists within the TME. In the ideal situation, once tumor cells are completely lysed by the OV, replicating virus dissipates and antibody production will cease thereby limiting the potential for long-term local tissue toxicity. Although our current approach is designed to produce a full-length antibody to directly target immune cells with IgGl and IgG4 options, our platform can be used to deliver other forms of mAbs such as single chain mAbs (scFv) or any mAh with diverse functions such as T cell checkpoint blockade including anti- PD1, anti-PD-Ll, anti-CTL4 or mAbs that directly target tumor cells, e.g., the anti-EGFR mAh (see, for example, Refs. 41-42).
[0221] Herein, data has shown development of a novel, effective oHSV platform to loco- regionally deliver antibodies to treat GBM, combining immune checkpoint inhibition (in macrophages in our case) and Fc-dependent innate immune cell functions. This platform can be extended to express other transgenes to target immune cells and/or tumor cells in TME and as a result to enhance the overall efficacy of oncolytic virotherapy.
[0222] Also provided is a combination of monoclonal antibody (mAh) and oncolytic virus together to improve the efficacy of ovarian cancer therapy. The results showed that OV-aCD47- G1 could not only directly lysis tumor cell, but also activate NK cell ADCC and macrophages
ADCP function in vitro. Furthermore, OV-aCD47-Gl also blockaded the “don’t eat me” signal normally mediated by the interaction between SIRP-a and CD47 expressed by macrophages and ovarian tumor cells, respectively. Therefore, OV-aCD47-Gl treatment significantly improved the virotherapy efficacy against ovarian tumor in vivo.
[0223] Provided was OV-aCD47-Gl and OV-aCD47-G4, which are designed to secret aCD47-Gl and aCD47-G4 respectively to the ovarian cancer tumor microenvironment after intratumoral administration. CD47 is highly expressed on numerous types of tumors including ovarian cancer cell. By binding to its receptor SIRPa on the surfaces of macrophages, CD47 that expressed on ovarian cancer cell can bring a “don’t eat me” signal to macrophages and protect the tumor cells from been phagocytized (see, for example, Ref. 51). Anti-CD47 antibodies have been used for blocking CD47-SIRPa axis to enhance the phagocytosis of ovarian cancer cells and have been proved effective by many clinical and preclinical trials (see, for example, Refs.
51, 59, 61, 62).
[0224] We found that compared with aCD47-G4, aCD47-Gl induced much stronger phagocytosis of A2780 cells by both human and mouse macrophages, besides that, aCD47-Gl but not aCD47-G4 dramatically induced the cytotoxicity of A2780 cells by human NK cells. While aCD47-Gl and aCD47-G4 they shared identical CDRs, they should have a near-identical ability to interrupt the “don’t eat me” CD47-SIRPa interaction. Indeed, while both of aCD47-Gl and aCD47-G4 can block the CD47-SIRPa interaction, the aCD47-Gl antibody can induce Fc- dependent ADCP mediated by macrophages and ADCC mediated by NK cells, while the aCD47-G4 antibody can only interrupt the “don’t-eat-me” signal. Consistent with these, the in vivo results compared to OV-aCD47-G4 treatment, OV-aCD47-Gl showed a stronger anti tumor therapy effect.
[0225] In summary, provided herein is an effective oHSV platform coding full-length mAbs with IgGl scaffold to treat ovarian tumor, which combines direct tumor lysis, innate immune infiltration and activation, immune checkpoint inhibition of macrophages, and Fc-dependent innate immune cell cytotoxic functions.
[0226] Example 3: Methods and materials
[0227] Cells
[0228] Human GBM cell lines (Gli36AEGFR, U251T2 and LN229) and mouse GBM cells (CT2A-hCD47) were cultured with DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 pg/ml). CT2A-hCD47 cells were generated by transfecting CT2A cells to express the human CD47 gene. GBM43 spheroid cells derived from a GBM patient and modified to express an FFL gene were named GBM43-FFL and used for in vivo imaging. GBM43 and GBM43-FFL cells were maintained as tumor spheres with basic neurobasal medium supplemented with 2% B27 (Gibco), human epidermal growth factor (EGF, 20 ng/ml) and fibroblast growth factor (FGF, 20 ng/ml) in low-attachment cell culture flasks. BT422 cells derived from a GBM patient were cultured with NS-A basal medium (StemCell) with EGF (20 ng/ml) and FGF (20 ng/ml) in low-attachment cell culture flasks. Human ovarian cancer cell line A2780, Chinese hamster ovary cell line CHO, sand monkey kidney epithelium-derived Vero cells were cultured with DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 pg/ml). Monkey kidney epithelium-derived Vero cells used for viral propagation and plaque-assay -based viral titration were maintained with the same media as the GBM cell lines. Gli36AEGFR and U251T2 cells were authenticated by the University of Arizona Genetics Core via STR profiling in January 2015, and LN229 in March 2018. GBM43 were authenticated by the Cell Line Characterization Core at MD Anderson Cancer Center in February 2019. Vero cells were not authenticated after receipt. GBM43 was developed at Mayo Clinic and other cell lines were originally developed by our group or obtained from ATCC. All cell lines were routinely tested for absence of mycoplasma using the MycoAlert Plus Mycoplasma Detection Kit from Lonza (Walkersville, MD).
[0229] Generation and purification of aCD47-Gl and aCD47-G4
[0230] CHO cells were used to produce aCD47-Gl and aCD47-G4 for functionality tests. The light chain and heavy chain coding genes of aCD47-G4 were reconstructed as previously reported (see Ref. 20). aCD47-Gl used the same light chain coding gene as aCD47-G4, but a modified aCD47-G4 heavy chain coding gene that replaced the human IgG4 constant region with the human IgGl constant region as the heavy chain coding gene. Lentiviral vectors were
used to transduce CHO cells to express aCD47-Gl or aCD47-G4. The light chain and heavy chain coding genes were carried by different lentiviral vectors with GFP and mCherry selection markers, respectively, for sorting the double positive CHO cells by using a FACS Aria II cell sorter (BD Biosciences, San Jose, CA, USA). The conditional supernatants of the lentivirus- infected CHO cells were used to purify aCD47-Gl and aCD47-G4 by using a protein G column (Thermo Fisher, 89927). For the in vivo test, the purified aCD47-Gl was desalted by fast protein liquid chromatography (FPLC).
[0231] CD47 binding and blocking assays
[0232] U251T2 cells pre-blocked with 2% BSA were incubated with 0, 5, 10, 25, 50,100, 250,
500, 1000, 2500, 5000 and 10000 ng/ml purified aCD47-Gl or aCD47-G4 antibodies for 30 min. Then the cells were washed twice and stained with APC-conjugated anti -human Fc (Jackson ImmunoResearch, 209-605-098) for 20 min. After that the cells were washed twice and stained with BV786-conjunaged anti-CD47 antibody (clone, B6H12, BD, 563758) for 20 min. The cells were analyzed by using Fortessa X20 flow cytometer (BD Biosciences). Median of mean fluorescence intensity (MFI) of APC and BV786 was used to determine CD47 binding and blocking capacity of aCD47-Gl and aCD47-G4.
[0233] Measurement of antibody concentration
[0234] For gliablastoma studies: U251T2 cells were infected with OV-Q1, OV-aCD47-Gl or OV-aCD47-G4 at a MOI of 2. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 6, 12, 24, 48 and 72 hpi to measure antibody concentration by ELISA. A series amount of aCD47-Gl and aCD47-G4 antibodies purified from CHO cells with known concentrations served as standards. The ELISA was performed as previously reported with slight modification (see Ref. 43). Briefly recombinant human CD47 protein (abeam, abl 74029) was used as coating reagent. Anti-human Fc antibody (sigma, MAB1307) was used as detecting antibody.
[0235] For ovarian cancer studies: A2780 cells were saturated infected with OV-Q1, OV- aCD47-Gl or OV-aCD47-G4 at a MOI of 2. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 6, 12, 24, 48 and 72 hpi to measure antibody concentration by ELISA. A series amount of aCD47-Gl
and aCD47-G4 antibodies purified from CHO cells with known concentrations served as standards. The ELISA was performed as previously reported with slight modification (see Ref. 69). Briefly recombinant human CD47 protein (abeam, abl74029) was used as coating reagent. Anti-human Fc antibody (sigma, MAB1307) was used as detecting antibody.
[0236] Generation of OV-aCD47-Gl and OV-aCD47-G4
[0237] OV-aCD47-Gl and OV-aCD47-G4 were generated by using the fHsvQuik-1 system as previously described (see, for example, Refs. 4, 21). For driving expression of the light chain and heavy chain simultaneously with a strong viral promoter, the light chain and heavy chain coding genes were linked with a DNA sequence encoding a T2A self-cleaving peptide. The linked aCD47-Gl and aCD47-G4 light chain and heavy sequences were inserted into pT-oriSIE4/5 following the HSV pIE4/5 promoter to construct pT-oriSIE4/5-aCD47-Gl or pT-oriSIE4/5- aCD47-G4. pT-oriSIE4/5-aCD47-Gl, pT-oriSIE4/5-aCD47-G4 or pT-oriSIE4/5 was recombined with fHsvQuik-1 for engineering OV-aCD47-Gl, OV-aCD47-G4 and OV-Q1, respectively. Vero cells were used for propagating and titrating the viruses. Virus titration was performed using plaque assays. Briefly, monolayer Vero cells were seeded in a 96-well plate. After 12h, these cells were infected with gradient-diluted viral solutions. The infection media were replaced with DMEM supplemented with 10% FBS, after two-hour infection. GFP-positive plaques were observed and counted with a Zeiss fluorescence microscope (AXIO observer 7) 2 days after infection to calculate the viral titer. To concentrate and purify the viral particles of OV-Q1, OV-aCD47-Gl and OV-aCD47-G4, the culture media containing viruses were harvested and centrifugated at 3,000 g for 30 min. Then the supernatants were collected and ultra-centrifugated at 100,000 g for 1 hour. The pellets of virus were resuspended with saline as needed.
[0238] Oncolysis and viral production assay
[0239] For gliablastoma studies: The in vitro oncolysis assay was performed as previously reported with slight modification (see Ref. 44). Briefly, U251T2 and Gli36AEGFR cells were seeded onto 96-well plates at densities of 5,000 cells/well and allowed to attach for 24 h. Cells were then treated with graded concentrations of OV-Q1, OV-aCD47-Gl or OV-aCD47-G4.
After 3 days, cell lysis was measured by using the cell counting kit-8 (CCK-8, Abeam, ab228554) following the manufactory’s protocol. CCK8 tetrazolium salt is reduced by cellular
dehydrogenases to an orange formazan product that is soluble in tissue culture medium. The amount of formazan produced is directly proportional to the number of living cells and is measured by absorbance at 460 nm. Cell lysis and viral dose curves were established to evaluate the in vitro oncolytic efficacy of OV-aCD47-Gl and OV-aCD47-G4.
[0240] The viral replication assay was performed as previously reported (see Ref. 4). Briefly, monolayers of U251T2 and Gli36AEGFR cells were seeded on 96-well plates and infected with OV-Q1, OV-aCD47-Gl or OV-aCD47-G4 at a MOI of 2. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 24, 48 and 72 hpi and viral titers were determined by plaque assays.
[0241] For ovarian cancer studies: The in vitro oncolysis assay was analyzed by Real-Time Cell Analysis. Briefly, A2780 cells were seeded onto 96-well plates at densities of 5,000 cells/well and allowed to attach for 24 h. Cells were then treated with graded concentrations of OV-Q1, OV-aCD47-Gl or OV-aCD47-G4. After 3 days, cell lysis was measured by Real-Time Cell Analysis machine following the manufactory’s protocol.
[0242] Macrophage generation
[0243] For isolating and culturing mouse BMDM, BALB/c mice were sacrificed at the time of bone marrow harvest. Bone marrow cells were extracted from the tibias and femurs by flushing with culture medium using a 25 G needle. The cells were then passed through a 70 pm nylon mesh (BD Bioscience) and washed three times with PBS. Extracted BM cells were implanted with 2.4 x 107/100 mm culture dish (BD Falcon) and cultured for 7 days in the presence of murine M-CSF (PeproTech, 315-02) medium (replacing culture medium on day 3 and day 5).
[0244] For isolating and culturing human primary macrophages, peripheral blood was collected from health donors. Human monocytes were isolated and enriched by using the RosetteSep™ Human Monocyte Enrichment Cocktail kit (Stemcell, Cat# 15068) from the peripheral blood. The enriched human monocytes were cultured with RPMI-1640 medium containing 20 ng/ml human M-CSF (PeproTech, Cat#300-25-50UG) and 2 % human serum for 7 days to induce the macrophage differentiation (replacing culture medium on day 3 and day 5).
[0245] Flow cvtometrv-based phagocytosis assay
[0246] For gliablastoma studies: For the phagocytosis assay of mouse BMDM, GBM43 and BT422 cells stained with CFSE (Thermo fisher, C34554) were used as target cells. BMDM and target cells were cocultured at a ratio of 1:2 for 2 hours in the presence of vehicle control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml, in a humidified, 5% C02 incubator at 37 °C in ultra-low-attachment 96-well U-bottom plates (Coming) in serum-free 1640 (Life Technologies). Then the cells were harvested by centrifuging at 400 g for 5 min at 4 °C and stained with anti mouse CDllb (BD, 552850) to identify macrophages. For blocking Fc receptors, BMDM were pre-incubated with 10 pg/ml isotype human IgGl (Biolegend, 403505) for 30 min. All flow cytometry data were collected using an Fortessa X20 flow cytometer (BD Biosciences). Phagocytosis was measured as the number of CD1 lb+CFSE+ macrophages, quantified as a percentage of the total CDllb+ macrophages.
[0247] For the phagocytosis assay of human primary macrophage, GBM43 cells stained with CFSE (Thermo fisher, C34554) were used as target cells. Human macrophages and target cells were cocultured at a ratio of 1 :2 for 4 hours in the presence of vehicle control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml, in a humidified, 5% C02 incubator at 37 °C in ultra-low- attachment 96-well U-bottom plates (Coming) in serum-free 1640 (Life Technologies). Then the cells were harvested by centrifuging at 400 g for 5 min at 4 °C and stained with anti-human CD1 lb (BD, 552850) to identify macrophages. All flow cytometry data were collected using an Fortessa X20 flow cytometer (BD Biosciences). Phagocytosis was measured as the number of CD1 lb+CFSE+ macrophages, quantified as a percentage of the total CD1 lb+ macrophages.
[0248] For ovarian cancer studies: For the phagocytosis assay of human primary macrophage, A2780 cells stained with CFSE (Thermo fisher, C34554) were used as target cells human macrophages and target cells were cocultured at a ratio of 1:2 for 4 hours in the presence of vehicle control, aCD47-Gl or aCD47-G4 at the dose of 5 pg/ml, in a humidified, 5% C02 incubator at 37 °C in ultra-low-attachment 96-well U-bottom plates (Coming) in serum-free 1640 (Life Technologies). Then the cells were harvested by centrifuging at 400 g for 5 min at 4 °C and stained with anti-human CD45 (BD, 552850) to identify macrophages. All flow cytometry data were collected using an Fortessa X20 flow cytometer (BD Biosciences).
Phagocytosis was measured as the number of CD1 lb+CFSE+ macrophages, quantified as a percentage of the total CD45+ macrophages.
[0249] NK cell cytotoxicity and activation assay
[0250] For gliablastoma studies: GBM43, BT422, U251T2, GBM30, LN229 and Gli36AEGFR cells were used as target cells. Primary human NK cells isolated from leukopaks of health donors using an NK cell isolation kit (MACSxpress Miltenyi Biotec, San Diego, CA) and an erythrocyte depletion kit (Miltenyi Biotec) were used as effector cells. The target cells were labeled with 51Cr for 1 h. GBM43, BT422, U251T2, GBM30 and LN229 cells were cocultured with 1 pg/ml aCD47-Gl or aCD47-G4 antibodies or vehicle for 30 min. Gli36AEGFR cells were cocultured with gradient doses of aCD47-Gl or aCD47-G4 antibodies or vehicle for 30 min. Then the target cells were cocultured with isolated human primary NK cells at different effectortarget ratios at 37 °C for 4 h. Release of 51Crwas measured with a MicroBeta2 microplate radiometric counters (Perkin Elmer, Waltham, MA). Target cells incubated in complete media were for spontaneous and in 1% SDS media were used for maximal 51Cr release control. The cell lysis percentages were calculated using the standard formula: 100 c (cpm experimental release - cpm spontaneous release) / (cpm maximal release - cpm spontaneous release). The assays were performed in at least three technical replicates with NK cells from different donors. The expression of CD69, an NK cell activation marker, was measured after 4 hours coculture of NK cells and GBM43, GBM30 or U251T2 cells at a ratio of 1:1 with flow cytometer by using the anti-CD56 (BD, 557919) and anti-CD69 (BD, 562883) antibodies.
[0251] For ovarian cancer studies: A2780 cells were used as target cells. Primary human NK cells isolated from leukopaks of health donors using an NK cell isolation kit (MACSxpress Miltenyi Biotec, San Diego, CA) and an erythrocyte depletion kit (Miltenyi Biotec) were used as effector cells. The target cells were labeled with 51Cr for 1 h. A2780 cells were cocultured with 1 pg/ml aCD47-Gl or aCD47-G4 antibodies or vehicle for 30 min. Then the target cells were cocultured with isolated human primary NK cells at different effector: target ratios at 37 °C for 4 h. Release of 51Cr was measured with a MicroBeta2 microplate radiometric counters (Perkin Elmer, Waltham, MA). Target cells incubated in complete media were for spontaneous and in 1% SDS media were used for maximal 51Cr release control. The cell lysis percentages were calculated using the standard formula: 100 c (cpm experimental release - cpm spontaneous
release)/(cpm maximal release - cpm spontaneous release). The assays were performed in at least three technical replicates with NK cells from different donors. The expression of CD69 and granzyme B, NK cell activation markers, were measured after 12 hours coculture of NK cells and A2780 cells at the ratio of 1: 1 with flow cytometer by using the anti-CD56 antibody (BD, 557919) , anti-granzyme B antibody and anti-CD69 (BD, 562883) antibody.
[0252] Immunoblot and quantitative PCR
[0253] For gliablastoma studies: Immunoblotting was performed following a protocol as previously described4. U251T2 cells were infected with OV-Q1, OV-aCD47-Gl or OV-aCD47- G4 at a MOI of 2. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 24 hpi. The supernatants harvested at 24 hours after medium change from CHO cells that were used for producing standard aCD47-Gl and aCD47-G4 were included as control. The protein components in 10 ml supernatants were extracted by a chloroform-methanol method. Anti-human IgG heavy chain (sigma, MAB1307), anti-human kappa chain (Thermo fisher, MA5-12117) and the corresponding secondary antibodies (LI-COR, 925-32210) were used to detect the heavy chain and light chain.
[0254] To evaluate the effect of aCD47-Gl and aCD47-G4 on activating transcription of typical mouse macrophage cytokine genes, mouse BMDM and GBM43 were cocultured at a ratio of 1:1 for 6 hours with or without the presence of 5 pg/ml aCD47-Gl or aCD47-G4. Then the total RNA was extracted for measuring the relative transcription of murine Argl, Ccl2, Ccl4, Illb, 116, 1110, 1112b and Nos2 genes with the corresponding primers. 18s rRNA was used as internal control. To evaluate the effect of aCD47-Gl and aCD47-G4 on activating transcription of typical human macrophage cytokine genes, human macrophages and GBM43 were cocultured at a ratio of 1: 1 for 6 hours with or without the presence of 5 pg/ml aCD47-Gl or aCD47-G4. Then the total RNA was extracted for measuring the relative transcription of human IL1B, IL6, IL10, IL12A and NOS2 genes with the corresponding primers. 18s rRNA was used as internal control.
[0255] For ovarian cancer studies studies: To evaluate the effect of aCD47-Gl and aCD47-G4 on activating transcription of typical mouse macrophage cytokine genes. Human macrophages and A2780 cells were cocultured at the ratio of 1 : 1 for 6 hours with or without the presence of 5
pg/ml aCD47-Gl or aCD47-G4. Then human macrophages were sorted by staining with anti- CD45 antibody. The total RNA was extracted for measuring the relative transcription of human IL1B, IL6, IL10, IL12A and NOS2 genes with the corresponding primers. 18s rRNA was used as internal control.
Table 2. Primers used in this study _
Name _ Sapience _
mI16 F CTGCAAGAGACTTCCATCCAG 14 mI16 R AGTGGTATAGACAGGTCTGTTGG 15 mArgl F CTCCAAGCCAAAGTCCTTAGAG 16 mArgl R GGAGCTGTCATTAGGGACATCA 17 mCcl2 F ATCCACGGCATACTATCAACATC 18 mCcl2 R TCGTAGTCATACGGTGTGGTG 19 mCcl4 F CCAGCTCTGTGCAAACCTAACC 20 mCcl4 R GCCACGAGCAAGAGGAGAGA 21 mNos2 f TGACGGCAAACATGACTTCAG 22 mNos2 R GGTGCCATCGGGCATCT 23 mill O F CAGTACAGCCGGGAA GACAATAA 24 mill O R CCGCAGCTCTAGGAGCATGT 25 mil 12b F CCTGAAGTGTGAAGCACCAAATT 26 mill 2b R CTT C AAGTC C AT GTTT CTTT GCA 27 mil lb F GAAATGCCACCTTTTGACAGTG 28 mlllb R TGGATGCTCTCATCAGGACAG 29 hILIB F TTCGACACATGGGATAACGAGG 30 hILlB R TTTTTGCTGTGAGTCCCGGAG 31 hIL6 F CCTGAACCTTCCAAAGATGGC 32 hIL6 R TTCACCAGGCAAGTCTCCTCA 33 hIL12A F ATGGCCCTGTGCCTTAGTAGT 34 hIL12A R AGCTTTGCATTCATGGTCTTGA 35 hNOS2 F AGGGACAAGCCTACCCCTC 36 hNOS2 R CTCATCTCCCGTCAGTTGGT 37 hILlO F GACTTT AAGGGTT AC CT GGGTT G 38 hILlO R TCACATGCGCCTTGATGTCTG 39
18s rRNA F GTAACCCGTTGAACCCCATT 40
18s rRNA R CCATCCAATCGGTAGTAGCG 41
[0256] Animal Study
[0257] For gliablastoma studies: Six- to eight-week-old female athymic nude mice were purchased from Jackson Laboratories (Bar Harbor, Maine). For the survival studies, the mice were anesthetized and stereotactically injected with 1 c 105 GBM43-FFL cells, which express a firefly luciferase (FFL) gene, into the right frontal lobe of the brain (2 mm lateral and 1 mm anterior to bregma at a depth of 3 mm). The cells grew for 7 d, and animals were subsequently randomly divided into groups that were i.c. injected either with 2 c 105 PFU oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-G4) in 3 pi of saline or with saline as control. Mice were subsequently monitored and weighed frequently for GBM disease progression. Luciferase-based in vivo images were taken from 15 days after tumor implantation to evaluate the tumor development. The mice were euthanized when they became moribund, with neurologic impairments and obvious weight loss.
[0258] For the in vivo anti-CD47 antibody distribution study, nude mice were stereotactically injected with 1 c 105 GBM43 into the same site of the brain mentioned above. The GBM cells were allowed to grow for 21 days, and the mice were randomly divided to four groups: Group 1, saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus i.p. delivery of aCD47-Gl and Group 4, OV-aCD47-Gl. Group 1 received saline as control. Groups 2, 3, and 4 with OV treatment were i.c. injected with 2 c 105 PFU oHSV (OV-Q1 or OV-aCD47-Gl) on day 21. Group 3 received i.p. injection of purified aCD47-Gl once at the dose of 150 pg per mouse on day 22, while other groups received i.p. saline as control. Mice were euthanized on day 23 for harvesting blood and brain. To determine the continuous release of anti-CD47 antibody from OV-aCD47-Gl infection, the above experiment was modified with the following changes: Group 3 received i.p. injection of purified aCD47-Gl twice at the dose of 150 pg per mouse on day 22 and 24, while other groups received i.p. saline as control. Mice were euthanized on day 25 for harvesting blood and brain. aCD47-Gl levels in plasma of the experimental mice were measured by ELISA. Brains isolated from the experimental mice were used for histologic study.
[0259] For establishing the immunocompetent mouse GBM model, six- to eight-week-old female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). The mice were anesthetized and stereotactically injected with 1 c 105 CT2A-hCD47 cells, which express a human CD47 gene, into the right frontal lobe of the brain (2 mm lateral and 1 mm
anterior to bregma at a depth of 3 mm). The cells grew for 3 d, and animals were subsequently randomly divided into groups that were i.c. injected either with 2 c 105 PFU oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-G4) in 3 pi of saline or with saline as control. Mice were subsequently monitored and weighed frequently for GBM disease progression. Luciferase-based in vivo images were taken from 15 days after tumor implantation to evaluate the tumor development. The mice were euthanized when they became moribund, with neurologic impairments and obvious weight loss.
[0260] To continuously deliver aCD47-Gl into the tumor site of the CT2A GBM mouse model, osmotic pumps (Alzet, Cat#1003D) were filled with 100 pi of desalted and concentrated aCD47-Gl at the concentration of 1.0 pg/mΐ. The pumps were connected with the brain infusion kit (Alzet, Cat#0008851) and implanted into the mice for continuous delivery aCD47-Gl to the tumor site.
[0261] For ovarian cancer studies: Six- to eight-week-old female athymic nude mice were purchased from Jackson Laboratories (Bar Harbor, Maine). For the survival studies, the mice were anesthetized and s.c. injected with 5 c 106 A2780 cells over the flank. 1 day after A2780 cells injection, animals were subsequently randomly divided into groups that were injected intratumorally either with 1 c 105 pfu oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-G4) in 10 mΐ of saline or with saline as control. Mice were subsequently monitored for ovarian cancer progression. The mice were euthanized when the tumor diameter was over 30 mm.
[0262] For the in vivo anti-CD47 antibody distribution study, NSG were implanted with patient derived tumor fragments. The mice were randomly divided to 3 groups: Group 1: OV- Ql; Group 2: OV-aCD47-Gl; and Group 3: OV-aCD47-G4. All groups with OV treatment were intratumorally injected with 2 c 105 PFU oHSV on day 5. Mice were euthanized on day 7 for harvesting the tumor fragments. Tumor fragments isolated from the experimental mice were used for histologic study.
[0263] For establishing the immunocompetent mouse ovarian tumor model, six- to eight-week- old female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). The mice were anesthetized and i.p injected with 1 c 106 ID8-hCD47 cells, which express a human CD47 gene, The cells grew for 3 d, and animals were subsequently randomly divided into groups that were i.p injected either with 2 c 105 PFU oHSV (OV-Q1, OV-aCD47-Gl or OV-aCD47-
G4) in 10 mΐ of saline or with saline as control. Mice were subsequently monitored and weighed frequently for ovarian cancer disease progression. Luciferase-based in vivo images were taken from 15 days after tumor implantation to evaluate the tumor development. The mice were euthanized when they became moribund and obvious weight increased.
[0264] Immunohistochemistrv assay
[0265] For gliablastoma studies: Brains isolated from the experimental mice were placed in 10% neutral buffered formalin for a minimum of 72 h. After paraffin embedding, 4-pm-thick sections were cut from the blocks. H&E staining and immunohistochemical staining with anti- HSV (Cell marque, 361A-15-ASR), anti-human Fc (Jackson ImmunoResearch, 109-005-098), anti-CDllb (abeam, abl33357) antibodies were performed by the Pathology Core of Shared Resources at City of Hope Beckman Research Institute and National Medical Center. Stained slides were mounted and scanned for observation.
[0266] For ovarian cancer studies, tumor fragments isolated from the experimental mice were placed in 10% neutral buffered formalin for a minimum of 72 h. After paraffin embedding, 4- pm-thick sections were cut from the blocks. H&E staining and immunohistochemical staining with anti-HSV (Cell marque, 361A-15-ASR) and anti-human Fc (Jackson ImmunoResearch, 109-005-098) antibodies were performed by the Pathology Core of Shared Resources at City of Hope Beckman Research Institute and National Medical Center. Stained slides were mounted and scanned for observation.
[0267] Statistical analysis
[0268] Descriptive statistics (means, standard deviations, median, counts, etc.) were used to summarize data. Continuous endpoints that are normally distributed with or without prior log transformation were compared between two or more independent conditions by Student’s t test or one-way ANOVA, respectively. For data with repeated measures from the same subject/donor, a linear mixed model was used to compare matched groups by accounting for the underlying variance and covariance structure. For survival data, survival functions were estimated by the Kaplan-Meier method and compared by log rank test. All tests were two-sided. P values were adjusted for multiple comparisons by Holm’s procedure or the Bonferroni method
and a P value of 0.05 or less was defined as statistically significant. Statistical software GraphPad, R.3.6.3. and SAS 9.4 were used for the statistical analysis.
OTHER EMBODIMENTS
[0269] It is to be understood that while the disclosure has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
[0270] Embodiments disclosed herein include embodiments PI to P25 following.
[0271] Embodiment PI. A recombinant oncolytic herpes simplex virus (HSV) comprising: an expression cassette encoding a CD47 antibody.
[0272] Embodiment P2. The recombinant oncolytic virus of Embodiment PI, wherein the CD47 antibody comprises an IgG scaffold.
[0273] Embodiment P3. The recombinant oncolytic virus of Embodiment P2, wherein the IgG scaffold is selected from IgGl, IgG2, IgG3, and IgG4 scaffold.
[0274] Embodiment P4. The recombinant oncolytic virus of Embodiment P3 wherein the IgG scaffold is an IgGl scaffold.
[0275] Embodiment P5. The recombinant oncolytic virus of Embodiment P3, wherein the IgG scaffold is an IgG4 scaffold.
[0276] Embodiment P6. The recombinant oncolytic virus of any one of Embodiment P1-P5, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding ay34.5 gene.
[0277] Embodiment P7. The recombinant oncolytic virus of any one of Embodiment P1-P6, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional ICP6 gene.
[0278] Embodiment P8. The recombinant oncolytic virus of any of the preceding Embodiments, wherein the nucleic acid encoding the CD47 antibody is under the control of a viral or tumor specific promoter.
[0279] Embodiment P9. The recombinant virus of any of the preceding Embodiments, wherein the viral promoter is a herpes simplex virus (HSV) immediate early (IE) promoter.
[0280] Embodiment P10. The recombinant oncolytic virus of Embodiment P9, wherein the HSV IE promoter is the IE 4/5 promoter.
[0281] Embodiment PI 1. The recombinant oncolytic virus of any of the preceding Embodiments, wherein the recombinant oncolytic virus comprises a nucleic acid encoding a marker within an ICP6 gene.
[0282] Embodiment PI 2. A pharmaceutical composition comprising: the recombinant oncolytic virus of any of the preceding Embodiments, and a pharmaceutically acceptable carrier.
[0283] Embodiment PI 3. A method for killing tumor cells in a subject comprising: administering to a subject an effective amount of the recombinant oncolytic virus of any of Embodiments P 1 -P 11.
[0284] Embodiment P14. A method of treating a patient having cancer comprising administering to the patient an effective amount of the pharmaceutical composition of Embodiment P12 or the recombinant oncolytic virus of any of Embodiments Pl-Pll.
[0285] Embodiment P15. The method of Embodiment P14, wherein the cancer is a chronic cancer.
[0286] Embodiment PI 6. The method of any one of Embodiments P14-P15, wherein the cancer is an inflammatory chronic cancer.
[0287] Embodiment P17. The method of Embodiment P14, wherein the cancer is a CD47 expressing cancer.
[0288] Embodiment PI 8. The method of Embodiment P17, wherein the CD47 expressing cancer is selected from glioblastoma, ovarian cancer, pancreatic cancer, leukemia, and lymphoma.
[0289] Embodiment P19. The method of any of Embodiments P14-P18, wherein administering is by intratumoral, systemic, or intracavitary administration.
[0290] Embodiment P20. A method for immune modulation in a subject, comprising administering an effective amount of the recombinant oncolytic virus of any of Embodiments Pl-Pll.
[0291] Embodiment P21. The method of Embodiment P20, wherein immune modulation comprises activating natural killer (NK) cells.
[0292] Embodiment P22. The method of Embodiment P21, wherein activation ofNK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity.
[0293] Embodiment P23. The method of Embodiment P21, wherein activation ofNK cells is measured as expression of CD69 on NK cells.
[0294] Embodiment P24. The method of any of Embodiments P21-P22, wherein activation is measured as increased NK cell cytotoxicity.
[0295] Embodiment P25. The method of any of Embodiments P21-P24, wherein administering is by intratumoral, systemic, or intracavitary administration.
[0296] Embodiments disclosed herein include Embodiments 1 to 38 following.
[0297] Embodiment 1. A recombinant oncolytic herpes simplex virus (HSV) comprising a nucleic acid encoding an anti-CD47 antibody.
[0298] Embodiment 2. The recombinant oncolytic virus of Embodiment 1 wherein the anti- CD47 antibody is an IgGl isotype.
[0299] Embodiment 3. The recombinant oncolytic virus of Embodiment 1 or 2, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional g34.5 gene.
[0300] Embodiment 4. The recombinant oncolytic virus of any one of Embodiments 1 to 3, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional ICP6 gene.
[0301] Embodiment 5. The recombinant oncolytic virus of any one of Embodiments 1 to 4, wherein the nucleic acid encoding the anti-CD47 antibody is under the control of a viral or tumor specific promoter.
[0302] Embodiment 6. The recombinant virus of Embodiment 5, wherein the viral promoter is a herpes simplex virus (HSV) immediate early (IE) promoter.
[0303] Embodiment 7. The recombinant oncolytic virus of Embodiment 6, wherein the HSV IE promoter is the IE 4/5 promoter.
[0304] Embodiment 8. The recombinant oncolytic virus of any one of Embodiments 1 to 7, wherein the recombinant oncolytic virus comprises a nucleic acid encoding a marker within an ICP6 gene.
[0305] Embodiment 9. A pharmaceutical composition comprising: the recombinant oncolytic virus of any one of Embodiments 1 to 8, and a pharmaceutically acceptable carrier.
[0306] Embodiment 10. A pharmaceutical composition comprising: the recombinant oncolytic virus of any one of Embodiments 1 to 9, an anti-cancer agent, and a pharmaceutically acceptable carrier.
[0307] Embodiment 11. The pharmaceutical composition of Embodiment 10, wherein the anti cancer agent is a checkpoint inhibitor.
[0308] Embodiment 12. The pharmaceutical composition of Embodiment 10, wherein the anti cancer agent is a PARP inhibitor.
[0309] Embodiment 13. The pharmaceutical composition of Embodiment 12, wherein the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3-aminobenzamide.
[0310] Embodiment 14. A method for killing tumor cells in a subject comprising: administering to a subject an effective amount of the recombinant oncolytic virus of any one of Embodiments 1 to 8.
[0311] Embodiment 15. A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the pharmaceutical composition of Embodiment 10 to 13 or the recombinant oncolytic virus of any one of Embodiments 1 to 8.
[0312] Embodiment 16. The method of Embodiment 15, wherein the cancer is a chronic cancer.
[0313] Embodiment 17. The method of Embodiment 16, wherein the cancer is an inflammatory chronic cancer.
[0314] Embodiment 18. The method of Embodiment 15, wherein the cancer is a CD47 expressing cancer.
[0315] Embodiment 19. The method of Embodiment 18, wherein the CD47 expressing cancer is selected from glioblastoma, ovarian cancer, pancreatic cancer, leukemia, and lymphoma.
[0316] Embodiment 20. The method of any of Embodiments 15-19, wherein administering is by intratumoral, systemic, or intracavitary administration.
[0317] Embodiment 21. A method for immune modulation in a subject, comprising administering an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
[0318] Embodiment 22. The method of Embodiment 21, wherein immune modulation comprises activating natural killer (NK) cells.
[0319] Embodiment 23. The method of Embodiment 22, wherein activation of NK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity.
[0320] Embodiment 24. The method of Embodiment 22, wherein activation of NK cells is measured as expression of CD69 on NK cells.
[0321] Embodiment 25. The method of Embodiment 22 or 23, wherein activation is measured as increased NK cell cytotoxicity.
[0322] Embodiment 26. The method of any one of Embodiments 21 to 25, wherein administering is by intratumoral, systemic, or intracavitary administration.
[0323] Embodiment 27. A method of treating an overactive immune reaction in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
[0324] Embodiment 28. The method of Embodiment 27, wherein said overactive immune reaction is asthma, eczema, or allergic rhinitis.
[0325] Embodiment 29. A method of treating an autoimmune disease in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
[0326] Embodiment 30. The method of Embodiment 29, wherein said autoimmune disease is arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison’s disease, Vitiligo, asthma, or allergic asthma.
[0327] Embodiment 31. A method of treating an infectious disease in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9.
[0328] Embodiment 32. The method of Embodiment 31, wherein the infectious disease is human immunodeficiency virus (HIV), COVID-19, influenza, pneumonia, syphilis, anthrax, gonorrhea, HPV, mononucleosis, West Nile fever, Zika, malaria, or plague
[0329] Embodiment 33. A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9 in a first dosage form and an anti-cancer agent in a second dosage form.
[0330] Embodiment 34. The method of Embodiment 33, wherein the anti-cancer agent is a checkpoint inhibitor.
[0331] Embodiment 35. The method of Embodiment 33, wherein the anti-cancer agent is a PARP inhibitor.
[0332] Embodiment 36. The method of Embodiment 35, wherein the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3- aminobenzamide.
[0333] Embodiment 37. A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of any of Embodiments 1-8 or the pharmaceutical composition of Embodiment 9 and an anti cancer therapy.
[0334] Embodiment 38. The method of Embodiment 37, wherein the anti-cancer therapy is chemotherapy, radiation therapy, surgery, targeted therapy, immunotherapy, or cell therapy.
[0335] References
1 Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996, doi:10.1056/NEJMoa043330 (2005).
2 Andtbacka, R. H. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 33, 2780-2788, doi: 10.1200/JCO.2014.58.3377 (2015).
3 Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 22, 1048-1055, doi:10.1038/mt.2014.22 (2014).
4 Xu, B. et al. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature biotechnology, doi:10.1038/nbt.4302 (2018).
5 Chen, X. et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 7, 27764-27777, doi: 10.18632/oncotarget.8526 (2016).
6 Han, J. et al. TGFbeta Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res 75, 5273-5282, doi: 10.1158/0008-5472. CAN-15- 0894 (2015).
7 Bolyard, C. et al. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23, 1809-1819, doi: 10.1158/1078-0432. CCR-16-1818 (2017).
8 Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18, 1827-1834, doi : 10.1038/nm.3013 (2012).
9 Matlung, H. L., Szilagyi, K., Barclay, N. A. & van den Berg, T. K. The CD47-SIRP alpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev 276, 145-164, doi: 10.1111/imr.12527 (2017).
10 Bewersdorf, J. P., Shallis, R. M. & Zeidan, A. M. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Rev, 100709, doi: 10.1016/j. hire.2020.100709 (2020).
11 Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217, doi : 10.1016/j . ccr.2005.02.013 (2005).
Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392, doi:l 0.1126/science.1067100 (2002).
Wang, Y. et al. Polymeric nanoparticles promote macrophage reversal from M2 to Ml phenotypes in the tumor microenvironment. Biomaterials 112, 153-163, doi : 10.1016/j . biomaterials.2016.09.034 (2017).
Saha, D., Martuza, R. L. & Rabkin, S. D. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell 32, 253-267 e255, doi:10.1016/j.ccell.2017.07.006 (2017). Veillette, A. & Chen, J. SIRPalpha-CD47 Immune Checkpoint Blockade in Anticancer Therapy. Trends Immunol 39, 173-184, doi: 10.1016/j.it.2017.12.005 (2018).
Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109, 6662-6667, doi : 10.1073/pnas.1121623109 (2012).
Gholamin, S. et al. Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med 9, doi:10.1126/scitranslmed.aaf2968 (2017).
Hutter, G. et al. Microglia are effector cells of CD47-SIRPalpha antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci USA 116, 997-1006, doi : 10.1073/pnas.1721434116 (2019).
Sikic, B. I. et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol 37, 946-953, doi: 10.1200/JCO.18.02018 (2019).
Liu, J. et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti- Cancer Therapeutic Potential. PLoS One 10, e0137345, doi: 10.1371/j oumal. pone.0137345 (2015).
Terada, K., Wakimoto, H., Tyminski, E., Chiocca, E. A. & Saeki, Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13, 705-714, doi: 10.1038/sj.gt.3302717 (2006).
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. & Martuza, R. L. Attenuated multi- mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938- 943, doi: 10.1038/nm0995-938 (1995).
Sharma, P. et al. 2A peptides provide distinct solutions to driving stop-carry on translational recoding. Nucleic Acids Res 40, 3143-3151, doi:10.1093/nar/gkrll76 (2012).
Iwamoto, C. et al. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment. Exp Hematol 42, 163-171 el61, doi:10.1016/j.exphem.2013.11.005 (2014). Weischenfeldt, J. & Porse, B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protoc 2008, pdb prot5080, doi:10.1101/pdb.prot5080 (2008).
Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285, doi: 10.1016/j. cell.2009.05.046 (2009).
Okazawa, H. et al. Negative regulation of phagocytosis in macrophages by the CD47- SHPS-1 system. J Immunol 174, 2004-2011, doi: 10.4049/jimmunol.174.4.2004 (2005).
Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E. & Brezski, R. J. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs 7, 494-504, doi: 10.1080/19420862.2015.1022692 (2015). Martinez, F. O. Analysis of gene expression and gene silencing in human macrophages. Curr Protoc Immunol Chapter 14, Unit 1428 11-23, doi: 10.1002/0471142735.iml428s96 (2012). Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5, 520, doi:10.3389/fimmu.2014.00520 (2014). Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. Nat Rev Cancer 12, 278-287, doi:10.1038/nrc3236 (2012). Kitange, G. J. et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11, 281-291, doi: 10.1215/15228517- 2008-090 (2009). Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R. & Chiu, M. L. Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcgamma receptors. Immunol Lett 197, 1-8, doi:10.1016/j.imlet.2018.02.006 (2018). Keizer, R. J., Huitema, A. D., Schellens, J. H. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49, 493-507, doi : 10.2165/11531280-000000000-00000 (2010). Quail, D. F. & Joyce, J. A. The Microenvironmental Landscape of Brain Tumors. Cancer Cell 31, 326-341, doi:10.1016/j.ccell.2017.02.009 (2017). Brown, E. J. & Frazier, W. A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11, 130-135, doi:10.1016/s0962-8924(00)01906-l (2001). Rivera, A., Fu, X., Tao, L. & Zhang, X. Expression of mouse CD47 on human cancer cells profoundly increases tumor metastasis in murine models. BMC Cancer 15, 964, doi: 10.1186/s 12885-015-1980-8 (2015). Advani, R. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. NEnglJMed 379, 1711-1721, doi:10.1056/NEJMoal 807315 (2018). Yu, X. Y. et al. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. Biochimie 151, 54-66, doi:10.1016/j.biochi.2018.05.019 (2018). Kwong, L. S., Brown, M. H., Barclay, A. N. & Hatherley, D. Signal -regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity- implications for engraftment of human cells. Immunology 143, 61-67, doi: 10.1111/imm.12290 (2014). Kimura, H. et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98, 1275- 1280, doi: 10.1111/j .1349-7006.2007.00510.x (2007). Barok, M. et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6, 2065-2072, doi: 10.1158/1535-7163. MCT-06-0766 (2007). Chen, L. et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia 31, 1830-1834, doi:10.1038/leu.2017.147 (2017).
Passaro, C. et al. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res 25, 290-299, doi:10.1158/1078-0432.CCR-18-2311 (2019). C. Stewart, C. Ralyea, S. Lockwood, Ovarian Cancer: An Integrated Review. Semin Oncol Nurs 35, 151-156 (2019). M. A. Roett, P. Evans, Ovarian cancer: an overview. Am Fam Physician 80, 609-616 (2009). M. Kossai, A. Leary, J. Y. Scoazec, C. Genestie, Ovarian Cancer: A Heterogeneous Disease. Pathohiology 85, 41-49 (2018). T. Grunewald, J. A. Ledermann, Targeted Therapies for Ovarian Cancer. Best Pract Res Clin Ohstet Gynaecol 41, 139-152 (2017). M. E. W. Logtenberg, F. A. Scheeren, T. N. Schumacher, The CD47-SIRPalpha Immune Checkpoint. Immunity 52, 742-752 (2020). S. M. G. Hayat et al., CD47: role in the immune system and application to cancer therapy. Cell Oncol (Dordr) 43, 19-30 (2020). S. B. Willingham et al., The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109, 6662-6667 (2012). R. M. Brightwell et al., The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. Gynecol Oncol 143, 393-397 (2016). Y. Kojima et al., CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86-90 (2016). M. Feng et al., Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19, 568-586 (2019). R. Liu et al., CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget 8, 39021-39032 (2017). Y. Huang et al., A SIRPalpha-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol 14, 657-668 (2020). G. P. Adams, L. M. Weiner, Monoclonal antibody therapy of cancer. Nat Biotechnol 23, 1147-1157 (2005). C. Touzeau, P. Moreau, C. Dumontet, Monoclonal antibody therapy in multiple myeloma. Leukemia 31, 1039-1047 (2017). J. Liu et al., Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti- Cancer Therapeutic Potential. PLoS One 10, e0137345 (2015). G. J. Kitange et al., Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11, 281-291 (2009).
61. A. Veillette, J. Chen, SIRPalpha-CD47 Immune Checkpoint Blockade in Anticancer Therapy. Trends Immunol 39, 173-184 (2018).
62. B. I. Sikic et ak, First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol 37, 946-953 (2019).
63. E. Cruz, V. Kayser, Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologies 13, 33-51 (2019).
64. I. Melero, S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, L. Chen, Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7, 95-106 (2007).
65. S. Crescioli et ak, IgG4 Characteristics and Functions in Cancer Immunity. Curr Allergy Asthma Rep 16, 7 (2016).
66. J. D. Isaacs et ak, A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 106, 427-433 (1996).
67. K. Terada, H. Wakimoto, E. Tyminski, E. A. Chiocca, Y. Saeki, Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13, 705-714 (2006).
68. B. Xu et ak, An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature biotechnology, (2018).
69. L. Chen et ak, Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia 31, 1830-1834 (2017).
INFORMAL SEQUENCE LISTING [0336] HSV pIE4/5 promoter
TTCGCACTTCGTCCCAATATATATATATTATTAGGGCGAAGTGCGAGCACTGGCGCC GTGCCCGACTCCGCGCCGGCCCCGGGGGCGGGCCCGGGCGGCGGGGGGCGGGTCTC TCCGGCGCACATAAAGGCCCGGCGCGACCGA (SEQ ID NO:l)
[0337] Anti-CD47 light chain signal peptide
ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCTCAGGA GCCAGATGT (SEQ ID NO: 2)
[0338] Anti-CD47 light chain variable region
GATATAGTGATGACCCAGTCTCCTTTGAGCCTTCCGGTCACGCCCGGTGAACCTGCC
AGTATCTCATGTCGGTCCAGTCAATCCATAGTTTATTCTAATGGAAATACGTATCTTG
GTTGGTATCTCCAGAAGCCGGGTCAGTCCCCACAGCTGTTGATATATAAGGTCTCCA
ATAGATTCAGCGGCGTCCCGGATCGGTTCAGCGGCAGCGGCTCAGGAACAGACTTT ACTCTCAAAATTTCTCGCGTAGAAGCTGAAGATGTAGGCGTCTATTATTGTTTTCAA GGGAGTCACGTCCCCTATACATTCGGACAAGGAACAAAATTGGAGATAAAA (SEQ ID NO: 3)
[0339] Anti-CD47 light chain constant region
CGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAA
TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAA
GTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCAC
AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAACACCCTGACGCTGAGCA
AAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGCTAG (SEQ ID NO:4)
[0340] IgGl and IgG4 heavy chain signal peptide
ATGGAATTTGGGCTGCGCTGGGTTTTCCTTGTTGCTATTTTAAAAGATGTCCAGTGTG AC (SEQ ID NO:5)
[0341] Anti-CD47 heavy chain variable region
GTCCAACTCGTGCAGTCCGGCGCGGAGGTTAAGAAGCCTGGAGCGAGCGTCAAGGT
ATCATGCAAAGCCTCCGGGTACACATTCACCAACTATAACATGCACTGGGTTAGGCA
GGCACCTGGCCAACGGCTCGAATGGATGGGAACCATATATCCGGGCAACGATGATA
CTAGCTACAATCAAAAATTTAAGGACCGCGTTACCATTACCGCAGACACTTCAGCTT
CTACCGCATATATGGAGCTGAGCAGCCTCCGCTCCGAAGACACGGCCGTCTATTATT
GCGCTCGCGGCGGATACCGAGCCATGGATTACTGGGGACAAGGGACACTTGTGACT
(SEQ ID NO: 6)
[0342] IgGl heavy chain constant region CHi
GTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAG AGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCC CGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT CCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC ACCAAGGTGGACAAGAAAGTT (SEQ ID NO: 7)
[0343] IgGl heavy chain hinge
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCA (SEQ ID NO: 8)
[0344] IgGl heavy chain CEE region
CCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGT
GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTG
GTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTG
CAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCA
AA (SEQ ID NO: 9)
[0345] IgGl heavy chain CEE region
GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGAC
CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGC
CGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGC
AGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAA
CCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA (SEQ ID NO: 10)
[0346] IgG4 heavy chain CH2 region
GCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGAC
ACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAG
GAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGC
CAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCC
TCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCC
AACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAA (SEQ ID
NO: 11)
[0347] IgG4 heavy chain CEE region
GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGAC
CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGC AGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAA CCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA (SEQ ID NO: 12)
[0348] T2A
GAGGGCAGAGGCAGTCTGCTGACATGCGGTGACGTGGAAGAGAATCCCGGCCCT (SEQ ID NO: 13)
[0349] mI16, forward sequence:
CTGCAAGAGACTTCCATCCAG (SEQ ID NO: 14)
[0350] mI16, reverse sequence:
AGTGGTATAGACAGGTCTGTTGG (SEQ ID NO: 15)
[0351] mArgl, forward sequence:
CTCCAAGCCAAAGTCCTTAGAG (SEQ ID NO: 16)
[0352] mArgl, reverse sequence:
GGAGCTGTCATTAGGGACATCA (SEQ ID NO: 17)
[0353] mCcl2, forward sequence:
ATCCACGGCATACTATCAACATC (SEQ ID NO: 18)
[0354] mCcl2, reverse sequence:
TCGTAGTCATACGGTGTGGTG (SEQ ID NO: 19)
[0355] mCcl4, forward sequence:
CCAGCTCTGTGCAAACCTAACC (SEQ ID NO:20)
[0356] mCcl4, reverse sequence:
GCCACGAGCAAGAGGAGAGA (SEQ ID NO:21)
[0357] mNos2, forward sequence:
TGACGGCAAACATGACTTCAG (SEQ ID NO:22) [0358] mNos2, reverse sequence: GGTGCCATCGGGCATCT (SEQ ID NO:23)
[0359] mil 10, forward sequence: CAGTACAGCCGGGAA GACAATAA (SEQ ID NO:24) [0360] mil 10, reverse sequence: CCGCAGCTCTAGGAGCATGT (SEQ ID NO:25)
[0361] mil 12b, forward s equence : CCTGAAGTGTGAAGCACCAAATT (SEQ ID NO: 26) [0362] mI112b, reverse sequence:
CTTCAAGTCCATGTTTCTTTGCA (SEQ ID NO: 27) [0363] mlllb, forward sequence: GAAATGCCACCTTTTGACAGTG (SEQ ID NO:28) [0364] mlllb, reverse sequence: TGGATGCTCTCATCAGGACAG (SEQ ID NO: 29) [0365] hILIB, forward sequence:
TTC GAC AC AT GGGAT AAC GAGG (SEQ ID NO:30) [0366] hILIB, reverse sequence: TTTTTGCTGTGAGTCCCGGAG (SEQ ID NO:31) [0367] hIL6, forward sequence: CCTGAACCTTCCAAAGATGGC (SEQ ID NO:32) [0368] hIL6, reverse sequence: TTCACCAGGCAAGTCTCCTCA (SEQ ID NO:33)
[0369] ML12A, forward sequence: ATGGCCCTGTGCCTTAGTAGT (SEQ ID NO: 34) [0370] ML12A, reverse sequence: AGCTTTGCATTCATGGTCTTGA (SEQ ID NO:35) [0371] hNOS2, forward sequence: AGGGACAAGCCTACCCCTC (SEQ ID NO:36)
[0372] hNOS2, reverse sequence: CTCATCTCCCGTCAGTTGGT (SEQ ID NO: 37) [0373] hILlO, forward sequence: GACTTTAAGGGTTACCTGGGTTG (SEQ ID NO:38) [0374] hILlO, reverse sequence: TCACATGCGCCTTGATGTCTG (SEQ ID NO:39) [0375] 18s rRNA, forward sequence:
GTAACCCGTTGAACCCCATT (SEQ ID NO:40) [0376] 18s rRNA, reverse sequence:
CCATCCAATCGGTAGTAGCG (SEQ ID NO:41)
Claims
1. A recombinant oncolytic herpes simplex virus (HSV) comprising a nucleic acid encoding an anti-CD47 antibody.
2. The recombinant oncolytic virus of claim 1 wherein the anti-CD47 antibody is an IgGl isotype.
3. The recombinant oncolytic virus of claim 1, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional g34.5 gene.
4. The recombinant oncolytic virus of claim 1, wherein the recombinant oncolytic virus does not comprise nucleic acid encoding a functional ICP6 gene.
5. The recombinant oncolytic virus of claim 1, wherein the nucleic acid encoding the anti- CD47 antibody is under the control of a viral or tumor specific promoter.
6. The recombinant oncolytic virus of claim 5, wherein the viral promoter is a herpes simplex virus (HSV) immediate early (IE) promoter.
7. The recombinant oncolytic virus of claim 6, wherein the HSV IE promoter is the IE 4/5 promoter.
8. The recombinant oncolytic virus of claim 1, wherein the recombinant oncolytic virus comprises a nucleic acid encoding a marker within an ICP6 gene.
9. A pharmaceutical composition comprising: the recombinant oncolytic virus of claim 1, and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising: the recombinant oncolytic virus of claim 1, an anti-cancer agent, and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10, wherein the anti-cancer agent is a checkpoint inhibitor.
12. The pharmaceutical composition of claim 10, wherein the anti-cancer agent is a PARP inhibitor.
13. The pharmaceutical composition of claim 12, wherein the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3- aminobenzamide.
14. A method for killing tumor cells in a subject comprising: administering to a subject an effective amount of the recombinant oncolytic virus of claim 1.
15. A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of claim 1
16. The method of claim 15, wherein the cancer is a chronic cancer.
17. The method of claim 15, wherein the cancer is an inflammatory chronic cancer.
18. The method of claim 15, wherein the cancer is a CD47 expressing cancer.
19. The method of claim 18, wherein the CD47 expressing cancer is selected from glioblastoma, ovarian cancer, pancreatic cancer, leukemia, and lymphoma.
20. The method of claim 15, wherein administering is by intratumoral, systemic, or intracavitary administration.
21. A method for immune modulation in a subject, comprising administering an effective amount of the recombinant oncolytic virus of claim 1.
22. The method of claim 21, wherein immune modulation comprises activating natural killer (NK) cells.
23. The method of claim 22, wherein activation of NK cells is measured as induction of cell-mediated antibody-dependent cellular cytotoxicity.
24. The method of claim 22, wherein activation of NK cells is measured as expression of CD69 on NK cells.
25. The method of claim 22, wherein activation is measured as increased NK cell cytotoxicity.
26. The method of claim 21, wherein administering is by intratumoral, systemic, or intracavitary administration.
27. A method of treating an overactive immune reaction in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of claim 1.
28. The method of claim 27, wherein said overactive immune reaction is asthma, eczema, or allergic rhinitis.
29. A method of treating an autoimmune disease in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of claim 1.
30. The method of claim 29, wherein said autoimmune disease is arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, scleroderma, systemic scleroderma, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto’s encephalitis, Hashimoto’s thyroiditis, ankylosing spondylitis, psoriasis, Sjogren’s syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet’s disease, Crohn’s disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison’s disease, Vitiligo, asthma, or allergic asthma.
31. A method of treating an infectious disease in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of claim 1
32. The method of claim 31, wherein the infectious disease is human immunodeficiency virus (HIV), COVID-19, influenza, pneumonia, syphilis, anthrax, gonorrhea, HPV, mononucleosis, West Nile fever, Zika, malaria, or plague.
33. A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of claim 1 in a first dosage form and an anti-cancer agent in a second dosage form.
34. The method of claim 33, wherein the anti-cancer agent is a checkpoint inhibitor.
35. The method of claim 33, wherein the anti-cancer agent is a PARP inhibitor.
36. The method of claim 35, wherein the PARP inhibitor is olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, CEP 9722, E7016, or 3-aminobenzamide.
37. A method of treating a cancer in a subject in need, said method comprising administering to said subject an effective amount of the recombinant oncolytic virus of claim 1 and a cancer therapy.
38. The method of claim 37, wherein the cancer therapy is chemotherapy, radiation therapy, surgery, targeted therapy, immunotherapy, or cell therapy.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/797,681 US20230227549A1 (en) | 2020-02-07 | 2021-02-06 | Oncolytic virus compositions and methods for the treatment of cancer |
EP21750415.8A EP4100030A4 (en) | 2020-02-07 | 2021-02-06 | Oncolytic virus compositions and methods for the treatment of cancer |
CN202180017560.6A CN115916226A (en) | 2020-02-07 | 2021-02-06 | Oncolytic viral compositions and methods for treating cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062971768P | 2020-02-07 | 2020-02-07 | |
US62/971,768 | 2020-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021159035A1 true WO2021159035A1 (en) | 2021-08-12 |
Family
ID=77200421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/016973 WO2021159035A1 (en) | 2020-02-07 | 2021-02-06 | Oncolytic virus compositions and methods for the treatment of cancer |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230227549A1 (en) |
EP (1) | EP4100030A4 (en) |
CN (1) | CN115916226A (en) |
WO (1) | WO2021159035A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110248671A (en) * | 2017-01-04 | 2019-09-17 | 杭州康万达医药科技有限公司 | Therapeutic agent comprising oncolytic poxvirus and NK cell and its application in the drug for the treatment of tumour and/or cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
US20160244740A1 (en) * | 2013-09-27 | 2016-08-25 | Ohio State Innovation Foundation | Mutant chondroitinase abc i compositions and methods of their use |
US20190048082A1 (en) * | 2016-06-30 | 2019-02-14 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
WO2019129233A1 (en) * | 2017-12-29 | 2019-07-04 | 广州威溶特医药科技有限公司 | Use of parp inhibitor and oncolytic virus in preparing anti-tumor drug |
WO2020163721A1 (en) * | 2019-02-08 | 2020-08-13 | Integrity Bioventures, Inc. | Anti-cd47 antibodies and uses thereof |
-
2021
- 2021-02-06 US US17/797,681 patent/US20230227549A1/en active Pending
- 2021-02-06 EP EP21750415.8A patent/EP4100030A4/en active Pending
- 2021-02-06 WO PCT/US2021/016973 patent/WO2021159035A1/en unknown
- 2021-02-06 CN CN202180017560.6A patent/CN115916226A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
US20160244740A1 (en) * | 2013-09-27 | 2016-08-25 | Ohio State Innovation Foundation | Mutant chondroitinase abc i compositions and methods of their use |
US20190048082A1 (en) * | 2016-06-30 | 2019-02-14 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
WO2019129233A1 (en) * | 2017-12-29 | 2019-07-04 | 广州威溶特医药科技有限公司 | Use of parp inhibitor and oncolytic virus in preparing anti-tumor drug |
WO2020163721A1 (en) * | 2019-02-08 | 2020-08-13 | Integrity Bioventures, Inc. | Anti-cd47 antibodies and uses thereof |
Non-Patent Citations (2)
Title |
---|
GLORIOSO JOSEPH C., COHEN JUSTUS B., GOINS WILLIAM F., HALL BONNIE, JACKSON JOSEPH W., KOHANBASH GARY, AMANKULOR NDUKA, KAUR BALVE: "Oncolytic HSV Vectors and Anti-Tumor Immunity", CURRENT ISSUES IN MOLECULAR BIOLOGY, vol. 41, 17 September 2020 (2020-09-17), pages 381 - 468, XP055848954 * |
See also references of EP4100030A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110248671A (en) * | 2017-01-04 | 2019-09-17 | 杭州康万达医药科技有限公司 | Therapeutic agent comprising oncolytic poxvirus and NK cell and its application in the drug for the treatment of tumour and/or cancer |
CN110325200A (en) * | 2017-01-04 | 2019-10-11 | 杭州康万达医药科技有限公司 | Therapeutic agent and its application in the drug for the treatment of tumour and/or cancer |
Also Published As
Publication number | Publication date |
---|---|
CN115916226A (en) | 2023-04-04 |
EP4100030A4 (en) | 2024-03-27 |
US20230227549A1 (en) | 2023-07-20 |
EP4100030A1 (en) | 2022-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
TWI794171B (en) | Combination therapies of hdac inhibitors and pd-l1 inhibitors | |
EP3454844B1 (en) | Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor | |
US20240207393A1 (en) | Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy | |
US20230081443A1 (en) | Anti-il1rap antibodies | |
JP7023929B2 (en) | Chimeric poxvirus composition and its use | |
US20230192846A1 (en) | Anti-ror-2 antibodies and methods of use | |
US20230227549A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
US20240117047A1 (en) | Monoclonal antibodies specific for human ror1 | |
US20230147832A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
US20230312708A1 (en) | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers | |
WO2022093857A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
US20240041865A1 (en) | Combination therapies of wdr-5 inhibitors and pd-1 inhibitors | |
WO2022197866A1 (en) | Anti-hvem antibodies | |
WO2023056391A1 (en) | Anti-cd3 antibodies and uses thereof | |
WO2021231982A1 (en) | Smc1a antibodies and uses thereof | |
WO2024158859A1 (en) | Methods and compositions comprising a cardio-tolerated hdac inhibitor | |
EP3618857A1 (en) | Antibody variable domains and antibody constructs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21750415 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021750415 Country of ref document: EP Effective date: 20220907 |